

# CITATION REPORT

List of articles citing

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

DOI: 10.1056/nejm199808273390903

New England Journal of Medicine, 1998, 339, 584-90.

**Source:** <https://exaly.com/paper-pdf/29580879/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1913	Iron treatment: impact of safety issues. <b>1998</b> , 32, S152-6		11
1912	Two-embryo transfer--the future looks bright. <i>New England Journal of Medicine</i> , <b>1998</b> , 339, 624-5	59.2	6
1911	Quantifying leukemia. <i>New England Journal of Medicine</i> , <b>1998</b> , 339, 627-9	59.2	35
1910	Improvements to the Journal's site on the World Wide Web. <i>New England Journal of Medicine</i> , <b>1998</b> , 339, 629	59.2	0
1909	Erythropoietin for end-stage renal disease. <i>New England Journal of Medicine</i> , <b>1998</b> , 339, 625-7	59.2	49
1908	Effects of normal as compared with low hematocrit values in patients with cardiac disease undergoing hemodialysis and receiving epoetin. <i>New England Journal of Medicine</i> , <b>1998</b> , 339, 2023; author reply 2023-4	59.2	4
1907	Cardiac Ischemia in the Diabetic Patient with End-Stage Renal Disease. <b>1999</b> , 19, 305-308		
1906	The Normal Haematocrit Trial in dialysis patients with cardiac disease. <b>1999</b> , 14, 2043-4		7
1905	The Care of Patients Undergoing Hemodialysis. <i>New England Journal of Medicine</i> , <b>1999</b> , 340, 735-737	59.2	1
1904	Blood pressure variability as an adverse prognostic risk factor in end-stage renal disease. <b>1999</b> , 14, 1976-81		73
1903	Impact of aortic stiffness on survival in end-stage renal disease. <b>1999</b> , 99, 2434-9		1756
1902	Vascular access for hemodialysis. <b>1999</b> , 55, 2078-90		288
1901	Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. <b>1999</b> , 56, 253-60		30
1900	Intravenous iron for the treatment of predialysis anemia. <b>1999</b> , 69, S79-85		35
1899	Pathogenesis of Cardiac Disease in Dialysis Patients. <b>1999</b> , 12, 62-68		17
1898	Briefly Noted. <b>1999</b> , 12, 209-210		
1897	Anemia, hypoxia and hypercapnia thresholds. Lessons from physiological limits in critically ill patients. <b>1999</b> , 46, R145-55		

1896	Anemia as a Risk Factor for Cardiac Disease in Dialysis Patients. <b>1999</b> , 12, 84-86	1
1895	A possible side-effect of human erythropoietin therapy: thrombosis of peripheral arterial reconstruction. <b>1999</b> , 18, 273-4	7
1894	[Adequate dialysis treatment in hemodialysis and peritoneal dialysis patients]. <b>1999</b> , 40, 22-36	10
1893	[Long-term management of dialysis patients. I. Hypertension and anemia]. <b>1999</b> , 40, 55-63	
1892	Iron and cardiac disease in the end-stage renal disease setting. <b>1999</b> , 34, s18-s24	16
1891	A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEPO study). <b>1999</b> , 34, 1089-95	159
1890	A study of parenteral iron regimens in hemodialysis patients. <b>1999</b> , 34, 21-8	71
1889	Normalizing hematocrit in dialysis patients improves brain function. <b>1999</b> , 33, 1122-30	197
1888	What crit?. <b>1999</b> , 33, 1177-9	1
1887	Erythropoietin and iron use in peritoneal dialysis patients. Report from the 1997 HCFA end-stage renal disease core indicators project. <b>1999</b> , 33, 1187-9	12
1886	Mechanism of erythropoietin-induced hypertension. <b>1999</b> , 33, 821-8	133
1885	Anemia and Cardiovascular Disease. <b>1999</b> , 1, 24-30	
1884	Renal disease and the heart. <b>1999</b> , 60, 85-9	
1883	Management of anaemia in renal failure. <b>1999</b> , 25, 19-22	
1882	Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT(1) antagonists. <b>2000</b> , 2, 393-8	42
1881	Cardiac complications of end-stage renal disease. <b>2000</b> , 7, 210-9	7
1880	Trends in patient and technique survival in peritoneal dialysis and strategies: how are we doing and how can we do better?. <b>2000</b> , 7, 324-37	15
1879	Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. <b>2000</b> , 15, 1425-30	111

1878 Current World Literature. **2000**, 10, 161-192

1877 Bibliography Current World Literature. **2000**, 7, B51-B87

1876 AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. **2000**, 31, 2751-66 189

1875 Clinical use of growth factors in chronic renal failure. **2000**, 9, 5-10 4

1874 Cardiovascular disease in chronic renal failure: the challenge continues. Registro Lombardo Dialisi e Trapianto. **2000**, 15 Suppl 5, 69-80 74

1873 Normalization of hematocrit in hemodialysis patients does not affect silent ischemia. **2000**, 22, 205-11 19

1872 Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. **2000**, 58, 1325-35 262

1871 Comorbidities and their impact on outcome in patients with end-stage renal disease. **2000**, 57, S100-S104 39

1870 Outcome comparisons by prescribable treatment options. **2000**, 57, S105-S112 2

1869 Quality of life for patient groups. **2000**, 57, S121-S130 24

1868 Hematocrit level associated mortality in hemodialysis patients, by Ma JZ, Ebben J, Xia H, Collins AJ. J Am Soc Nephrol 10:610-619, 1999. **2000**, 13, 112-3 6

1867 Target haemoglobin levels for the treatment of the anaemia of chronic renal failure. **2000**, 5, 161-165

1866 Erythropoietin, iron, and erythropoiesis. **2000**, 96, 823-833 277

1865 Erythropoietin Therapy in Peritoneal Dialysis Patients. **2000**, 20, 178-182 5

1864 Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. **2000**, 1, 11-31 51

1863 Aspects of cardiovascular burden in pre-dialysis patients. **2000**, 85 Suppl 1, 9-14 25

1862 Morbidity and mortality reduction associated with the use of erythropoietin. **2000**, 85 Suppl 1, 2-8 24

1861 Iron Metabolism, Anemias. Diagnosis and Therapy. **2000**, 2

1860	Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. <b>2000</b> , 15 Suppl 5, 58-68	62
1859	Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors?. <b>2000</b> , 15, 454-7	117
1858	Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure. <b>2000</b> , 22, 435-44	28
1857	European guidelines for renal anaemia-predicting 85% compliance. <b>2000</b> , 15, 439-40	7
1856	Cardiovascular disease and chronic renal disease: a new paradigm. <b>2000</b> , 35, S117-31	396
1855	Parenteral iron use in the management of anemia in end-stage renal disease patients. <b>2000</b> , 35, 1-12	371
1854	Current status of prevention, diagnosis, and management of coronary artery disease in patients with kidney failure. <b>2000</b> , 139, 1000-8	22
1853	Cardiovascular disease in chronic renal insufficiency. <b>2000</b> , 36, S24-30	105
1852	Anemia management in patients with chronic renal insufficiency. <b>2000</b> , 36, S39-51	40
1851	Premature cardiovascular disease in chronic renal failure. <b>2000</b> , 356, 147-52	427
1850	Risks Associated with Under-Transfusion. <b>2000</b> , 2, 21-26	2
1849	AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. <b>2000</b> , 102, 2284-99	1204
1848	Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. <b>2000</b> , 37, 93-130	113
1847	Economic evaluation and end-stage renal disease: from basics to bedside. <b>2000</b> , 36, 12-28	32
1846	The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. <b>2000</b> , 35, 1737-44	534
1845	IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. <b>2001</b> , 37, S182-238	505
1844	Treatment of anemia of chronic kidney disease. <b>2001</b> , 37, 191-194	2
1843	The CREATE trial--building the evidence. <b>2001</b> , 16 Suppl 2, 16-8	29

1842	Revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. <b>2001</b> , 131, 132-46	87
1841	Experience with a Large Dose (500 MG) of Intravenous Iron Dextran and Iron Saccharate in Peritoneal Dialysis Patients. <b>2001</b> , 21, 290-295	26
1840	Target hemoglobin in patients with renal failure. <b>2001</b> , 89, 135-43; discussion 143-4	4
1839	Should the hematocrit be normalized in dialysis and in pre-ESRD patients?. <b>2001</b> , 19, 157-67	7
1838	Economic evaluation and the treatment of end-stage renal disease. <b>2001</b> , 10, 295-9	3
1837	Cardiovascular effects of erythropoietin and anemia correction. <b>2001</b> , 10, 633-7	63
1836	The use of pretransplant erythropoietin to normalize hemoglobin levels has no deleterious effects on renal transplantation outcome. <b>2001</b> , 71, 79-82	12
1835	Anaemia, renal insufficiency and cardiovascular outcome. <b>2001</b> , 16 Suppl 1, 102-4	13
1834	Haemoglobin, not haematocrit, should be the preferred parameter for the evaluation of anaemia in renal patients. <b>2001</b> , 16, 1085-7	4
1833	Individualizing target haemoglobin concentrations--tailoring treatment for renal anaemia. <b>2001</b> , 16 Suppl 7, 9-14	10
1832	Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. <b>2001</b> , 16, 459-68	104
1831	Should the hematocrit (hemoglobin) be normalized in Pre-ESRD or dialysis patients? Yes!. <b>2001</b> , 19, 168-74	11
1830	Present and future strategies in the treatment of renal anaemia. <b>2001</b> , 16 Suppl 5, 50-5	27
1829	Anaemia in chronic renal disease: lessons learned since Seville 1994. <b>2001</b> , 16 Suppl 7, 41-5	12
1828	[Perioperative anemia]. <b>2001</b> , 50, 73-86	20
1827	Long-term survival of chronic dialysis patients in comparison to that of stroke and acute myocardial infarction patients. <b>2001</b> , 5, 109-113	4
1826	Coronary artery disease in uremia: Etiology, diagnosis, and therapy. <b>2001</b> , 60, 2059-78	73
1825	Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. <b>2001</b> , 60, 1525-31	59

1824	A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. <b>2001</b> , 59, 1935-42	68
1823	Correlation between carotid intima-media thickness and hematocrit and hemoglobin values in renal transplant recipients. <b>2001</b> , 15, 349-53	6
1822	Quality of life in end-stage renal disease patients. <b>2001</b> , 38, 443-64	357
1821	Effect of erythropoietin on cardiovascular diseases. <b>2001</b> , 38, S20-5	21
1820	The Evaluation of the Renal Transplant Candidates: Clinical Practice Guidelines. <b>2001</b> , 1, 1-95	13
1819	Blood transfusion in elderly patients with acute myocardial infarction. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 1230-6	59.2 813
1818	Nutrition and Renal Disease. <b>2001</b> , 617-636	1
1817	Anemia and iron target realization in 1998: clinical management of anemia in 1,639 patients on hemodialysis. <b>2001</b> , 47, 511-5	2
1816	Normalization of haemoglobin concentration with recombinant erythropoietin has minimal effect on blood haemostasis. <b>2001</b> , 16, 313-9	16
1815	Imputing physical health status scores missing owing to mortality: results of a simulation comparing multiple techniques. <b>2001</b> , 39, 61-71	15
1814	When should we start erythropoietin therapy?. <b>2001</b> , 16, 891-2	10
1813	A heart price to pay for anaemia. <b>2001</b> , 16, 445-8	22
1812	Anaemia in end-stage renal disease: pathophysiological considerations. <b>2001</b> , 16 Suppl 7, 2-8	74
1811	How to diagnose and treat coronary artery disease in the uraemic patient: an update. <b>2001</b> , 16, 1103-8	11
1810	After 15 years of success--perspectives of erythropoietin therapy. <b>2001</b> , 16, 1745-9	21
1809	Biology of erythropoietin. <b>2001</b> , 502, 169-87	43
1808	Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. <b>2002</b> , 20, 4083-107	343
1807	Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness. <b>2002</b> , 13, 1412-4	45

1806	Recommendations for the screening and management of patients with chronic kidney disease. <b>2002</b> , 17 Suppl 1, 19-28	54
1805	Anaemia management and cardiomyopathy in renal failure. <b>2002</b> , 17 Suppl 1, 37-40	4
1804	Pure red-cell aplasia and recombinant erythropoietin. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 1584-6; author reply 1584-6	59.2 111
1803	Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). <b>2002</b> , 162, 1401-8	482
1802	Anaemia: cardiovascular adaptations and maladaptive responses in chronic kidney disease. <b>2002</b> , 17 Suppl 11, 32-4	87
1801	Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress. <b>2002</b> , 17 Suppl 5, 32-7	67
1800	The role of anaemia in the genesis of cardiac abnormalities in patients with chronic kidney disease. <b>2002</b> , 17, 207-10	10
1799	A need for an individualized approach to end-stage renal disease patients. <b>2002</b> , 17 Suppl 6, 17-21	5
1798	Re-evaluating the transfusion trigger: how low is safe?. <b>2002</b> , 9, 411-6	16
1797	Epidemiology of anemia associated with chronic renal insufficiency. <b>2002</b> , 11, 337-41	26
1796	Influence of progressive renal dysfunction in chronic heart failure. <b>2002</b> , 4, 125-30	21
1795	A rationale for an individualized haemoglobin target. <b>2002</b> , 17 Suppl 6, 2-7	6
1794	The relationship of haemoglobin level and survival: direct or indirect effects?. <b>2002</b> , 17 Suppl 5, 8-13	19
1793	The importance of anemia and its correction in the management of severe congestive heart failure. <b>2002</b> , 4, 681-6	102
1792	Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. <b>2002</b> , 100, 2303-20	179
1791	Improved iron utilization and reduced erythropoietin resistance by on-line hemodiafiltration. <b>2002</b> , 20, 349-56	44
1790	Cardiovascular disease in patients with chronic kidney disease. <b>2002</b> , 22, 459-73	23
1789	Optimal hematocrit based on regional cerebral blood flow in hemodialysis patients with diabetic nephropathy. <b>2002</b> , 6, 140-6	



1788	Potential cost savings of erythropoietin administration in end-stage renal disease. <b>2002</b> , 112, 169-75	43
1787	Reply. <b>2002</b> , 39, 1704-1705	1
1786	Complications of vascular closure devices--not yet evidence based. <b>2002</b> , 39, 1705-6; author reply 1706-8	3
1785	Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. <b>2002</b> , 39, 1780-6	534
1784	Reply. <b>2002</b> , 40, 2204	1
1783	Effect of anemia on 1-year mortality in patients with acute myocardial infarction. <b>2002</b> , 144, 636-641	78
1782	Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors. <b>2002</b> , 2, 157-62	22
1781	Effect of anemia on 1-year mortality in patients with acute myocardial infarction. <b>2002</b> , 144, 636-41	84
1780	Anemia and Blood Transfusion in the Critically Ill:The Role of Erythropoietin. <b>2002</b> , 4, 139-143	
1779	Posthemodialysis hemoglobin levels: overdue or not?. <b>2002</b> , 40, 873	7
1778	Endocrine abnormalities in chronic renal failure. <b>2002</b> , 31, 107-19	40
1777	Erythropoietin therapy and the cardiovascular system. <b>2002</b> , 137, 431-5	1
1776	Darbepoetin Alfa. <b>2002</b> , 37, 46-58	3
1775	Clinical characteristics and survival in end-stage renal disease patients with arteriosclerosis obliterans. <b>2002</b> , 22, 422-8	12
1774	Responsibilities of the Data Monitoring Committee and Motivating Illustrations. 19-43	
1773	Darbepoetin-alpha: a review of the literature. <b>2002</b> , 22, 889-97	18
1772	Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy. <b>2002</b> , 39, 850-3	28
1771	Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. <b>2002</b> , 40, 90-103	174

1770	Influence of the cyclic variation of hydration status on hemoglobin levels in hemodialysis patients. <b>2002</b> , 40, 549-55	44
1769	Unexpectedly high prevalence of posttransplant anemia in pediatric and young adult renal transplant recipients. <b>2002</b> , 40, 1306-18	60
1768	ESRD in Australia and New Zealand at the end of the millennium: a report from the ANZDATA registry. <b>2002</b> , 40, 1122-31	52
1767	Cardiac disease in diabetic patients with renal disease. <b>2002</b> , 39 Suppl 1, S9-14	5
1766	Novel erythropoiesis-stimulating protein in the management of the anemia of chronic renal failure. <b>2002</b> , 62, 720-9	11
1765	Strategies to decrease cardiovascular mortality in patients with end-stage renal disease. <b>2002</b> , 5-10	14
1764	Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. <b>2002</b> , 35-8	82
1763	What should the optimal target hemoglobin be?. <b>2002</b> , 39-43	9
1762	Influence of target hemoglobin in dialysis patients on morbidity and mortality. <b>2002</b> , 44-8	45
1761	Do AV fistulas contribute to cardiac mortality in hemodialysis patients?. <b>2002</b> , 15, 14-7	41
1760	Should hemoglobin be normalized in patients with chronic kidney disease?. <b>2002</b> , 15, 8-13	17
1759	An introduction to epidemiology and biostatistics and issues in interpretation of studies. <b>2002</b> , 15, 60-5	3
1758	Cardiovascular abnormalities and hypertension in the elderly dialysis patient. <b>2002</b> , 15, 121-6	1
1757	Congestive heart failure due to systolic dysfunction: the Cinderella of cardiovascular management in dialysis patients. <b>2002</b> , 15, 135-40	24
1756	Study designs and their potential influence on conclusions. <b>2002</b> , 15, 207-11	5
1755	How can the cardiac death rate be reduced in dialysis patients?. <b>2002</b> , 15, 18-20	3
1754	How can the cardiac death rate be reduced in dialysis patients?. <b>2002</b> , 15, 20-1	
1753	How can the cardiac death rate be reduced in dialysis patients?. <b>2002</b> , 15, 22-4	2

1752	Nitric oxide in RBCs. <b>2002</b> , 42, 1603-9	54
1751	Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. <b>2002</b> , 32 Suppl 1, 42-9	75
1750	Evaluation of coagulation and fibrinolysis in haemodialysis patients at different haematocrit levels: Comparison between patients with and without diabetes. <b>2002</b> , 7, 37-42	
1749	Nitric oxide in the human respiratory cycle. <b>2002</b> , 8, 711-7	391
1748	Past, present and future of erythropoietin use in the elderly. <b>2002</b> , 33, 187-93	8
1747	Effect of variability in anemia management on hemoglobin outcomes in ESRD. <b>2003</b> , 41, 111-24	359
1746	Can evidence drive the development of a sound national EPO reimbursement policy?. <b>2003</b> , 41, 254-8	10
1745	USRDS the united states renal data system. <b>2003</b> , 42, 1-230	58
1744	Safety in iron management. <b>2003</b> , 41, 18-26	141
1743	Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. <b>2003</b> , 98, 1514-20	125
1742	The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. <b>2003</b> , 64, 295-304	53
1741	High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. <b>2003</b> , 64, 728-36	65
1740	Renal insufficiency and anemia are independent risk factors for death among patients with acute myocardial infarction. <b>2003</b> , 64, 1398-405	77
1739	Hemoglobin variability in epoetin-treated hemodialysis patients. <b>2003</b> , 64, 1514-21	92
1738	Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients. <b>2003</b> , 63, 1086-93	30
1737	Adequacy of dialysis revisited. <b>2003</b> , 63, 1587-99	21
1736	The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. <b>2003</b> , 63, 1908-14	143
1735	Cardiovascular risk in patients with mild renal insufficiency. <b>2003</b> , S192-6	48

1734	Traditional and emerging cardiovascular risk factors in end-stage renal disease. <b>2003</b> , S105-10	132
1733	Anemia of chronic disease: past, present, and future. <b>2003</b> , S20-3	11
1732	Anemia as a risk factor for cardiovascular disease. <b>2003</b> , S32-9	49
1731	Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. <b>2003</b> , 16, 111-7	119
1730	When Bubbles Settle. <b>2003</b> , 16, 117-117	
1729	Hemodynamic cardiovascular risk factors in chronic kidney disease: what are the effects of intervention?. <b>2003</b> , 16, 128-39	9
1728	Applying multiple interventions in chronic kidney disease. <b>2003</b> , 16, 157-64	13
1727	Management of heart failure and coronary artery disease in patients with chronic kidney disease. <b>2003</b> , 16, 165-72	8
1726	Thrombosis in end-stage renal disease. <b>2003</b> , 16, 245-56	106
1725	Chronic renal insufficiency and renoprotective strategies. <b>2003</b> , 33, 237-41	
1724	Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. <b>2003</b> , 108, 2154-69	2515
1723	Anaemia in patients with diabetes: unrecognised, undetected and untreated?. <b>2003</b> , 19, 395-401	34
1722	[Therapy and prophylaxis of renal failure]. <b>2003</b> , 44, 819-24, 826-30	2
1721	Transfusion medicine: looking to the future. <b>2003</b> , 361, 161-9	227
1720	Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. <b>2003</b> , 90, 303-8	108
1719	Anemia: not just an innocent bystander?. <b>2003</b> , 163, 1400-4	147
1718	Transfusion et cardiopathies en ranimationTransfusion and heart disease in ICU. <b>2003</b> , 12, 557-563	
1717	Protocolized anemia management with erythropoietin in hemodialysis patients: a randomized controlled trial. <b>2003</b> , 14, 2654-61	32

1716	A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. <b>2003</b> , 18, 353-61	154
1715	Renal Disease. <b>2003</b> ,	1
1714	Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. <b>2003</b> , 42, 1050-65	802
1713	Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). <b>2003</b> , 14, 3270-7	576
1712	Information Recovery in a Study With Surrogate Endpoints. <b>2003</b> , 98, 1052-1062	20
1711	Management of anemia in erythropoietin-resistant hemodialysis patients. <b>2003</b> , 37, 1768-73	2
1710	Intra- and post-dialytic changes of haemoglobin concentrations in non-anaemic haemodialysis patients. <b>2003</b> , 18, 2606-12	18
1709	Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. <b>2003</b> , 107, 294-9	429
1708	Prediction of time-averaged concentration of haemoglobin in haemodialysis patients. <b>2003</b> , 18, 2082-7	5
1707	Epidemiology of cardiovascular risk in patients with chronic kidney disease. <b>2003</b> , 18 Suppl 7, vii2-9	48
1706	Left ventricular hypertrophy: a surrogate end point or correlate of cardiovascular events in kidney disease?. <b>2003</b> , 18, 2479-82	1
1705	How to design a clinical trial. <b>2003</b> , 86, 475-89	
1704	[Moderate renal failure: a significant cardiovascular risk factor]. <b>2003</b> , 128, 1247-51	
1703	Reply. <b>2003</b> , 18, 1415-1416	1
1702	Anaemia, cardiovascular disease and kidney disease: integrating new knowledge in 2002. <b>2003</b> , 12, 133-8	15
1701	The high incidence of left atrial appendage thrombosis in patients on maintenance haemodialysis. <b>2003</b> , 18, 2339-47	12
1700	Anemia, Blood Transfusion, and Erythropoietin in the Critically Ill. <b>2003</b> , 10, 219-225	2
1699	Congestive heart failure in patients with chronic kidney disease and on dialysis. <b>2003</b> , 325, 179-93	39

1698	Anemia in chronic kidney disease and congestive heart failure. <b>2003</b> , 21, 124-30	14
1697	Diagnosis and therapy of coronary artery disease in renal failure, end-stage renal disease, and renal transplant populations. <b>2003</b> , 325, 214-27	38
1696	Haemoglobin and haematocrit targets for the anaemia of chronic renal disease. <b>2003</b> , CD003967	15
1695	Vascular permeability factors in steroid-sensitive nephrotic syndrome and focal segmental glomerulosclerosis. <b>2003</b> , 18 Suppl 6, vi21-5	16
1694	A novel protective effect of erythropoietin in the infarcted heart. <b>2003</b> , 112, 999-1007	392
1693	Clinical Practice Guidelines of the Canadian Society of Nephrology for the treatment of patients with chronic renal failure: a re-examination. <b>2003</b> , 140, 163-9	4
1692	Anemia and Epoetin Alfa in the Intensive Care Unit. <b>2003</b> , 38, 1009-1014	2
1691	25 Lebensqualität bei Dialysepatienten. <b>2004</b> ,	
1690	Thrombotic events of arteriovenous fistulae in hemodialysis patients related to the C677T thermolabile variant of methylenetetrahydrofolate reductase. <b>2004</b> , 5, 83-8	0
1689	The role of anemia in congestive heart failure and chronic kidney insufficiency: the cardio renal anemia syndrome. <b>2004</b> , 47, 575-89	14
1688	The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <b>2004</b> , 164, 969-76	56
1687	[Cardiovascular risk and renal failure]. <b>2004</b> , 129, 2479-81	1
1686	Platelet dysfunction in renal failure. <b>2004</b> , 30, 579-89	312
1685	Hemoglobin levels and erythropoietin doses in hemodialysis and peritoneal dialysis patients in the United States. <b>2004</b> , 15, 174-9	39
1684	Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. <b>2004</b> , 25, 1021-8	141
1683	Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. <b>2004</b> , 110, 1006-12	163
1682	Anemia and diabetes. <b>2004</b> , 24, 522-6	42
1681	Cardiac disease in chronic kidney disease: current understandings and opportunities for change. <b>2004</b> , 22, 21-7	11

1680	Atherosclerosis in dialyzed patients. <b>2004</b> , 22, 28-37	23
1679	SECTION III. Treatment of renal anaemia. <b>2004</b> , 19, ii16-ii31	15
1678	Erythropoietin in cardiovascular diseases. <b>2004</b> , 25, 285-91	109
1677	SECTION II. Targets for anaemia treatment. <b>2004</b> , 19, ii6-ii15	11
1676	Anaemia and heart failure. <b>2004</b> , 90, 977-9	10
1675	Prospective study of the immune effects of normalizing the hemoglobin concentration in hemodialysis patients who receive recombinant human erythropoietin. <b>2004</b> , 15, 1339-46	25
1674	Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. <b>2004</b> , 15, 3154-65	125
1673	An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. <b>2004</b> , 63, 208-16	111
1672	Erythropoietic agents, iron and hemoglobin--What happens beyond the trial setting: observational data from the ANZDATA registry. <b>2004</b> , 8, 257-64	1
1671	Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. <b>2004</b> , 65, 626-33	57
1670	Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. <b>2004</b> , 65, 1864-9	44
1669	Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. <b>2004</b> , 66, 832-40	39
1668	A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. <b>2004</b> , 66, 1239-47	61
1667	Projecting the United States ESRD population: issues regarding treatment of patients with ESRD. <b>2004</b> , S3-7	61
1666	Are associational studies obfuscating?. <b>2004</b> , 66, 462; author reply 462-3	
1665	Reply from the Authors. <b>2004</b> , 66, 462-463	
1664	Underuse of Hardy-Weinberg equilibrium. <b>2004</b> , 66, 1711; author reply 1711	1
1663	Different meanings of "glomerular tip lesion". <b>2004</b> , 66, 1716; author reply 1716-7	2

1662	Reply from the Authors. <b>2004</b> , 66, 1716-1717	1
1661	How can we be sure that renal dysfunction after coronary angiography is just explained by contrast nephropathy?. <b>2004</b> , 66, 1717; author reply 1717-8	4
1660	Reply from the Authors. <b>2004</b> , 66, 1717-1718	0
1659	Reply from the Authors. <b>2004</b> , 66, 1711	
1658	Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. <b>2004</b> , 66, 1712; author reply 1712-3	1
1657	Reply from the Authors. <b>2004</b> , 66, 1712-1713	
1656	Mycophenolate mofetil in IgA nephropathy. <b>2004</b> , 66, 1713; author reply 1713-4	
1655	Reply from the Authors. <b>2004</b> , 66, 1713-1714	
1654	Hepatic iron in hemodialysis patients. <b>2004</b> , 66, 1714-5	6
1653	The impact of serum uric acid on cardiovascular outcomes in the LIFE study. <b>2004</b> , 66, 1714-5	24
1652	Heterozygous NPHS1 or NPHS2 mutations in responsive nephrotic syndrome and the multifactorial origin of proteinuria. <b>2004</b> , 66, 1715-6	6
1651	Improved survival with higher hematocrits: where is the evidence?. <b>2004</b> , 17, 181-3	10
1650	Inadequate treatment of cardiovascular disease and cardiovascular disease risk factors in dialysis patients: a commentary. <b>2004</b> , 17, 342-5	9
1649	Strategies to optimize the use of erythropoietin and iron therapy in oncology patients. <b>2004</b> , 44, 15S-25S	4
1648	Mechanisms and treatment of anemia in chronic heart failure. <b>2004</b> , 10, 243-7	17
1647	Percentage of hypochromic red blood cells is an independent risk factor for mortality in kidney transplant recipients. <b>2004</b> , 4, 2075-81	30
1646	Anemia management in heart failure: a thick review of thin data. <b>2004</b> , 24, 757-67	7
1645	The beneficial effect of effective control of anemia on hyperinsulinemia and hypoxemia in a hemodialysis patient with corrected transposition of the great arteries. <b>2004</b> , 8, 163-7	4



1644	Anemia and heart failure. <b>2004</b> , 1, 176-82	26
1643	Clinical and economic impact of epoetins in cancer care. <b>2004</b> , 22, 1029-45	22
1642	Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). <b>2004</b> , 19, 121-32	320
1641	Cardiovascular diseases in kidney transplant recipients: the role of anemia. <b>2004</b> , 11, 328-33	7
1640	Epidemiology and prevention of cardiovascular complication in chronic kidney disease patients. <b>2004</b> , 24, 417-22	10
1639	Anemia as a risk factor and therapeutic target in heart failure. <b>2004</b> , 44, 959-66	192
1638	The renal patient with coronary artery disease: current concepts and dilemmas. <b>2004</b> , 44, 1343-53	35
1637	What are the clinical consequences of anemia in patients with chronic heart failure?. <b>2004</b> , 10, S10-2	15
1636	Treatment of anemia in patients with chronic heart failure. <b>2004</b> , 10, S13-6	12
1635	A study of the response of elderly patients with end-stage renal disease to epoetin alfa or beta. <b>2004</b> , 21, 187-201	5
1634	Quality of life in male hemodialysis patients. Role of erectile dysfunction. <b>2004</b> , 96, c21-7	46
1633	Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. <b>2004</b> , 57, 1086-95	45
1632	Cardiovascular disease and chronic kidney disease: insights and an update. <b>2004</b> , 148, 230-42	58
1631	Neurocognitive function and quality of life in relation to hematocrit levels in chronic hemodialysis patients. <b>2004</b> , 57, 5-10	26
1630	2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. <b>2004</b> , 8, 443-59	59
1629	Appendix A: Haematology methodology. <b>2004</b> , 19, ii37-ii38	
1628	Molecular biology of erythropoietin. <b>2004</b> , 43, 649-59	274
1627	The renal patient with coronary artery diseaseCurrent concepts and dilemmas. <b>2004</b> , 44, 1343-1353	84

1626	Chronic renal dysfunction as an independent risk factor for the development of cardiovascular disease. <b>2005</b> , 13, 98-107	36
1625	The clinical epidemiology of cardiovascular disease in chronic kidney disease. <b>2005</b> , 14, 550-7	24
1624	Cardio-renal insufficiency: the search for management strategies. <b>2005</b> , 14, 442-7	14
1623	Cardio-renal insufficiency: the search for management strategies. <b>2005</b> , 4, 590-595	
1622	Cardio-renal insufficiency: the search for management strategies. <b>2005</b> , 4, 476-481	
1621	Screening and confirmation of recombinant human erythropoietin and darbepoetin- $\alpha$ in spiked plasma samples from drug-free horses. <b>2005</b> , 552, 96-109	10
1620	Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?. <b>2005</b> , 18, 22-9	11
1619	Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. <b>2005</b> , 68, 2323-30	83
1618	Clinical benefits of slowing the progression of renal failure. <b>2005</b> , S152-6	3
1617	Anaemia and the heart. <b>2005</b> , 35 Suppl 3, 20-5	19
1616	Diabetic nephropathy and anaemia. <b>2005</b> , 35 Suppl 3, 66-74	27
1615	EPO therapy during acute kidney disease: to use or not to use, that is the question. <b>2005</b> , 46, 967-9	2
1614	Hypothesis versus association: the optimal hemoglobin target debate. <b>2005</b> , 46, 970-3	11
1613	Anemia, chronic heart failure, and the impact of male vs. female gender. <b>2005</b> , 11, 129-32	2
1612	Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus. <b>2005</b> , 25, 862-75	
1611	Erythropoietin mimics ischemic preconditioning. <b>2005</b> , 42, 233-41	57
1610	[Chronic kidney disease]. <b>2005</b> , 100, 714-21	1
1609	Treatment of anemia in the patient with heart failure. <b>2005</b> , 7, 327-32	3

1608	Anemia in chronic heart failure patients: comparison between invasive and non-invasive prognostic markers. <b>2005</b> , 64, 124-33	4
1607	Cardiovascular Disease in Patients with Chronic Kidney Disease. <b>2005</b> , 158-173	
1606	The Impact of Guidelines for the Prevention of Anemia on Clinical Outcome. <b>2005</b> , 25, 99-101	2
1605	. <b>2005</b> ,	2
1604	Effects of erythropoietin on brain function. <b>2005</b> , 6, 65-79	68
1603	Frequent non-cardiac comorbidities in patients with chronic heart failure. <b>2005</b> , 7, 309-16	71
1602	Nosocomial Infections in Hemodialysis Units. <b>2005</b> , 429-450	2
1601	Association of achieved dialysis dose with mortality in the hemodialysis study: an example of "dose-targeting bias". <b>2005</b> , 16, 3371-80	66
1600	Anaemia, Polycythaemia and Chronic Heart Failure. <b>2005</b> , 1, 117-126	1
1599	Does full versus partial correction of anemia have additional cardiac benefit in incident hemodialysis patients?. <b>2005</b> , 1, 70-1	
1598	Anaemia in diabetes: an emerging complication of microvascular disease. <b>2005</b> , 1, 107-26	54
1597	Anaemia and heart failure: aetiology and treatment. <b>2005</b> , 20 Suppl 7, vii7-10	5
1596	Beyond Framingham: cardiovascular risk profiling in ESRD. <b>2005</b> , 16, 1539-41	19
1595	Recombinant human erythropoietin in oncology: current status and further developments. <b>2005</b> , 16, 1584-95	26
1594	A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. <b>2005</b> , 165, 2214-20	304
1593	Inflammation and resistance to erythropoiesis-stimulating agents--what do we know and what needs to be clarified?. <b>2005</b> , 20 Suppl 8, viii2-7	44
1592	Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. <b>2005</b> , 112, 1121-7	195
1591	Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. <b>2005</b> , 165, 2237-44	95

1590	Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. <b>2005</b> , 16, 2180-9	289
1589	Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome. <b>2005</b> , 2, 95-100	22
1588	Optimized heart failure therapy and complete anemia correction on left-ventricular hypertrophy in nondiabetic and diabetic patients undergoing hemodialysis. <b>2005</b> , 28, 353-62	3
1587	Anemia in the elderly: time for new blood in old vessels?. <b>2005</b> , 165, 2187-9	22
1586	Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients. <b>2005</b> , 25, 211-20	32
1585	Managing a fateful alliance: anaemia and cardiovascular outcomes. <b>2005</b> , 20 Suppl 6, vi16-20	19
1584	Intravenous iron supplementation in the anaemia of renal and cardiac failure--a double-edged sword?. <b>2005</b> , 20 Suppl 7, vii16-23	14
1583	Optimizing renal anaemia management--benefits of early referral and treatment. <b>2005</b> , 20 Suppl 8, viii22-26	9
1582	Cardio-renal failure: an emerging clinical entity. <b>2005</b> , 20, 1780-3	5
1581	Haemoglobin level and vascular access survival in haemodialysis patients. <b>2005</b> , 20, 2453-7	17
1580	Individualizing anaemia treatment: a discussion of case histories. <b>2005</b> , 20 Suppl 6, vi37-43	3
1579	Pleiotropic renal actions of erythropoietin. <b>2005</b> , 365, 1890-2	67
1578	Anemia of chronic disease. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 1011-23	59.2 2218
1577	Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors. <b>2005</b> , 34, 1303-8	17
1576	Argumentaire. <b>2005</b> , 1, S9-S48	
1575	Potential risk for infection and atherosclerosis due to iron therapy. <b>2005</b> , 15, 105-10	24
1574	Traditional and nontraditional cardiovascular risk factors in chronic kidney disease. <b>2005</b> , 89, 587-611	42
1573	Anemia and heart failure in chronic kidney disease. <b>2005</b> , 25, 392-6	12

1572	Management of cardiovascular disease in the renal transplant recipient. <b>2005</b> , 23, 331-42	7
1571	Multiple risk factor intervention in chronic kidney disease: management of cardiac disease in chronic kidney disease patients. <b>2005</b> , 89, 511-23	9
1570	Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. <b>2005</b> , 97, 489-98	208
1569	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians. <b>2005</b> , 113, 166-187	1915
1568	Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. <b>2005</b> , 149, 408-13	97
1567	[Anemia as a new predictor of mortality in patients hospitalized with congestive heart failure]. <b>2005</b> , 125, 647-53	2
1566	Cartas al editor. <b>2005</b> , 124, 158	
1565	Dialyzer membrane permeability and survival in hemodialysis patients. <b>2005</b> , 45, 565-71	96
1564	Evidence-based medicine: can it be applied to stimulation of erythropoiesis for patients with malignancy?. <b>2005</b> , 18, 439-48	3
1563	Reply. <b>2005</b> , 45, 1550-1551	1
1562	Further aspects of anemia, heart failure, and erythropoietin. <b>2005</b> , 45, 1549-50; author reply 1550-1	2
1561	Is there an optimal hematocrit value for cardiac patients?. <b>2005</b> , 45, 1549; author reply 1550-1	1
1560	ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). <b>2005</b> , 46, e1-82	1119
1559	Darbepoetin alfa: its use in anemia associated with chronic kidney disease. <b>2005</b> , 19, 327-43	10
1558	Preoperative Management and Preparation for Transfusion-Free Surgery. 60-74	
1557	Chemical physiology of blood flow regulation by red blood cells: the role of nitric oxide and S-nitrosohemoglobin. <b>2005</b> , 67, 99-145	380
1556	Efficacy and safety of intravenous iron therapy for HCV-positive haemodialysis patients. <b>2005</b> , 100, c78-85	4
1555	Dialysis outcomes as a measure of adequacy of dialysis. <b>2005</b> , 25, 70-5	2

1554	Complications of chronic kidney disease: anemia, mineral metabolism, and cardiovascular disease. <b>2005</b> , 89, 549-61	20
1553	Congestive heart failure in chronic kidney disease: disease-specific mechanisms of systolic and diastolic heart failure and management. <b>2005</b> , 23, 275-84	43
1552	Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. <b>2006</b> , CD006254	20
1551	Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. <b>2006</b> , 22, 1929-37	43
1550	Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. <b>2006</b> , 368, 947-53	123
1549	Haemoglobin concentrations in chronic kidney disease. <b>2006</b> , 368, 2191-3	18
1548	Anemia, renal transplantation, and the anemia paradox. <b>2006</b> , 26, 307-12	19
1547	Anemia and the heart in chronic kidney disease. <b>2006</b> , 26, 290-5	15
1546	Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. <b>2006</b> , 48, 2161-7	157
1545	Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. <b>2006</b> , 17, 1181-91	532
1544	The high prevalence of anemia in diabetes is linked to functional erythropoietin deficiency. <b>2006</b> , 26, 275-82	33
1543	Correction of anemia with epoetin alfa in chronic kidney disease. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 2085-98	59.2 2017
1542	Prevalence and prognostic significance of anemia in patients with congestive heart failure treated with standard vs high doses of enalapril. <b>2006</b> , 25, 333-8	16
1541	. <b>2006</b> ,	1
1540	Implementing iron management clinical practice guidelines in patients with chronic kidney disease having dialysis. <b>2006</b> , 185, 310-4	20
1539	Role of Erythropoietin in the Correction of Anemia in Patients with Heart Failure. 205-216	
1538	Erythropoiesis-stimulating agents in kidney and cardiac disease. <b>2006</b> , 67, 533-7	2
1537	Anémie de l'insuffisance rénale chronique. <b>2006</b> , 1, 1-12	

1536	Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. <b>2006</b> , CD003967	30
1535	Metabolic syndrome is associated with severe coronary artery disease and poor cardiac outcome in end-stage renal disease patients with acute coronary syndrome. <b>2006</b> , 17, 593-6	7
1534	Anemia and cardiovascular and kidney disease. <b>2006</b> , 15, 117-22	5
1533	[Treatment of nephrogenic anemia]. <b>2006</b> , 95, 140-7	
1532	The effects of nocturnal hemodialysis compared to conventional hemodialysis on change in left ventricular mass: rationale and study design of a randomized controlled pilot study. <b>2006</b> , 7, 2	15
1531	Anaemia in diabetic kidney disease: An area for improvement?. <b>2006</b> , 23, 22-26	2
1530	Recombinant human erythropoietin: has treatment reached its full potential?. <b>2006</b> , 19, 1-4	22
1529	Managing erythropoietin hyporesponsiveness. <b>2006</b> , 19, 146-51	42
1528	Anemia management in chronic kidney disease: what have we learned after 17 years?. <b>2006</b> , 19, 269-72	11
1527	Nonhematologic complications of erythropoietin therapy. <b>2006</b> , 19, 279-84	24
1526	Intravenous iron therapy in end-stage renal disease. <b>2006</b> , 19, 285-90	22
1525	Prognostic implications of clinical practice guidelines among hemodialysis patients. <b>2006</b> , 10, 399-407	5
1524	Overview of clinical studies in hemodiafiltration: what do we need now ?. <b>2006</b> , 10 Suppl 1, S5-S12	31
1523	Bases of cardiovascular and hematological effects. <b>2006</b> , 10 Suppl 1, S39-42	
1522	Health-related quality of life among haemodialysis patients--relationship with clinical indicators, morbidity and mortality. <b>2006</b> , 15, 498-504	63
1521	Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects. <b>2006</b> , 69, 679-84	33
1520	Time to consider the role of epoetin. <b>2006</b> , 69, 1917; author reply 1917-8	1
1519	Challenging the boundaries of anemia management: a balanced approach to i.v. iron and EPO therapy. <b>2006</b> , S1-3	7

1518	Overcoming barriers that inhibit proper treatment of anemia. <b>2006</b> , S9-12	5
1517	Response to time to consider the role of epoetin. <b>2006</b> , 69, 1917-1918	
1516	Can higher hemoglobin prolongs life for patients with kidney disease?. <b>2006</b> , 70, S17-S20	1
1515	Introduction: improving outcomes in chronic kidney disease. <b>2006</b> , S1-4	1
1514	The epidemics of cardiovascular disease in elderly patients with chronic kidney disease--two facets of the same problem. <b>2006</b> , 38, 371-9	12
1513	Anemia, chronic renal disease and congestive heart failure--the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. <b>2006</b> , 38, 295-310	86
1512	A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. <b>2006</b> , 20, 135-41	156
1511	Nonhypotensive dose of beta-adrenergic blocker ameliorates capillary deficits in the hearts of rats with moderate renal failure. <b>2006</b> , 449, 207-14	10
1510	Recombinant human erythropoietin in the treatment of nonrenal anemia. <b>2006</b> , 85, 69-78	8
1509	[Renal anemia - an important secondary disease in renal insufficiency]. <b>2006</b> , 47, 233-4, 236-8, 240-1	
1508	Anemia and cardiovascular disease in diabetic nephropathy. <b>2006</b> , 6, 213-8	22
1507	Anemia and diabetic nephropathy. <b>2006</b> , 6, 469-72	8
1506	Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. <b>2006</b> , 47, 24-36	88
1505	Challenging the validity of the EPO index. <b>2006</b> , 47, 166	43
1504	Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO Study. <b>2006</b> , 47, 131-8	73
1503	Target hemoglobin level for EPO therapy in CKD. <b>2006</b> , 47, 171-3	18
1502	Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. <b>2006</b> , 47, 715-26	48
1501	Effect of early correction of anemia on the progression of CKD. <b>2006</b> , 47, 738-50	106



1500 References. **2006**, 47, S132-S145

1499 Impact of comorbidities on mortality in managed care patients with CKD. **2006**, 48, 212-20 43

1498 Anemia and the role of erythropoietin in diabetes. **2006**, 20, 262-72 57

1497 Controversies in renal anemia management. **2006**, 35, 120-135

1496 Proven strategies to reduce cardiovascular mortality in hemodialysis patients. **2006**, 24, 100-6 4

1495 How to optimise anaemia therapy in peritoneal dialysis patients. **2006**, 150, 202-213 6

1494 Long-term erythropoietin therapy decreases CC-chemokine levels and intima-media thickness in hemodialyzed patients. **2006**, 26, 497-502 9

1493 Frequency of anti-heparin-PF4 complex antibodies (HIT antibodies) in uremic patients on chronic intermittent hemodialysis. **2006**, 35, 445-50 22

1492 Haemoglobin at time of referral prior to dialysis predicts survival: an association of haemoglobin with long-term outcomes. **2006**, 21, 370-7 57

1491 Anaemia and mortality in haemodialysis patients: interaction of propensity score for predicted anaemia and actual haemoglobin levels. **2006**, 21, 1652-62 24

1490 A prospective study of anaemia and long-term outcomes in kidney transplant recipients. **2006**, 21, 3559-66 47

1489 Improving outcomes for dialysis patients in the international Dialysis Outcomes and Practice Patterns Study. **2006**, 1, 246-55 81

1488 Therapy insight: management of cardiovascular disease in the renal transplant recipient. **2006**, 2, 514-26 13

1487 Cancer-related anemia and recombinant human erythropoietin--an updated overview. **2006**, 3, 152-64 90

1486 Do we know the correct hemoglobin target for anemic patients with chronic kidney disease?. **2006**, 1, 678-84 4

1485 Percutaneous endocardial injection of erythropoietin: assessment of cardioprotection by electromechanical mapping. **2006**, 8, 443-50 15

1484 Clinical Research Methods in CJASN. **2006**, 1, 1115-1116 1

1483 Correction of anemia--payoffs and problems. *New England Journal of Medicine*, **2006**, 355, 2144-6 59.2 39

1482	Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. <b>2006</b> , 291, F932-44	60
1481	Translating epoetin research into practice: the role of government and the use of scientific evidence. <b>2006</b> , 25, 1249-59	26
1480	Update on erythropoietin treatment: should hemoglobin be normalized in patients with chronic kidney disease?. <b>2006</b> , 17, S74-7	23
1479	Cohort studies: marching forward. <b>2006</b> , 1, 1117-23	54
1478	Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis. <b>2006</b> , 17, 2878-85	50
1477	The Diabetic Kidney. <b>2006</b> ,	1
1476	Anemia and cardiovascular risk: the lesson of the CREATE Trial. <b>2006</b> , 17, S262-6	25
1475	Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. <b>2006</b> , 113, 2713-23	388
1474	Erythropoietins and Erythropoiesis. <b>2006</b> ,	2
1473	Mechanisms of disease: erythropoietin--an old hormone with a new mission?. <b>2006</b> , 3, 563-72	27
1472	Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. <b>2006</b> , 103, 5965-70	114
1471	Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. <b>2006</b> , 113, 2454-61	286
1470	Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia. <b>2007</b> , 12, 362-5	23
1469	Kidney disease and cardiovascular risk. <b>2007</b> , 58, 123-39	54
1468	Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. <b>2007</b> , 28, 1193-204	216
1467	Pharmacist's role in managing anemia in patients with chronic kidney disease: potential clinical and economic benefits. <b>2007</b> , 64, S15-22; quiz S23-5	13
1466	Does correction of anemia slow the progression of chronic kidney disease?. <b>2007</b> , 3, 638-9	4
1465	Anaemia of CKD--the CHOIR study revisited. <b>2007</b> , 22, 1806-10	11

1464	Structure, production and function of erythropoietin: implications for therapeutical use in cardiovascular disease. <b>2007</b> , 14, 2278-87	40
1463	Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. <b>2007</b> , 22, 794-800	65
1462	History of acute coronary events during the predialysis phase of chronic kidney disease is a strong risk factor for major adverse cardiac events in patients initiating haemodialysis. <b>2007</b> , 22, 2917-23	13
1461	Management of anaemia in haemodialysis and peritoneal dialysis patients (chapter 8). <b>2007</b> , 22 Suppl 7, vii78-104	6
1460	Time to target haemoglobin concentration (11 g/dl)--risk of hospitalization and mortality among incident dialysis patients. <b>2007</b> , 22, 2247-55	10
1459	Latest US KDOQI Anaemia Guidelines update--what are the implications for Europe?. <b>2007</b> , 22, 2738-42	20
1458	Use of erythropoietin after solid organ transplantation. <b>2007</b> , 22 Suppl 8, viii47-viii49	2
1457	Negative outcome studies in end-stage renal disease: how dark are the storm clouds?. <b>2008</b> , 23, 56-61	10
1456	Hemoglobin level in dialysis patients: revisiting the normal hematocrit study. <b>2007</b> , 72, 1161; author reply 1161-2	
1455	Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients. <b>2007</b> , 27, 221-5	5
1454	Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. <b>2007</b> , 28, 2018-27	193
1453	Chronic kidney disease, anemia, and epoetin. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 956; author reply 958-9	59.2 1
1452	Anemia in patients with chronic kidney disease: defining the optimal hemoglobin target. <b>2007</b> , 3, 244-5	1
1451	Anemia as a risk factor for chronic kidney disease. <b>2007</b> , S4-9	38
1450	The new FDA label for erythropoietin treatment: how does it affect hemoglobin target?. <b>2007</b> , 72, 806-13	28
1449	Comparative costs of treatment with epoetin alfa and darbepoetin alfa for anemia in the oncology and nephrology settings. <b>2007</b> , 7, 59-73	4
1448	Adverse effects on hemostatic function of drugs used in hematologic malignancies. <b>2007</b> , 33, 355-64	32
1447	Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. <b>2007</b> , 18, 975-84	305

1446	Role of oral iron in the management of long-term hemodialysis patients. <b>2007</b> , 2, 688-93	16
1445	End-stage renal disease in the United States: an update from the United States Renal Data System. <b>2007</b> , 18, 2644-8	334
1444	Nandrolone decanoate as anabolic therapy in chronic kidney disease: a randomized phase II dose-finding study. <b>2007</b> , 106, c125-35	36
1443	Course of vascular access and relationship with treatment of anemia. <b>2007</b> , 2, 1163-9	6
1442	Hemoglobin variability and mortality in ESRD. <b>2007</b> , 18, 3164-70	364
1441	Use of epoetin in chronic renal failure. <b>2007</b> , 297, 1713-6	19
1440	Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. <b>2007</b> , 298, 1291-9	497
1439	Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C. <b>2007</b> , 41, 268-75	8
1438	Anemia of chronic kidney disease: CHOIR and the FDA. <b>2007</b> , 3, 406-7	2
1437	Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin. <b>2007</b> , 49, 1142-8	86
1436	Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease. <b>2007</b> , 22 Suppl 4, iv10-iv18	7
1435	Hemoglobin variability in dialysis patients. <b>2007</b> , 18, 2218-20	13
1434	Reducing versus discontinuing erythropoietin at high hemoglobin levels. <b>2007</b> , 18, 3184-91	11
1433	What is needed to achieve a hemoglobin of 11.0-13.0 g/dl in end-stage renal disease. <b>2007</b> , 25, 53-7	4
1432	Influence of industry on renal guideline development. <b>2007</b> , 2, 3-7; discussion 13-4	51
1431	Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. <b>2007</b> , 2, 1274-82	97
1430	Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. <b>2007</b> , 2, 898-905	117
1429	An integrated approach to prognosis using protein microarrays and nonparametric methods. <b>2007</b> , 3, 123	17

1428 [Chronic kidney disease and various other diseases: 9. Anemia]. **2007**, 96, 935-41

1427 Vitamin D in patients with chronic kidney disease: nothing new under the sun. **2007**, 147, 880-1 13

1426 Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. **2007**, 292, H522-9 79

1425 Response to hemoglobin level in dialysis patients: Revisiting the normal hematocrit study. **2007**, 72, 1161-1162

1424 Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. **2007**, 297, 1667-74 82

1423 Erythropoietin Safety Concerns. **2007**, 110, 919-921

1422 A report of the Lisbon Conference on the care of the kidney transplant recipient. **2007**, 83, S1-22 74

1421 Epoetin-induced pure red cell aplasia: diagnosis and treatment. **2007**, 16, 585-8 12

1420 Nononcologic use of human recombinant erythropoietin therapy in hospitalized patients. **2007**, 167, 840-6 8

1419 Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. **2007**, 9, 110-2 65

1418 Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: results of a double-blind, placebo-controlled randomized trial. **2007**, 154, 494.e1-7 7

1417 Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. **2007**, 154, 645.e9-15 100

1416 Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study. **2007**, 29, 2010-21 7

1415 Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward. **2007**, 103, 487-90 37

1414 Congestive heart failure-related anemia and a role for erythropoietin. **2007**, 117, 296-305 10

1413 Chronic kidney disease and cardiovascular risk. **2007**, 1, 178-84 22

1412 [Hemoglobin target for chronic kidney disease patients?]. **2007**, 3, 369-71

1411 Haemoglobin targets: we were wrong, time to move on. **2007**, 369, 346-50 70

1410	Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. <b>2007</b> , 369, 381-8	461
1409	Target haemoglobin concentrations in chronic kidney disease. <b>2007</b> , 369, 1515-1516	1
1408	Target haemoglobin concentrations in chronic kidney disease – Authors' reply. <b>2007</b> , 369, 1516-1517	
1407	Target haemoglobin concentrations in chronic kidney disease. <b>2007</b> , 369, 1517	3
1406	Risks and benefits of erythropoiesis-stimulating agents in cancer management. <b>2007</b> , 44, 157-65	14
1405	Erythropoietin and treatment of non-anemic conditions--cardiovascular protection. <b>2007</b> , 44, 212-7	38
1404	Anemia in diabetes: marker or mediator of microvascular disease?. <b>2007</b> , 3, 20-30	63
1403	Cardiorenal anemia syndrome in chronic kidney disease. <b>2007</b> , 70, 424-9	12
1402	The Kidney Disease: improving Global Outcomes website: comparison of guidelines as a tool for harmonization. <b>2007</b> , 71, 1054-61	25
1401	Current trends in pharmacy benefit designs: a threat to disease management in chronic complex diseases. <b>2007</b> , 10, 74-82	2
1400	Anemia in patients undergoing percutaneous coronary intervention: current issues and future directions. <b>2007</b> , 7, 225-33	1
1399	Vitamin D levels and early mortality among incident hemodialysis patients. <b>2007</b> , 72, 1004-13	593
1398	Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. <b>2007</b> , 72, 1130-7	374
1397	Chronic kidney disease mineral bone disorder and health-related quality of life among incident end-stage renal-disease patients. <b>2007</b> , 17, 305-13	15
1396	Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies. <b>2007</b> , 82, 1371-80	27
1395	Pharmaceutical erythropoietin use in patients with cancer: is it time to abandon ship or just drop anchor?. <b>2007</b> , 82, 1316-8	7
1394	Drug-induced cardiovascular disorders. <b>2007</b> , 30, 783-804	26
1393	Musings on Guidelines and Evidence: A Pragmatic and Nephrocentric View. <b>2007</b> , 27, 31-35	3

1392 Hemoglobin Normalization Studies. **2007**, 27, 395-399

1391 Risk of Vascular access Thrombosis in Patients with Systemic Lupus Erythematosus on Hemodialysis. **2007**, 8, 103-108 15

1390 Defining and Estimating Intervention Effects for Groups that will Develop an Auxiliary Outcome. **2007**, 22, 57

1389 Causes and consequences of chronic kidney disease: implications for managed health care. **2007**, 13, S1-9 36

1388 The consultant pharmacist's role in dialysis: an introduction. **2007**, 22, 1035-44 1

1387 Dialysis and the Chronic Renal Failure Patient. **2007**, 1-18

1386 Stimulating erythropoiesis in inflammatory bowel disease associated anemia. **2007**, 13, 4798-806 28

1385 Disease progression and the application of evidence-based treatment guidelines diagnose it early: a case for screening and appropriate management. **2007**, 13, S6-12 25

1384 . **2007**, 1

1383 Anemia and Heart Failure: A Cause of Progression or Only a Consequence?. **2007**, 3, 182618680700300 1

1382 The pathogenesis of late-life anemia. 203-213

1381 Treatment of late-life anemia. 214-222

1380 Chronic kidney disease and cardiovascular disease: A bi-directional relationship?. **2007**, 36, 113-120 2

1379 The target hemoglobin level in patients on dialysis. **2007**, 36, 284-286

1378 Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations. **2007**, 1, 14 22

1377 Survival in end stage renal disease: calcium carbonate vs. sevelamer. **2007**, 32, 617-24 26

1376 CHOIR, CREATE, and anemia treatment in patients with CKD. **2007**, 20, 277-9 5

1375 The optimal hemoglobin in dialysis patients- a critical review. **2008**, 21, 1-6 17

1374	Hypertension is harmful to dialysis patients and should be controlled. <b>2007</b> , 20, 518-22	9
1373	Effectiveness of oral and intravenous iron therapy in haemodialysis patients. <b>2008</b> , 62, 416-22	7
1372	Diabetes, kidney disease and anaemia: time to tackle a troublesome triad?. <b>2007</b> , 61, 281-9	15
1371	Modification of cardiovascular risk in hemodialysis patients: an evidence-based review. <b>2007</b> , 11, 1-14	51
1370	Anemia management in chronic kidney disease. <b>2007</b> , 11, 15-20	2
1369	Exceeding hemoglobin target levels in US hemodialysis patients receiving epoetin, 1999 to 2002. <b>2007</b> , 11, 333-9	2
1368	Incidence of symptomatic deep venous thrombosis with epoetin alfa or darbepoetin alfa treatment of anemia in patients with ovarian or primary peritoneal cancer. <b>2007</b> , 105, 414-7	15
1367	Which issues should trials address in hemodialysis?. <b>2007</b> , 11, S44-S47	
1366	Erythropoietin after a century of research: younger than ever. <b>2007</b> , 78, 183-205	292
1365	Anaemia of chronic kidney disease. <b>2007</b> , 35, 457-460	6
1364	EPO adjustments in patients with elevated hemoglobin levels: provider practice patterns compared with recommended practice guidelines. <b>2007</b> , 49, 135-42	27
1363	In the literature: on clinical performance measures and outcomes among hemodialysis patients. <b>2007</b> , 49, 352-5	8
1362	KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. <b>2007</b> , 50, 471-530	545
1361	Dialysis facility ownership and epoetin dosing in hemodialysis patients: a US physician perspective. <b>2007</b> , 50, 354-7	3
1360	Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). <b>2007</b> , 50, 602-11	94
1359	Dialysis facility ownership and epoetin dosing in hemodialysis patients: a dialysis provider's perspective. <b>2007</b> , 50, 366-70	5
1358	Dialysis facility ownership and epoetin dosing in hemodialysis patients: a view from Europe. <b>2007</b> , 50, 358-61	4
1357	Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis: the authors respond. <b>2007</b> , 50, 538-41	1



1356	Imperial or empirical measures of dialysis quality?. <b>2007</b> , 50, 691-5	2
1355	Management of Anemia in Dialysis Patientsâ€”The Whats and Hows. <b>2007</b> , 9, 55-57	
1354	Reduction of the interferences of biochemicals and hematocrit ratio on the determination of whole blood glucose using multiple screen-printed carbon electrode test strips. <b>2007</b> , 389, 1623-31	5
1353	Relation between level or change of hemoglobin and generic and disease-specific quality of life measures in hemodialysis. <b>2007</b> , 16, 755-65	14
1352	Erythropoietin attenuates the development of experimental autoimmune myocarditis. <b>2007</b> , 21, 17-27	14
1351	Therapeutic potential of erythropoietin in cardiovascular disease: erythropoiesis and beyond. <b>2007</b> , 4, 127-33	7
1350	Erythropoietin: physiology and molecular mechanisms. <b>2008</b> , 13, 405-14	32
1349	Iron and anemia in human biology: a review of mechanisms. <b>2008</b> , 13, 393-404	83
1348	Anemia treatment in chronic kidney disease: shifting uncertainty. <b>2008</b> , 13, 425-30	4
1347	[Regarding the optimal hemoglobin target range in renal anemia]. <b>2008</b> , 103, 633-7	1
1346	Eisen- und ESA*-Therapie bei renaler Anämie. <b>2008</b> , 3, 88-95	2
1345	Anemia in children with chronic kidney disease. <b>2008</b> , 23, 209-19	52
1344	Optimal and continuous anaemia control in a cohort of dialysis patients in Switzerland. <b>2008</b> , 9, 16	0
1343	Transplantation of genetically engineered cardiac fibroblasts producing recombinant human erythropoietin to repair the infarcted myocardium. <b>2008</b> , 1, 7	10
1342	Health-related quality of life in the era of erythropoietin. <b>2008</b> , 12, 6-15	30
1341	Correlates affecting survival in chronic hemodialysis patients: the combined impact of albumin and high hemoglobin levels on improving outcomes, local and national results. <b>2008</b> , 12, 450-62	8
1340	Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: methods and data comparison results. <b>2008</b> , 12, 480-91	11
1339	From anemia trials to clinical practice: understanding the risks and benefits when setting goals for therapy. <b>2008</b> , 21, 212-6	10

1338	Thrombosis with erythropoietic stimulating agents--does iron-deficient erythropoiesis play a role?. <b>2008</b> , 21, 210-1	30
1337	The influence of age on changes in health-related quality of life over three years in a cohort undergoing hemodialysis. <b>2008</b> , 56, 1608-17	52
1336	Hematopoietic growth factors--use in normal blood and stem cell donors: clinical and ethical issues. <b>2008</b> , 48, 2008-25	22
1335	The CARI guidelines. Biochemical and haematological targets. Haemoglobin. <b>2008</b> , 13 Suppl 2, S44-56	10
1334	Anaemia in diabetic renal failure: is there a role for early erythropoietin treatment in preventing cardiovascular mortality?. <b>2008</b> , 10, 843-9	5
1333	Developments in the therapeutic use of erythropoiesis stimulating agents. <b>2008</b> , 141, 287-97	44
1332	The non-haematopoietic biological effects of erythropoietin. <b>2008</b> , 141, 14-31	287
1331	Ascorbyl free radical reflects catalytically active iron after intravenous iron saccharate injection. <b>2008</b> , 45, 1302-7	6
1330	Erythropoietin in cardiac disease: new features of an old drug. <b>2008</b> , 585, 270-7	15
1329	Model predictive control of erythropoietin administration in the anemia of ESRD. <b>2008</b> , 51, 71-9	47
1328	Evaluation of dialysis performance measures. <b>2008</b> , 51, 867-8; author reply 868-9	
1327	The evolution of the fractional excretion of urea as a diagnostic tool in oliguric states. <b>2008</b> , 51, 869-70; author reply 871	3
1326	Approaching the end of the homocysteine hype?. <b>2008</b> , 51, 549-53	3
1325	Relative mortality and epoetin alpha dose among hemodialysis patients. <b>2008</b> , 51, 866-7; author reply 867	1
1324	In Reply. <b>2008</b> , 51, 868-869	
1323	In Reply. <b>2008</b> , 51, 867	2
1322	The TREAT study answers a question, not the question. <b>2008</b> , 52, 626-7; author reply 627-8	1
1321	Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. <b>2008</b> , 52, 727-36	110

1320	Normalization of hemoglobin in patients with CKD may cause harm: but what is the mechanism?. <b>2008</b> , 52, 642-4	5
1319	Improving outcomes in hemodialysis patients: the need for well-designed clinical trials. <b>2008</b> , 52, 400-2	4
1318	Temporal trends in red blood transfusion among US dialysis patients, 1992-2005. <b>2008</b> , 52, 1115-21	45
1317	Introduction to "A road map for intravenous iron and anemia management: preparing for the future". <b>2008</b> , 52, S1-4	1
1316	Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron. <b>2008</b> , 52, S21-8	6
1315	The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?. <b>2008</b> , 52, S5-13	14
1314	Racial differences in erythropoietin responsiveness. <b>2008</b> , 52, 1035-8	4
1313	Erythropoietin-stimulating agents: ongoing concerns with safety. <b>2008</b> , 52, 1039-41	2
1312	Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. <b>2008</b> , 74, 782-90	39
1311	CERA: third-generation erythropoiesis-stimulating agent. <b>2008</b> , 9, 839-49	31
1310	Chronic Kidney Disease: Pathophysiology and Influence of Dietary Protein. <b>2008</b> , 2615-2669	
1309	Acute Heart Failure. <b>2008</b> ,	7
1308	Anemia in cystic fibrosis: incidence, mechanisms, and association with pulmonary function and vitamin deficiency. <b>2008</b> , 23, 557-63	33
1307	Sleep and Quality of Life in Clinical Medicine. <b>2008</b> ,	22
1306	Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. <b>2008</b> , 4, 672-81	117
1305	Target Hemoglobin. <b>2008</b> , 845-854	1
1304	The effects of pre- and post-transplant anemia on 1-year survival after cardiac transplantation. <b>2008</b> , 27, 394-9	15
1303	Broken pump or leaky filter? Renal dysfunction in heart failure a contemporary review. <b>2008</b> , 128, 154-65	9

1302	[Hemoglobin targets in anemic patients with chronic kidney disease treated with erythropoietin]. <b>2008</b> , 29, 846-51	1
1301	[Correction of anemia in renal insufficiency: what target?]. <b>2008</b> , 4 Spec No 2, 1-8	
1300	Anemia and chronic heart failure implications and treatment options. <b>2008</b> , 52, 501-11	202
1299	Misconceptions, challenges, uncertainty, and progress in guideline recommendations. <b>2008</b> , 45, 167-75	14
1298	Erythropoietic agents and the elderly. <b>2008</b> , 45, 267-75	12
1297	The erythropoietin receptor in normal and cancer tissues. <b>2008</b> , 67, 39-61	131
1296	Anemia, chronic renal disease and chronic heart failure: the cardiorenal anemia syndrome. <b>2008</b> , 10, 189-196	1
1295	Chronic kidney disease, heart failure and anemia. <b>2008</b> , 24 Suppl B, 22B-4B	15
1294	Chronic kidney disease and its complications. <b>2008</b> , 35, 329-44, vii	205
1293	Traditional and novel approaches to management of heart failure: successes and failures. <b>2008</b> , 26, 59-72, vi	15
1292	Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. <b>2008</b> , 18, 91-8	49
1291	Recognition and treatment of anemia in the setting of heart failure due to systolic left ventricular dysfunction. <b>2008</b> , 6, 199-208	3
1290	Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy. <b>2008</b> , 4, 216-26	148
1289	Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). <b>2008</b> , 74, 1237-40	90
1288	Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). <b>2009</b> , 24, 348-54	133
1287	Randomized trials in hemodialysis patients: time to step up to the plate. <b>2008</b> , 299, 2205-7	5
1286	Anemia of chronic kidney disease. <b>2008</b> , 3, 3-6	9
1285	Hemoglobin level variability: associations with mortality. <b>2008</b> , 3, 133-8	128

1284	History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. <b>2008</b> , 3, 777-82	61
1283	Critiques of clinical guidelines in nephrology: anaemia. <b>2008</b> , 110, c115-25	2
1282	Contemporary trends in the pharmacological and extracorporeal management of heart failure: a nephrologic perspective. <b>2008</b> , 117, 975-83	77
1281	Psychometric evaluation of the National Kidney Dialysis and Kidney Transplantation Study symptom checklist: reliability and validity. <b>2009</b> , 24, 619-25	5
1280	Influence of atherosclerosis on the relationship between anaemia and mortality risk in haemodialysis patients. <b>2008</b> , 23, 2329-36	8
1279	Risk factors for non-fatal myocardial infarction and cardiac death in incident dialysis patients. <b>2009</b> , 24, 258-66	27
1278	Controversies in chronic kidney disease, anaemia and cardiovascular disease. <b>2008</b> , 69, 580-6	1
1277	Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. <b>2008</b> , 74, 265-75	34
1276	Guidelines have done more harm than good. <b>2008</b> , 26, 73-6	18
1275	Insights in anemia management. <b>2008</b> , 161, 240-246	1
1274	Red cell survival in relation to changes in the hematocrit: more important than you think. <b>2008</b> , 26, 355-60	16
1273	Blind Pew sends a black spot: the current haemoglobin controversy. <b>2008</b> , 26, 54-8	
1272	The role of anemia management in improving outcomes for African-Americans with chronic kidney disease. <b>2008</b> , 28, 732-43	20
1271	Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. <b>2008</b> , 4, 47-57	125
1270	Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. <b>2009</b> , 24, 1082-8	54
1269	Darbepoetin alfa for anemia in chronic kidney disease. <b>2008</b> , 1, 369-79	1
1268	Vascular Complications after Kidney Transplantation. <b>2008</b> , 439-461	5
1267	White thrombus formation in blood tubing lines in a chronic hemodialysis unit. <b>2008</b> , 3, 382-6	7

1266	Clinical practice guidelines for evidence-based use of erythropoietic-stimulating agents. <b>2008</b> , S12-8	19
1265	Clinical practice guidelines for supplemental therapies and issues. <b>2008</b> , S19-24	4
1264	Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study. <b>2008</b> , S82-7	15
1263	The role of correction of anaemia in patients with congestive heart failure: a short review. <b>2008</b> , 10, 819-23	38
1262	Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair. <b>2008</b> , 79, 611-20	55
1261	The Role of Correction of Anemia in Patients With Congestive Heart Failure Associated with Chronic Kidney Failure. <b>2008</b> , 21, 420-423	
1260	Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. <b>2008</b> , 10, 22-9	61
1259	Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties. <b>2008</b> , 79, 405-15	43
1258	Recombinant human epoetin beta in the treatment of renal anemia. <b>2008</b> , 5, 91-98	
1257	Left ventricular dysfunction in the haemodialysis population. <b>2008</b> , 1, 199-205	12
1256	Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. <b>2008</b> , 117, 526-35	209
1255	Interpreting results of clinical trials: a conceptual framework. <b>2008</b> , 3, 1246-52	5
1254	Immunogenicity of Biopharmaceuticals. <b>2008</b> ,	6
1253	Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?. <b>2008</b> , 3, 935-7	2
1252	The effect of altitude on dosing and response to erythropoietin in ESRD. <b>2008</b> , 19, 1389-95	49
1251	Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. <b>2008</b> , 19, 372-9	133
1250	Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. <b>2008</b> , 299, 914-24	543
1249	Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. <b>2008</b> , 3, 1077-83	142

1248	Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. <b>2008</b> , 3, 1669-75	26
1247	Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. <b>2008</b> , 74, 791-8	368
1246	The effect of epoetin dose on hematocrit. <b>2008</b> , 73, 347-53	24
1245	The mortality risk associated with higher hemoglobin: is the therapy to blame?. <b>2008</b> , 74, 695-7	13
1244	Anemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease?. <b>2008</b> , 4, 436-45	26
1243	Renal disease: a common and a silent killer. <b>2008</b> , 5 Suppl 1, S27-35	7
1242	The normal hematocrit study--follow-up. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 433-4	59.2 60
1241	Negative trials in nephrology: what can we learn?. <b>2008</b> , 74, 1121-7	20
1240	Managing anemia in dialysis patients: hemoglobin cycling and overshoot. <b>2008</b> , 74, 679-83	24
1239	Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients. <b>2008</b> , 23, 2948-56	11
1238	The (re)challenging question of erythropoiesis-stimulating agents inducing pure red cell aplasia. <b>2008</b> , 23, 3053-5	2
1237	Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?. <b>2008</b> , 23, 2450-3	60
1236	Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response?. <b>2008</b> , 179, 333-7	86
1235	Acquired Platelet Function Defects: An Underestimated but Frequent Cause of Bleeding Complications in Clinical Practice. <b>2008</b> , 296-316	1
1234	Triumph and tragedy: anemia management in chronic kidney disease. <b>2008</b> , 17, 580-8	8
1233	Recent clinical trials of pharmacologic cardiovascular interventions in patients with chronic kidney disease. <b>2008</b> , 3, 79-88	22
1232	Erythropoietin-stimulating agents in oncology. <b>2008</b> , 14, 75-84	3
1231	Erythropoietin protects critically perfused flap tissue. <b>2008</b> , 248, 919-29	32

1230 Anemia in Chronic Renal Disease. **2008**, 761-772

1229 Erworbene Plättchenfunktionsstörungen. **2008**, 28, 299-311

5

1228 Intravenous Iron: Not Just for Hemodialysis Patients Anymore. **2008**, 28, 126-129

5

1227 The Effect of Hemoglobin Level on Arteriovenous Fistula Survival in Iranian Hemodialysis Patients. **2008**, 9, 133-136

4

1226 Use of Erythropoietic-Stimulating Agents in Hemodialysis Patients. **2008**, 771-786

1225 Erythropoietin and Quality of Life in Chronic Kidney Disease. **2008**, 832-844

1224 Latest Strategy in Renal Anemia Management in Peritoneal Dialysis Patients. **2008**, 28, 76-80

5

1223 Associations of anemia persistency with medical expenditures in Medicare ESRD patients on dialysis. **2009**, 5, 319-30

3

1222 Effect of hemodialysis on whole blood viscosity. **2009**, 32, 329-35

19

1221 Molecular basis of cardioprotection by erythropoietin. **2009**, 2, 56-69

48

1220 Low mortality and key aspects of delivery of care for end-stage renal disease in Italy. **2009**, 9, 349-59

2

1219 Cardiovascular disease in patients with chronic kidney disease. **2009**, 5, 713-22

58

1218 Recombinant human epoetin beta in the treatment of chemotherapy-related anemia. **2009**, 5, 261-70

4

1217 Erythropoietin, Anemia and Kidney Disease. **2009**, 49-60

2

1216 Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms. **2009**, 27, 4217-26

43

1215 Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. **2009**, 20, 2651-60

90

1214 Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease. **2009**, 8, 145-53

4

1213 Update on anemia management in nephrology, including current guidelines on the use of erythropoiesis-stimulating agents and implications of the introduction of "biosimilars". **2009**, 14 Suppl 1, 16-21

13



1212	Cardiovascular risk and management in chronic kidney disease. <b>2009</b> , 5, 287-96	49
1211	Managing Anemia of Chronic Kidney Disease. <b>2009</b> , 3, 135-146	
1210	Prevalence of anemia in heart failure and its effects on prognosis. <b>2009</b> , 7, 131-8	5
1209	2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. <b>2009</b> , 119, e391-479	1178
1208	Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients. <b>2009</b> , 2, i3-i8	1
1207	Erythropoietins, Erythropoietic Factors, and Erythropoiesis. <b>2009</b> ,	10
1206	Treating anemia with erythropoiesis-stimulating agents: effects on quality of life. <b>2009</b> , 169, 1100-1	2
1205	Health-related quality of life and hemoglobin levels in chronic kidney disease patients. <b>2009</b> , 4, 33-8	100
1204	Impact of anemia on aortic pulse wave velocity in hemodialysis patients. <b>2009</b> , 32, 210-6	5
1203	Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. <b>2009</b> , 4, 755-62	82
1202	Correction towards normal hemoglobin values in chronic kidney disease: what is the current evidence regarding mortality and morbidity outcomes?. <b>2009</b> , 32, 1-10	
1201	The randomized controlled trial. <b>2009</b> , 113, c337-42	12
1200	The anemia of heart failure. <b>2009</b> , 122, 109-19	20
1199	Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. <b>2009</b> , 14 Suppl 1, 22-33	196
1198	Hemoglobin variability in anemia of chronic kidney disease. <b>2009</b> , 20, 479-87	289
1197	Optimizing anemia management in hospitalized patients with end-stage renal disease. <b>2009</b> , 43, 276-82	3
1196	Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL. <b>2009</b> , 4, 630-7	39
1195	Cardiac disease in the dialysis patient: good, better, best clinical practice. <b>2009</b> , 27, 99-113	9

1194	Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients. <b>2009</b> , 24, 1956-62	11
1193	Comparison of methodologies to characterize haemoglobin variability in the US Medicare haemodialysis population. <b>2009</b> , 24, 1378-83	14
1192	Dialysis: Phosphorus binders and survival: need for randomized trials. <b>2009</b> , 5, 368-70	1
1191	Anemia in heart failure: pathophysiologic insights and treatment options. <b>2009</b> , 5, 71-81	5
1190	Erythropoiesis-stimulating agent treatment with full anemia correction: a new perspective. <b>2009</b> , 75, 358-65	8
1189	Iron deficiency in non-dialysis chronic kidney disease. <b>2009</b> , 75, 752-4	3
1188	Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease. <b>2009</b> , 75, 1316-1321	27
1187	Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data. <b>2009</b> , CD007303	75
1186	Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older. <b>2009</b> , 24, 3138-43	14
1185	The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. <b>2009</b> , 11, 1071-7	22
1184	Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro. <b>2009</b> , 20, 1436-41	19
1183	Posttransplant anemia: the role of sirolimus. <b>2009</b> , 76, 376-82	20
1182	Key insights into present and future treatments of anaemia in CKD patients. <b>2009</b> , 2, i1-i2	3
1181	The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis. <b>2009</b> , 169, 1104-12	64
1180	Development of Recombinant Erythropoietin and Erythropoietin Analogs. <b>2009</b> , 35-48	
1179	Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. <b>2009</b> , 11, 795-801	88
1178	Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks. <b>2009</b> , 14 Suppl 1, 57-62	9
1177	Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). <b>2009</b> , 4, 470-80	126

1176	Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients. <b>2009</b> , 4, 623-9	8
1175	Is lipid control necessary in hemodialysis patients?. <b>2009</b> , 4 Suppl 1, S95-101	19
1174	Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. <b>2009</b> , 4, 638-44	40
1173	Key comorbid conditions that are predictive of survival among hemodialysis patients. <b>2009</b> , 4, 1818-26	54
1172	Erythropoiesis-stimulating agents: creation and validation of a computerized prescriber order entry alert. <b>2009</b> , 43, 1143-4	1
1171	Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. <b>2009</b> , 4, 726-33	50
1170	Meeting new challenges in the management of anemia of chronic kidney disease through collaborative care with pharmacists. <b>2009</b> , 43, 1857-66	0
1169	Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials. <b>2009</b> , 39, 123-31	39
1168	Intracardiac injection of erythropoietin induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model. <b>2009</b> , 13, 664-79	55
1167	Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access. <b>2009</b> , 53, 79-90	101
1166	Randomized and observational studies in nephrology: how strong is the evidence?. <b>2009</b> , 53, 377-88	27
1165	Thrombocytosis in EPO-treated dialysis patients may be mediated by EPO rather than iron deficiency. <b>2009</b> , 53, 733-6	20
1164	Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. <b>2009</b> , 53, 823-34	126
1163	Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <b>2009</b> , 54, 59-69	48
1162	Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization. <b>2009</b> , 54, 498-510	27
1161	Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations. <b>2009</b> , 54, 554-60	23
1160	The D&T report. <b>2009</b> , 38, 484-487	
1159	Estimating cerebral blood volume with expanded vascular space occupancy slice coverage. <b>2009</b> , 61, 1193-200	13

1158	The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions. <b>2009</b> , 13, 101-106	26
1157	Olmesartan clinical trial in Okinawan patients under OKIDS (OCTOPUS) study: design and methods. <b>2009</b> , 13, 145-151	12
1156	Hemoglobin target in chronic kidney disease: a pediatric perspective. <b>2009</b> , 24, 431-4	12
1155	Target hemoglobin trials in chronic kidney disease: design and interpretation issues. <b>2009</b> , 24, 2279-85	2
1154	Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS). <b>2009</b> , 28, 489-95	23
1153	Perioperative management of acute and chronic anemia: has the pendulum swung too far?. <b>2009</b> , 56, 183-9	4
1152	Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. <b>2009</b> , 18, 932-40	23
1151	Anaemia management with subcutaneous epoetin delta in patients with chronic kidney disease (predialysis, haemodialysis, peritoneal dialysis): results of an open-label, 1-year study. <b>2009</b> , 10, 5	5
1150	The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. <b>2009</b> , 10, 6	19
1149	Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. <b>2009</b> , 2, 2	349
1148	Biological functions and therapeutic use of erythropoiesis-stimulating agents: perplexities and perspectives. <b>2009</b> , 146, 127-41	14
1147	Low testosterone and anaemia in men with type 2 diabetes. <b>2009</b> , 70, 547-53	47
1146	Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events. <b>2009</b> , 101, 1961-71	41
1145	Hemodialysis vascular access monitoring: current concepts. <b>2009</b> , 13, 153-62	61
1144	Management of mineral and bone disorder in chronic kidney disease: quo vadis?. <b>2009</b> , 13 Suppl 1, S2-6	4
1143	To treat or not to treat renal anemia of chronic kidney disease patients?. <b>2010</b> , 14, 235-9	
1142	Potential for erythropoietin synthesis in kidney of uraemic rat alters depending on severity of renal failure. <b>2009</b> , 14, 735-42	7
1141	Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease. <b>2009</b> , 14, 408-15	26

1140	Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents?. <b>2010</b> , 50, 719-32	29
1139	Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence. <b>2009</b> , 22, 64-9	8
1138	Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer. <b>2009</b> , 22, 1-4	13
1137	Managing anemia in for-profit dialysis chains: when ethics and business conflict. <b>2009</b> , 22, 18-21	5
1136	The normal hematocrit cardiac trial revisited. <b>2009</b> , 22, 495-502	12
1135	Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. <b>2009</b> , 22, 636-43	90
1134	The inhibition of postinfarct ventricle remodeling without polycythaemia following local sustained intramyocardial delivery of erythropoietin within a supramolecular hydrogel. <b>2009</b> , 30, 4161-7	58
1133	Cardiovascular risk factors in patients with chronic kidney disease. <b>2009</b> , 6, 580-9	54
1132	Creating research infrastructure and functionality to address chronic kidney disease: the Kidney Research Institute. <b>2009</b> , 29, 457-66	1
1131	Anemia: the point of convergence or divergence for kidney disease and heart failure?. <b>2009</b> , 53, 639-47	84
1130	The scope of coronary heart disease in patients with chronic kidney disease. <b>2009</b> , 53, 2129-40	166
1129	Coagulation in Cancer. <b>2009</b> ,	4
1128	Why is protein-energy wasting associated with mortality in chronic kidney disease?. <b>2009</b> , 29, 3-14	146
1127	Assessing the quality of prescribing and monitoring erythropoiesis-stimulating agents in the nursing home setting. <b>2009</b> , 10, 436-9	1
1126	Association between repeat hospitalization and early intervention in dialysis patients following hospital discharge. <b>2009</b> , 76, 331-41	59
1125	Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. <b>2009</b> , 75, 15-24	100
1124	Cardiovascular effects of home intensive hemodialysis. <b>2009</b> , 16, 173-8	13
1123	Erythropoietic stress and anemia in diabetes mellitus. <b>2009</b> , 5, 204-10	63

1122	[Hemoglobin rate and cardiovascular risk]. <b>2009</b> , 5, 10-4	0
1121	Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. <b>2009</b> , 373, 1532-42	467
1120	Clinical relevance of FGF-23 in chronic kidney disease. <b>2009</b> , S34-42	71
1119	2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. <b>2009</b> , 53, e1-e90	1224
1118	Is normalising haemoglobin in patients with CKD harmful and if so, why?. <b>2009</b> , 35 Suppl 2, 25-8	2
1117	Haemoglobin fluctuations in patients on haemodialysis treated with ESAs: clinical observations from two centres. <b>2009</b> , 25, 2971-6	6
1116	Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?. <b>2009</b> , 16, 143-51	38
1115	Acute kidney injury in the intensive care unit. <b>2009</b> , 30, 29-43, vii-viii	9
1114	What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway?. <b>2009</b> , 16, 131-42	25
1113	Past, present, and future of chronic kidney disease anemia management in the United States. <b>2009</b> , 16, 101-8	12
1112	Anemia in chronic kidney disease: status of new therapies. <b>2009</b> , 18, 112-5	5
1111	Anemia and heart failure. <b>2009</b> , 24, 172-8	37
1110	Lessons from TREAT: Lower Hemoglobin Target, Avoid ESA if Possible. <b>2009</b> , 2, 6-7	2
1109	Hemoglobin variability in chronic kidney disease: a cross-sectional study. <b>2009</b> , 337, 340-3	4
1108	Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study. <b>2009</b> , 339, b4018	64
1107	Anemia after intensive care unit stay: more questions than answers. <b>2009</b> , 37, 2108-9	0
1106	Do resource utilization and clinical measures still vary across dialysis chains after controlling for the local practices of facilities and physicians?. <b>2010</b> , 48, 726-32	9
1105	Erythropoiesis stimulating agents and anaemia of end-stage renal disease. <b>2010</b> , 8, 164-72	10

1104	Adverse Safety Events in Chronic Kidney Disease: The Frequency of “Multiple Hits”	2010, 2010, 242-243	
1103	A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease.	2010, 2010, 240-242	0
1102	Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?.	2010, 19, 567-72	9
1101	What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?.	2010, 19, 420-4	50
1100	Reducing ESA Dose: We Can, and We Should.	2010, 3, 2	
1099	Treatment of anemia in heart failure: potential risks and benefits of intravenous iron therapy in cardiovascular disease.	2010, 18, 240-50	10
1098	Cardiorenal syndrome and heart failure.	2010, 25, 141-7	7
1097	ACP Journal Club. Review: Erythropoiesis-stimulating agents targeted to higher hemoglobin levels increase risk for adverse outcomes in CKD.	2010, 153, JC5-3	
1096	ACP Journal Club. Darbepoetin decreased transfusions and fatigue, but increased adverse effects in patients with chronic kidney disease, diabetes, and anemia.	2010, 152, JC3-9	1
1095	Management of chronic kidney disease: what is the evidence?.	2010, 103, 222-30	2
1094	Anemia management in chronic kidney disease: bursting the hemoglobin bubble.	2010, 153, 53-5	6
1093	Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.	2010, 153, 23-33	222
1092	Journal Club.	2010, 77, 839-840	
1091	[The role of platelets in atherosclerosis, diabetes mellitus, and chronic kidney disease. An attempt at explaining the TREAT study results].	2010, 105, 339-44	8
1090	Hemoglobin and hematocrit at the end of hemodialysis: a better way to adjust erythropoietin dose?.	2010, 13, 63-6	3
1089	Mitigating the cardiovascular risk of anemia in patients with type 2 diabetes and CKD: Does darbepoetin help? The TREAT Trial.	2010, 10, 87-9	
1088	Diabetes, anemia and CKD: Why TREAT?.	2010, 10, 291-6	8
1087	Iron in heart failure: friend or foe?.	2010, 7, 49-51	1

1086	Cardiovascular risks of anemia correction with erythrocyte stimulating agents: should blood viscosity be monitored for risk assessment?. <b>2010</b> , 24, 151-60	45
1085	Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008. <b>2010</b> , 55, 113-20	15
1084	Quality of life in CKD patients treated with erythropoiesis-stimulating agents. <b>2010</b> , 55, 423-5	11
1083	Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. <b>2010</b> , 55, 726-41	163
1082	TREAT: Implications for guideline updates and clinical care. <b>2010</b> , 55, 984-7	2
1081	An economic evaluation of erythropoiesis-stimulating agents in CKD. <b>2010</b> , 56, 1050-61	26
1080	Impact of pain and symptom burden on the health-related quality of life of hemodialysis patients. <b>2010</b> , 39, 477-85	180
1079	Erythropoietin suppresses epithelial to mesenchymal transition and intercepts Smad signal transduction through a MEK-dependent mechanism in pig kidney (LLC-PK1) cell lines. <b>2010</b> , 316, 1109-18	15
1078	Treatment of anemia with darbepoetin alfa in heart failure. <b>2010</b> , 16, 87-95	4
1077	Biosimilar epoetins and other "follow-on" biologics: update on the European experiences. <b>2010</b> , 85, 771-80	70
1076	Anemia in renal disease: diagnosis and management. <b>2010</b> , 24, 39-47	65
1075	Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol. <b>2010</b> , 11, 70	15
1074	Cardiovascular complications in diabetic kidney disease. <b>2010</b> , 23, 169-77	13
1073	Management of the diabetic patient with advanced chronic kidney disease. <b>2010</b> , 23, 140-7	14
1072	Confusion about the appropriate use of erythropoiesis-stimulating agents in patients undergoing maintenance dialysis. <b>2010</b> , 23, 486-91	2
1071	2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. <b>2010</b> , 14, 240-75	170
1070	Whole-blood viscosity increases significantly in small arteries and capillaries in hemodiafiltration. Does acute hemorheological change trigger cardiovascular risk events in hemodialysis patient?. <b>2010</b> , 14, 433-40	10
1069	Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents. <b>2010</b> , 31, 929-37	29



1068	Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. <b>2010</b> , 268, 456-67	229
1067	Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. <b>2010</b> , 102, 301-15	184
1066	How to read a nephrology systematic review. <b>2010</b> , 15, 158-64	4
1065	Come è cambiata la gestione dell'anemia per i pazienti in dialisi alla luce dello studio DOPPS. <b>2010</b> , 22, 27-33	1
1064	Erythropoiesis-stimulating agents in older adults with cancer. 338-350	
1063	Anemia in Chronic Kidney Disease. <b>2010</b> , 87-97	1
1062	Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease. <b>2010</b> , 5, e9246	37
1061	Anemia e resistenza all'eritropoietina nel paziente uremico in dialisi. <b>2010</b> , 22, 25-29	
1060	Managing anemia in patients with chronic heart failure: what do we know?. <b>2010</b> , 6, 237-52	9
1059	Rebuttal: CON Position. Should Hemoglobin Targets for Anemic Patients with Chronic Kidney Disease Be Changed. <b>2010</b> , 31, 563-564	
1058	ESAs in dialysis patients: are you a hedgehog or a fox?. <b>2010</b> , 21, 543-6	12
1057	2009: a requiem for rHuEPOs--but should we nail down the coffin in 2010?. <b>2010</b> , 5, 929-35	22
1056	It's time to compare anemia management strategies in hemodialysis. <b>2010</b> , 5, 740-2	12
1055	Hemoglobin variability does not predict mortality in European hemodialysis patients. <b>2010</b> , 21, 1765-75	262
1054	Nadir hemoglobin levels after discontinuation of epoetin in hemodialysis patients. <b>2010</b> , 5, 1621-7	2
1053	Determining optimum hemoglobin sampling for anemia management from every-treatment data. <b>2010</b> , 5, 1939-45	16
1052	Erythropoietic response and outcomes in kidney disease and type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 1146-55	59.2 344
1051	Prevalence of anemia and its impact on mortality and hospitalization rate in predialysis patients. <b>2010</b> , 115, c133-41	22

1050	Advancements in anemias related to chronic conditions. <b>2010</b> , 48, 1217-26	25
1049	Survival benefits with vitamin D receptor activation: new insights since 2003. <b>2010</b> , 5, 1704-9	13
1048	Antiviral therapy in HCV-infected decompensated cirrhotics. <b>2010</b> , 16, 310-4	6
1047	Hemoglobin Cycling in Hemodialysis Patients. <b>2010</b> , 2, 1-5	3
1046	Cardiovascular Disease in Chronic Kidney Disease. <b>2010</b> , 935-950	4
1045	Anemia in Chronic Kidney Disease. <b>2010</b> , 951-958	2
1044	Pharmacotherapy of end-stage renal disease. <b>2010</b> , 11, 597-613	9
1043	Chronic kidney disease: Are elevated doses of ESAs associated with adverse outcomes?. <b>2010</b> , 6, 566-8	2
1042	Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate. <b>2010</b> , 5, 1340-6	14
1041	Comparative mortality risk of anemia management practices in incident hemodialysis patients. <b>2010</b> , 303, 857-64	78
1040	The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. <b>2010</b> , 5, 553-6	11
1039	Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study. <b>2010</b> , 25, 2702-10	23
1038	Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury. <b>2010</b> , 299, F426-35	38
1037	Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. <b>2010</b> , 28, 2239-45	45
1036	Individualizing anaemia therapy. <b>2010</b> , 3, 519-26	
1035	Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA). <b>2010</b> , 25, 1734-7	13
1034	Sex-specific association of time-varying haemoglobin values with mortality in incident dialysis patients. <b>2010</b> , 25, 2715-22	8
1033	Message to the FDA on ESAs: REMS is not enough, more studies are needed. <b>2010</b> , 5, 1355-8	3

1032	Debate: PRO Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?. <b>2010</b> , 31, 552-6; discussion 563-4	2
1031	Debate: CON Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?. <b>2010</b> , 31, 557-60; discussion 561-2	6
1030	Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. <b>2010</b> , CD007613	36
1029	Reevaluating erythropoiesis-stimulating agents. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 1742; author reply 1743-4	59.2 4
1028	Anemia: What can we learn from a secondary analysis of CHOIR?. <b>2010</b> , 6, 251-2	2
1027	Anemia: To TREAT or not to TREAT--that is the question. <b>2010</b> , 6, 254-5	
1026	Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure. <b>2010</b> , 77, 175-7	2
1025	Anemia trials: lessons for clinicians, politicians, and third-party payers. <b>2010</b> , 77, 479-80	3
1024	Thrombotic complications of erythropoiesis-stimulating agents. <b>2010</b> , 36, 537-49	75
1023	Management der renalen Anämie - Epoetine und Eisen. <b>2010</b> , 14, s20-s23	
1022	A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. <b>2010</b> , 77, 239-46	48
1021	Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. <b>2010</b> , 78, 769-73	55
1020	Vitamin D deficiency and anemia in early chronic kidney disease. <b>2010</b> , 77, 715-20	88
1019	Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients. <b>2010</b> , 25, 3701-6	29
1018	Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial. <b>2010</b> , 25, 4002-9	241
1017	Pathophysiology of anemia in heart failure. <b>2010</b> , 6, 279-88	35
1016	Future directions in management of anemia in heart failure. <b>2010</b> , 6, 385-95	5
1015	Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes. <b>2010</b> , 6, 323-32	3

1014	Anemia in chronic kidney disease: new advances. <b>2010</b> , 6, 347-57		13
1013	Iron supplementation to treat anemia in patients with chronic kidney disease. <b>2010</b> , 6, 699-710		93
1012	Hemodialysis vascular access training and practices are key to improved access outcomes. <b>2010</b> , 56, 1032-42		63
1011	Anemia management in chronic kidney disease. <b>2010</b> , S3-9		17
1010	Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma!. <b>2010</b> , 19, 1179-86		14
1009	Erythropoietin and iron therapy in patients with renal failure. <b>2010</b> , 11, 20-29		
1008	Erythropoietic stimulating agents. <b>2010</b> , 15, 119-38		13
1007	[Update on the management of anemia. Nephrology World Congress 2009]. <b>2010</b> , 6, 1-9		
1006	Noninvasive evaluation of large artery function and structure in dialysis patients: Clinical applications. <b>2010</b> , 4, 138		
1005	Erythropoiesis-stimulating agents--time for a reevaluation. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 189-92	59.2	194
1004	Hemodialysis. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 1833-45	59.2	187
1003	Bench to bedside: A role for erythropoietin in sepsis. <b>2010</b> , 14, 227		17
1002	Cardiovascular risk factors and prevention of cardiovascular disease in patients with chronic renal disease. <b>2010</b> , 11, 2687-98		19
1001	Simplifying anemia management in hemodialysis patients: ESAs administered at longer dosing intervals can enhance opportunities to provide patient-focused care. <b>2011</b> , 27, 1539-50		2
1000	Clinical Aspects and Laboratory Iron Metabolism, Anemias. <b>2011</b> ,		0
999	Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. <b>2011</b> , 124, 2903-8		68
998	Hemodialysis in children with end-stage renal disease. <b>2011</b> , 7, 650-8		24
997	IL-1 receptor antagonist reduces inflammation in hemodialysis patients. <b>2011</b> , 22, 437-42		81

- 996 Hematopoietic Growth Factors in Oncology. **2011**, 5
- 995 Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. **2011**, 106, 13-22 334
- 994 HIF prolyl hydroxylase inhibitors for anemia. **2011**, 20, 645-56 61
- 993 [TREAT or not to treat: anemia in type 2 diabetes and chronic kidney disease at stages 3 and 4]. **2011**, 7, 2-9 6
- 992 Subjective Well-Being Measures of Hemodialysis Patients. **2011**,
- 991 Journal Club. **2011**, 80, 229-230
- 990 Correlation of mortality and location of arteriovenous fistula in hemodialysis patients. **2011**, 34, 26-33 7
- 989 Anemia of Chronic Kidney Disease in Diabetic Patients: Pathophysiologic Insights and Implications of Recent Clinical Trials. **2011**,
- 988 Treatment of anemia in chronic kidney disease: known, unknown, and both. **2011**, 2, 103-12 2
- 987 Hemorheology and microvascular disorders. **2011**, 41, 287-95 68
- 986 Anaemia management—the key influences for modern treatment. **2011**, 3, 20-23
- 985 Erythropoietic therapy: time for some changes. **2011**, 3, 6-9
- 984 Doenç renal crônica: importância do diagnóstico precoce, encaminhamento imediato e abordagem interdisciplinar estruturada para melhora do desfecho em pacientes ainda não submetidos à diálise. **2011**, 33, 93-108 59
- 983 Journal Club. **2011**, 79, 929-930
- 982 Medications to reduce cardiovascular risk after kidney transplantation. **2011**, 91, 492-3
- 981 Nitric oxide transport in blood: a third gas in the respiratory cycle. **2011**, 1, 541-68 53
- 980 Critical appraisal of randomized controlled trials of anemia correction in patients with renal failure. **2011**, 20, 177-81 19
- 979 Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient. **2011**, 20, 465-70 5

978	Intravenous iron therapy: how far have we come?. <b>2011</b> , 33, 461-9	54
977	Blood transfusions in kidney transplant candidates are common and associated with adverse outcomes. <b>2011</b> , 25, 653-9	19
976	Transfusion: is merely not bad good enough?. <b>2011</b> , 55, 907-9	2
975	Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD?. <b>2011</b> , 16, 144-53	8
974	Understanding cardiac biomarkers in end-stage kidney disease: Frequently asked questions and the promise of clinical application. <b>2011</b> , 16, 251-60	12
973	How KDIGO will (or will not) influence the management of hyperphosphatemia. <b>2011</b> , 24, 35-6	1
972	Is it safe to use erythropoiesis-stimulating agents to treat anemia in chronic kidney disease patients with active malignancies?. <b>2011</b> , 24, 379-81	
971	Erythropoietin-stimulating agents in chronic kidney disease: a response to hyporesponsiveness. <b>2011</b> , 24, 495-7	1
970	Conditionally funded field evaluations--a solution to the economic barriers limiting evidence generation in dialysis?. <b>2011</b> , 24, 556-9	3
969	Anemia and iron management. <b>2011</b> , 24, 498-503	5
968	Implications of the Frequent Hemodialysis Network-Daily Trial. <b>2011</b> , 24, 621-8	3
967	Strategies and outcomes of cardiac surgery in Jehovah's Witnesses. <b>2011</b> , 26, 135-43	18
966	Dialysis patients treated with Epoetin β how improved exercise tolerance and physical function: A new analysis of the Canadian Erythropoietin Study Group trial. <b>2011</b> , 15, 87-94	8
965	Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. <b>2011</b> , 15, 431-40	34
964	Anaemia and chronic renal failure. <b>2011</b> , 39, 425-428	3
963	Hemoglobin variability as a predictor of mortality: What's a practitioner to do?. <b>2011</b> , 57, 190-3	5
962	Treatment of heart failure in long-term dialysis patients: a reappraisal. <b>2011</b> , 57, 760-72	11
961	Relationship of erythropoiesis-stimulating agent dose and responsiveness and adverse outcomes in CKD. <b>2011</b> , 57, 661-3	3

960	A proposal for improving evidence generation in nephrology. <b>2011</b> , 58, 13-8	6
959	Characteristics and outcomes among heart failure patients with anemia and renal insufficiency with and without blood transfusions (public discharge data from California 2000-2006). <b>2011</b> , 107, 69-73	15
958	Anaemia and heart failure. <b>2011</b> , 6, 11-25	
957	Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose. <b>2011</b> , 24, 603-13	38
956	Complete correction of anemia by erythropoiesis-stimulating agents is associated with insulin resistance in hemodialysis patients. <b>2011</b> , 11, 181-7	3
955	Extended dosing of darbepoetin alfa in peritoneal dialysis patients. <b>2011</b> , 12, 13	7
954	Macrocytosis may be associated with mortality in chronic hemodialysis patients: a prospective study. <b>2011</b> , 12, 19	20
953	Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysis. <b>2011</b> , 12, 22	3
952	Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors. <b>2011</b> , 12, 67	24
951	Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. <b>2011</b> , 117, 982-91	11
950	Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia. <b>2011</b> , 117, 3268-75	6
949	The association of red blood cell parameters with mortality in a population of hemodialysis patients. <b>2011</b> , 40, 72-77	2
948	ESA treatment in dialysis patients: Where do we go now?. <b>2011</b> , 40, 387-389	1
947	Epoetin bubble: a severe German case <i>Honi soit qui mal y pense</i> . <b>2011</b> , 26, 1750-2; author reply 1752	
946	Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. <b>2011</b> , 79, 340-6	37
945	Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009. <b>2011</b> , 26, 1583-91	21
944	Extraordinary popular delusions and the madness of crowds: puncturing the epoetin bubble--lessons for the future. <b>2011</b> , 26, 24-8	6
943	Erythropoietic response to erythropoiesis-stimulating agents and outcome: should we give up the haemoglobin target approach?. <b>2011</b> , 26, 2069-71	8

942	[Diagnosis and treatment of iron deficiency and anaemia in inflammatory bowel diseases. Consensus of the Austrian IBD Working Party]. <b>2011</b> , 49, 627-32	13
941	Bundled payment for ESRD—including ESAs in Medicare’s dialysis package. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 593-5	59.2 25
940	Erythropoiesis-stimulating agents in renal medicine. <b>2011</b> , 16 Suppl 3, 19-24	22
939	Prevention of vascular calcification: is pyrophosphate therapy a solution?. <b>2011</b> , 79, 490-3	15
938	Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. <b>2011</b> , 29, 3791-7	33
937	Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. <b>2011</b> , 305, 1119-27	465
936	Early outcomes among those initiating chronic dialysis in the United States. <b>2011</b> , 6, 2642-9	89
935	The future of intravenous iron in nephrology. <b>2011</b> , 4, i6-i9	
934	An update on the controversies in anemia management in chronic kidney disease: lessons learned and lost. <b>2011</b> , 2011, 623673	10
933	ERYTHROPOIETIN IN MYOCARDIAL INFARCTION: EXPERIMENTAL EVIDENCE AND CLINICAL STUDIES. <b>2011</b> , I,	1
932	Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials. <b>2011</b> , 2, 265-78	19
931	Cancer chemoprevention—the cardiovascular model. <b>2011</b> , 4, 307-10	5
930	Renal Association Clinical Practice Guideline on anaemia of chronic kidney disease. <b>2011</b> , 118 Suppl 1, c101-24	4
929	Efficacy of hemopoietic-stimulating factors in patients undergoing chronic hemodialysis. <b>2011</b> , 33, 923-8	1
928	Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. <b>2011</b> , 22, 358-65	45
927	Chronic kidney disease: Association between ESA use and stroke in patients with CKD. <b>2011</b> , 7, 365-6	2
926	Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. <b>2011</b> , 305, 1863-72	172
925	Flow-mediated vasodilation in end-stage renal disease. <b>2011</b> , 6, 2009-15	44



924	The effect of altitude change on anemia treatment response in hemodialysis patients. <b>2011</b> , 173, 768-77	10
923	Mortality risk in dialysis patients with naturally higher hemoglobins. <b>2011</b> , 22, 205-6	2
922	UK Renal Registry 13th Annual Report (December 2010): Chapter 12: clinical, haematological and biochemical parameters in patients receiving renal replacement therapy in paediatric centres in the UK in 2009: national and centre-specific analyses. <b>2011</b> , 119 Suppl 2, c225-37	1
921	Exploring the Relationships between Hemoglobin, the Endothelium and Vascular Health in Patients with Chronic Kidney Disease. <b>2011</b> , 1, 190-200	1
920	Implications of a reduction in the hemoglobin target in erythropoiesis-stimulating agent-treated hemodialysis patients. <b>2011</b> , 1, 212-6	0
919	Anemia trials in CKD and clinical practice: refining the approach to erythropoiesis-stimulating agents. <b>2011</b> , 171, 248-254	3
918	Correction of anaemia on dialysis: did we forget physiology?. <b>2011</b> , 26, 1120-2	4
917	What caused excess strokes in patients randomized to darbepoetin in the trial to reduce cardiovascular events with Aranesp therapy (TREAT)?: no smoking gun. <b>2011</b> , 124, 2805-8	5
916	Erythropoietin as a cardioprotective agent: down but not out. <b>2011</b> , 97, 1537-9	7
915	Choice of dialysis modality. <b>2011</b> , 80, 909-911	9
914	High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. <b>2011</b> , 80, 663-9	33
913	Is there a deleterious effect of erythropoietin in end-stage renal disease?. <b>2011</b> , 80, 569-71	11
912	Candidate biomarkers for erythropoietin response in end-stage renal disease. <b>2011</b> , 79, 488-90	7
911	Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients. <b>2011</b> , 80, 992-999	8
910	Iron treatment and the TREAT trial. <b>2011</b> , 4, i3-i5	3
909	Cardiovascular indications and complications of recombinant human erythropoietin. <b>2011</b> , 2, 43	
908	Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients. <b>2011</b> , 34, 298-308	15
907	[Influence of hemoglobin level and dose of administered recombinant human beta erythropoietin on survival of hemodialysis patients]. <b>2011</b> , 68, 749-55	0

906	Cardiac antiapoptotic and proproliferative effect of recombinant human erythropoietin in a moderate stage of chronic renal failure in the rat. <b>2012</b> , 4, 76-83	15
905	Physical activity in ESRD: time to get moving. <b>2012</b> , 7, 1927-9	2
904	The COPD Pipeline XVII. <b>2012</b> , 9, 432-4	1
903	Predictors of quality of life of hemodialysis patients in India. <b>2012</b> , 22, 18-25	12
902	The effect of high-flux hemodialysis on hemoglobin concentrations in patients with CKD: results of the MINOXIS study. <b>2012</b> , 7, 52-9	16
901	FGF-23: the rise of a novel cardiovascular risk marker in CKD. <b>2012</b> , 27, 3072-81	49
900	Clinical practice guidelines: an important tool in improving dialysis quality. <b>2012</b> , 178, 58-67	
899	Anemia management in patients on peritoneal dialysis. <b>2012</b> , 178, 89-94	3
898	A physician's perseverance uncovers problems in a key nephrology study. <b>2012</b> , 82, 135-7	6
897	New strategies for managing anemia of chronic kidney disease. <b>2012</b> , 10, 339-51	1
896	A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). <b>2012</b> , 38, 783-96	30
895	The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. <b>2012</b> , 82, 235-41	65
894	Hemoglobin variability with epoetin beta and continuous erythropoietin receptor activator in patients on peritoneal dialysis. <b>2012</b> , 32, 177-82	16
893	Ischemic heart disease in patients undergoing dialysis. <b>2012</b> , 40, 33-9	2
892	Safety of erythropoiesis-stimulating agents in patients with end-stage kidney disease: data are safer than extrapolations. <b>2012</b> , 11, 885-7	2
891	The normal HCT trial re-revisited: what were the actual findings?. <b>2012</b> , 82, 242; author reply 242-3	1
890	Anaemia: Does the KDIGO guideline move the needle in CKD anaemia?. <b>2012</b> , 8, 616-8	4
889	References. <b>2012</b> , 2, 331-335	7

888	Changes to the end-stage renal disease quality incentive program. <b>2012</b> , 81, 1167-71		13
887	Pretreatment with erythropoietin attenuates the neurological injury after spinal cord ischemia. <b>2012</b> , 50, 208-12		8
886	The Author Replies. <b>2012</b> , 82, 242-243		
885	Survival in daily home hemodialysis and matched thrice-weekly in-center hemodialysis patients. <b>2012</b> , 23, 895-904		151
884	Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 2482-94	59.2	655
883	Critical and honest conversations: the evidence behind the "Choosing Wisely" campaign recommendations by the American Society of Nephrology. <b>2012</b> , 7, 1664-72		125
882	The new FDA labeling for ESA--implications for patients and providers. <b>2012</b> , 7, 348-53		30
881	Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients. <b>2012</b> , 27, 2418-25		58
880	Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment. <b>2012</b> , 7, 354-7		31
879	Chapter 11 Clinical, haematological and biochemical parameters in patients receiving renal replacement therapy in paediatric centres in the UK in 2010: national and centre-specific analyses. <b>2012</b> , 120 Suppl 1, c219-32		3
878	Modulation of platelet activation in chronic kidney disease patients on erythropoiesis-stimulating agents. <b>2012</b> , 18, 453-61		5
877	Poor compliance with guidelines on anemia treatment in a cohort of chronic hemodialysis patients. <b>2012</b> , 34, 19-27		6
876	Lack of adequate predialysis care and previous hemodialysis, but not hemoglobin variability, are independent predictors of anemia-associated mortality in incident Brazilian peritoneal dialysis patients: results from the BRAZPD study. <b>2012</b> , 34, 298-305		3
875	Erythropoietin in brain development and beyond. <b>2012</b> , 2012, 953264		33
874	Factors predicting erythropoietin resistance among maintenance hemodialysis patients. <b>2012</b> , 33, 238-44		36
873	Anemia in chronic kidney disease. <b>2012</b> , 142-147		
872	Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR. <b>2012</b> , 27, 3606-14		22
871	Sleep and pain management are key components of patient care in ESRD. <b>2012</b> , 27, 2618-20		5

870	Total dose iron dextran infusion in cancer patients: is it SaFe2+?. <b>2012</b> , 10, 669-76	9
869	Anemia and chronic kidney disease: making sense of the recent trials. <b>2012</b> , 7, 187-96	13
868	Conséquences cardiaques de l'insuffisance rénale chronique. <b>2012</b> , 9, 1-14	
867	Bidirectional Nature of Cardiovascular and Kidney Disease. <b>2012</b> , 12, 168-182	
866	Changes in whole blood viscosity at low shear rates correlate with intravascular volume changes during hemodialysis. <b>2012</b> , 35, 425-34	5
865	Prospective randomized pilot study on the effects of two synthetic high-flux dialyzers on dialysis patient anemia. <b>2012</b> , 35, 346-51	2
864	High-flux versus low-flux membranes for end-stage kidney disease. <b>2012</b> , CD005016	27
863	Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. <b>2012</b> , 97, 15-20	33
862	Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. <b>2012</b> ,	4
861	[Renal dysfunction is a frequent complication in patients with advanced stage of Duchenne muscular dystrophy]. <b>2012</b> , 52, 211-7	19
860	Current perspectives on protective roles of erythropoietin in cardiovascular system: erythropoietin receptor as a novel therapeutic target. <b>2012</b> , 227, 83-91	21
859	Chapter 3: Use of ESAs and other agents to treat anemia in CKD. <b>2012</b> , 2, 299-310	30
858	Effect of processing and storage on red blood cell function in vivo. <b>2012</b> , 36, 248-59	57
857	Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. <b>2012</b> , 82, 570-80	94
856	Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations?. <b>2012</b> , 16, 819-26	38
855	Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. <b>2012</b> , 217, 1097-105	36
854	Implications and management of anemia in cardiac surgery: current state of knowledge. <b>2012</b> , 144, 538-46	46
853	Medical options to fight mortality in end-stage renal disease: a review of the literature. <b>2012</b> , 27, 4298-307	20

852	Observational studies versus randomized controlled trials: avenues to causal inference in nephrology. <b>2012</b> , 19, 11-8	64
851	Meeting the 2012 QIP (Quality Incentive Program) clinical measures: strategies for dialysis centers. <b>2012</b> , 60, S5-13; quiz S14-7	6
850	[COPD and erythropoiesis: interactions and consequences]. <b>2012</b> , 29, 213-31	4
849	Chronic kidney disease. <b>2012</b> , 379, 165-80	1107
848	The new label for erythropoiesis stimulating agents: the FDA'S sentence. <b>2012</b> , 25, 263-6	3
847	The role of erythropoietin in the "stroke belt" phenomenon. <b>2012</b> , 79, 181-5	7
846	Mortality in dialysis patients may not be associated with ESA dose: a 2-year prospective observational study. <b>2012</b> , 13, 40	7
845	Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study. <b>2012</b> , 13, 60	7
844	An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients. <b>2012</b> , 13, 95	9
843	Mechanisms of anemia in CKD. <b>2012</b> , 23, 1631-4	487
842	G-estimation and artificial censoring: problems, challenges, and applications. <b>2012</b> , 68, 275-86	30
841	Medicare's payment strategy for end-stage renal disease now embraces bundled payment and pay-for-performance to cut costs. <b>2012</b> , 31, 2051-8	40
840	The Impact of End-Stage Renal Disease Transfusion Demand on Blood Utilization and Blood Supply in the United States. <b>2012</b> , 3, e67-e77	
839	Cost-effectiveness of Treating Chronic Anemia with Epoetin Alfa among Hemodialysis Patients in the United States. <b>2012</b> , 3, e79-e89	2
838	Anaemia. <b>2012</b> , 329-341	
837	Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease. <b>2012</b> , 11, 923-31	9
836	Anemia and Cardiovascular Risk in the Kidney Disease Patients: What Is the Best Way to Achieve and What Is the Desired Hemoglobin?. <b>2012</b> , 13-24	
835	Proteinuria as a surrogate end point--more data are needed. <b>2012</b> , 8, 306-9	33

834	Endotoxaemia in haemodialysis: a novel factor in erythropoietin resistance?. <b>2012</b> , 7, e40209	9
833	Low-Dose Treatment with Erythropoiesis-Stimulating Agents and Cardiovascular Geometry in Chronic Kidney Disease: Is Darbepoetin- $\alpha$ More Effective than Expected?. <b>2012</b> , 2, 18-25	4
832	Erythropoietin-induced progenitor cell mobilisation in patients with acute ST-segment-elevation myocardial infarction and restenosis. <b>2012</b> , 107, 769-74	9
831	Morbidity and Mortality in Anemia. <b>2012</b> ,	
830	Biomarkers and surrogate endpoints in clinical trials. <b>2012</b> , 31, 2973-84	287
829	Erythropoietin: a future therapy for failing hearts?. <b>2012</b> , 17, 475-83	4
828	Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD. <b>2012</b> , 44, 499-507	34
827	The impact of ferritin fluctuations on stable hemoglobin levels in hemodialysis patients. <b>2012</b> , 16, 448-55	9
826	Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis. <b>2012</b> , 686, 81-9	31
825	New anemia therapies: translating novel strategies from bench to bedside. <b>2012</b> , 59, 444-51	43
824	The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) program in practice: does it really inform patients and limit risk?. <b>2012</b> , 59, 604-6	2
823	Anaemia, diabetes and chronic kidney disease: where are we now?. <b>2012</b> , 38 Suppl 1, 67-77	18
822	Relationship between erythropoietin resistance index and left ventricular mass and function and cardiovascular events in patients on chronic hemodialysis. <b>2012</b> , 16, 181-7	17
821	Erythropoietin-induced erythroid precursor pool depletion causes erythropoietin hyporesponsiveness. <b>2013</b> , 30, 1026-36	3
820	Regulation of erythropoiesis by hypoxia-inducible factors. <b>2013</b> , 27, 41-53	371
819	Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. <b>2013</b> , 37, 549-58	88
818	Management of neurogenic orthostatic hypotension in patients with autonomic failure. <b>2013</b> , 73, 1267-79	23
817	Neues zur Anämiekorrektur durch erythropoesestimulierende Faktoren (ESF) bei Kindern unter chronischer Peritonealdialyse. <b>2013</b> , 8, 258-264	

816	A pilot study of darbepoetin alfa for prophylactic neuroprotection in aortic surgery. <b>2013</b> , 18, 75-80	10
815	The MAINTAIN study--managing hemoglobin variability with darbepoetin alfa in dialysis patients experiencing a severe drop in hemoglobin. <b>2013</b> , 125, 71-82	2
814	Pharmacologic management of chronic reno-cardiac syndrome. <b>2013</b> , 10, 54-62	11
813	Iron deficiency anemia in heart failure. <b>2013</b> , 18, 485-501	17
812	[Patient Blood Management : three pillar strategy to improve outcome through avoidance of allogeneic blood products]. <b>2013</b> , 62, 519-27	8
811	Congestive Heart Failure. <b>2013</b> , 255-302	
810	A model of erythropoiesis in adults with sufficient iron availability. <b>2013</b> , 66, 1209-40	17
809	KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. <b>2013</b> , 62, 849-59	155
808	Update on erythropoiesis-stimulating agents. <b>2013</b> , 27, 121-9	9
807	Different analyses estimate different parameters of the effect of erythropoietin stimulating agents on survival in end stage renal disease: a comparison of payment policy analysis, instrumental variables, and multiple imputation of potential outcomes. <b>2013</b> , 66, S42-50	9
806	A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A "Half-and-Half" Combination Therapy. <b>2013</b> , 74, 5-8	6
805	Erythropoiesis-stimulating agents on trial: are higher dosages causing harm?. <b>2013</b> , 61, 6-8	4
804	Effects of recombinant human erythropoietin on resistance artery endothelial function in stage 4 chronic kidney disease. <b>2013</b> , 2, e000128	20
803	Performance variability of seven commonly used self-monitoring of blood glucose systems: clinical considerations for patients and providers. <b>2013</b> , 7, 144-52	47
802	RBC transfusions among hemodialysis patients (1999-2010): influence of hemoglobin concentrations below 10 g/dL. <b>2013</b> , 62, 919-28	15
801	Pocket Reference to Renal Anemia. <b>2013</b> ,	1
800	[Intravenous iron during predialysis period improves anemia management and cardiovascular parameters in incident hemodialysis patients]. <b>2013</b> , 9, 486-93	3
799	Therapy of anemia: is it only a number to reach or are there other variables to control?. <b>2013</b> , 36, 37-40	1

798	Interventions for erythropoietin-resistant anaemia in dialysis patients. <b>2013</b> , CD006861	5
797	Anaemia management and mortality risk in chronic kidney disease. <b>2013</b> , 9, 291-301	90
796	Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. <b>2013</b> , 62, 860-73	51
795	Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients. <b>2013</b> , 14, 200	14
794	Influence of safety warnings on ESA prescribing among dialysis patients using an interrupted time series. <b>2013</b> , 14, 172	9
793	Trends in anemia management in US hemodialysis patients 2004-2010. <b>2013</b> , 14, 264	17
792	Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. <b>2013</b> , 28, 1346-59	479
791	A dosing algorithm for erythropoietin alpha in older adults with heart failure and a preserved ejection fraction. <b>2013</b> , 31, 92-9	3
790	Commentary on 'The DOPPS Practice Monitor for US dialysis care: trends through December 2011': results from year one. <b>2013</b> , 61, 346-8	1
789	[EVOLVE: between disappointment and optimism]. <b>2013</b> , 9, 241-5	0
788	Blood management. <b>2013</b> , 31, 433-50	
787	Anemia, heart failure and exercise training. <b>2013</b> , 168, 1525-6	3
786	Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. <b>2013</b> , 61, 44-56	127
785	Anemia management in CKD patients in the era of new US Food and Drug Administration recommendations on the use of erythropoiesis-stimulating agents. <b>2013</b> , 61, 191-3	
784	High dose atorvastatin therapy and QTc interval in patients treated with coronary bypass surgery. <b>2013</b> , 168, 1526-8	1
783	Association of a change in erythropoiesis-stimulating agent dose during hospitalization and subsequent hemoglobin levels and transfusions in hemodialysis patients. <b>2013</b> , 62, 947-52	1
782	Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. <b>2013</b> , 61, 238-46	15
781	On peginesatide and anemia treatment in CKD. <b>2013</b> , 62, 659-61	4



780	Pathophysiology and Pathogenesis of Diabetic Nephropathy. <b>2013</b> , 2605-2632		3
779	Anaemia: The safety and efficacy of peginesatide in patients with CKD. <b>2013</b> , 9, 192-3		12
778	Novel techniques and innovation in blood purification: a clinical update from Kidney Disease: Improving Global Outcomes. <b>2013</b> , 83, 359-71		21
777	Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism. <b>2013</b> , 11, 435-43		58
776	Acute kidney injury: Creatinine and AKI--through a glass, darkly. <b>2013</b> , 9, 193-5		3
775	Cardiorenal syndrome: pathophysiology and potential targets for clinical management. <b>2013</b> , 9, 99-111		99
774	Peginesatide for the treatment of renal disease-induced anemia. <b>2013</b> , 14, 937-48		6
773	Treatment of anaemia with erythropoiesis-stimulating agents in patients with chronic kidney disease does not lower mortality and may increase cardiovascular risk: a meta-analysis. <b>2012</b> , 121, c95-101		18
772	Management of anemia in children receiving chronic peritoneal dialysis. <b>2013</b> , 24, 665-76		64
771	Treatment of anemia with darbepoetin alfa in systolic heart failure. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 1210-9	59.2	331
770	Anaemia in inflammatory rheumatic diseases. <b>2013</b> , 9, 205-15		79
769	Anemia. <b>2013</b> , 275-285		
768	Treating pain to improve quality of life in end-stage renal disease. <b>2013</b> , 26, 268-73		6
767	Alternatives to blood transfusion. <b>2013</b> , 381, 1855-65		174
766	Peginesatide in patients with anemia undergoing hemodialysis. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 307-19	59.2	75
765	Targets, trends, excesses, and deficiencies: refocusing clinical investigation to improve patient outcomes. <b>2013</b> , 83, 1001-9		11
764	Restoring invisible and abandoned trials: a call for people to publish the findings. <b>2013</b> , 346, f2865		97
763	Stable hemoglobin in hemodialysis patients: forest for the trees--a 12-week pilot observational study. <b>2013</b> , 14, 243		1

762	The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study. <b>2013</b> , 17, 106-14	6
761	Prognostic significance of left ventricular hypertrophy observed at dialysis initiation depends on the pre-dialysis use of erythropoiesis-stimulating agents. <b>2013</b> , 17, 294-303	7
760	Erythropoietin. <b>2013</b> , 3, a011619	159
759	Iron indices and survival in maintenance hemodialysis patients with and without polycystic kidney disease. <b>2013</b> , 28, 2889-98	8
758	Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. <b>2013</b> , 28, 1579-89	75
757	Why does the treatment of anaemia not improve cardiac outcomes in CKD?. <b>2013</b> , 9, 59-61	2
756	A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. <b>2013</b> , 28, 1733-43	42
755	Postinfarct active cardiac-targeted delivery of erythropoietin by liposomes with sialyl Lewis X repairs infarcted myocardium in rabbits. <b>2013</b> , 304, H1124-33	23
754	Evidence-based cardiology in hemodialysis patients. <b>2013</b> , 24, 1934-43	36
753	Should glucose-sparing prescriptions be expected to reduce the cardiovascular risk of peritoneal dialysis patients?. <b>2013</b> , 24, 1713-6	4
752	Strategies for postmarketing surveillance of drugs and devices in patients with ESRD undergoing dialysis. <b>2013</b> , 8, 2213-20	1
751	Clinical factors and the decision to transfuse chronic dialysis patients. <b>2013</b> , 8, 1942-51	19
750	Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa. <b>2013</b> , 8, 538-45	6
749	Proceedings of the Fourth Seattle Symposium in Biostatistics: Clinical Trials. <b>2013</b> ,	
748	Hospitalization and mortality in hemodialysis patients: association with hemoglobin variability. <b>2013</b> , 35, 247-57	6
747	Vascular access care and treatment practices associated with outcomes of arteriovenous fistula: international comparisons from the Dialysis Outcomes and Practice Patterns Study. <b>2013</b> , 124, 23-30	47
746	Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients. <b>2013</b> , 36, 29-36	17
745	Cardiorenal syndrome type 4: management. <b>2013</b> , 36, 200-9	15

744	How can erythropoietin-stimulating agent use be reduced in chronic dialysis patients?: Can reduction of inflammation improve ESA dose response?. <b>2013</b> , 26, 540-2	7
743	How important is transfusion avoidance in 2013?. <b>2013</b> , 28, 1092-9	36
742	How can erythropoietin-stimulating agent use be reduced in chronic dialysis patients?: The use of iron supplementation to reduce ESA dosing in hemodialysis. <b>2013</b> , 26, 534-6	3
741	How can erythropoietin-stimulating agent use be reduced in chronic dialysis patients?: The itsy bitsy anemia problem. <b>2013</b> , 26, 531-4	2
740	Exploring the effect of erythropoietin on mortality using USRDS data. <b>2013</b> , 22, 593-606	2
739	Emerging drugs for treatment of anemia of chronic kidney disease. <b>2013</b> , 18, 421-9	1
738	Cerebral oximetry values in dialyzed surgical patients: a comparison between hemodialysis and peritoneal dialysis. <b>2013</b> , 35, 855-9	13
737	Changes in dialysis treatment modalities during institution of flat rate reimbursement and quality assurance programs. <b>2013</b> , 84, 578-84	8
736	Increased blood viscosity is associated with reduced renal function and elevated urinary albumin excretion in essential hypertensives without chronic kidney disease. <b>2013</b> , 36, 247-51	13
735	Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). <b>2013</b> , 28, 2570-9	74
734	A Numerical Method for Structured Population Equations Modeling Control of Erythropoiesis. <b>2013</b> , 46, 93-96	4
733	Pretransplantation erythropoiesis-stimulating agent hyporesponsiveness is associated with increased kidney allograft failure and mortality. <b>2013</b> , 96, 807-13	4
732	Current status of pharmacologic therapies in patient blood management. <b>2013</b> , 116, 15-34	63
731	Erythropoietin combined with ACE inhibitor prevents heart remodeling in 5/6 nephrectomized rats independently of blood pressure and kidney function. <b>2013</b> , 38, 124-35	18
730	rhEPO for the Treatment of Erythropoietin Resistant Anemia in Hemodialysis Patients âRisks and Benefits. <b>2013</b> ,	
729	Surgery in the patient with renal disease. 299-330	
728	Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide. <b>2013</b> , 8, 3297-307	7
727	Cardiovascular disease in end-stage renal disease. <b>2013</b> , 56, 576	3

726	Prevalence of ventricular arrhythmia and its associated factors in nondialyzed chronic kidney disease patients. <b>2013</b> , 8, e66036	19
725	Effect of erythropoiesis-stimulating agents on blood pressure in pre-dialysis patients. <b>2013</b> , 8, e84848	6
724	International treatment guidelines for anaemia in chronic kidney disease - what has changed?. <b>2013</b> , 199, 84-5	5
723	Current Anemia Treatment in Hemodialysis Patients: The Challenge for Secure Use of Erythropoietin-Stimulating Agents. <b>2013</b> ,	1
722	Continuous quality improvement in daily clinical practice: a proof of concept study. <b>2014</b> , 9, e97066	6
721	Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status. <b>2014</b> , 40, 554-60	7
720	Heart failure in patients with chronic kidney disease: a systematic integrative review. <b>2014</b> , 2014, 937398	85
719	Cost-effectiveness of continuous erythropoietin receptor activator in anemia. <b>2014</b> , 6, 319-30	11
718	Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs. <b>2014</b> , 3, 156-68	53
717	Effect of occasional epoetin use in combination with a stable darbepoetin dosage on anemia management in hemodialysis patients. <b>2014</b> , 6, 531-5	2
716	Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. <b>2014</b> , 86, 845-54	98
715	FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. <b>2014</b> , 29, 2075-84	173
714	Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. <b>2014</b> , CD010590	56
713	Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. <b>2014</b> , CD006254	36
712	Erythropoiesis-stimulating agent use after changes in medicare reimbursement policies. <b>2014</b> , 10, 264-9	6
711	Difference between true functional haemoglobin and pre-dialysis haemoglobin is associated with plasma volume variation: a multicentre study. <b>2014</b> , 46, 2379-84	2
710	A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada. <b>2014</b> , 1, 28	3
709	[A WHO concept- patient blood management]. <b>2014</b> , 103, 1257-62	1

708	Erythropoietin Combined with Liposomal Amphotericin B Improves Outcome during Disseminated Aspergillosis in Mice. <b>2014</b> , 5, 502	4
707	Use of Aspirin in normalization of recombinant human erythropoietin-mediated hyper-reactivity of platelets in rats. <b>2014</b> , 46, 328-33	1
706	Efficacy of once or twice weekly administration of epoetin $\beta$ in patients receiving hemodialysis: A retrospective study. <b>2014</b> , 7, 27-30	2
705	Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients. <b>2014</b> , CD003895	10
704	Erythropoetin âDifferenzierter Einsatz unter Einbeziehung der neuen Leitlinien. <b>2014</b> , 17, S17-S20	
703	Early mortality in patients starting dialysis appears to go unregistered. <b>2014</b> , 86, 392-8	62
702	Effectiveness and safety of erythropoiesis-stimulating agent use in the perioperative period. <b>2014</b> , 14, 51-61	17
701	Age and anemia management: relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patients. <b>2014</b> , 29, 2316-26	20
700	Patient satisfaction with in-centre haemodialysis care: an international survey. <b>2014</b> , 4, e005020	25
699	The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. <b>2014</b> , 29, 263-73	48
698	Erythropoietin and resistant hypertension in CKD. <b>2014</b> , 34, 540-9	15
697	Low hemoglobin levels and hypo-responsiveness to erythropoiesis-stimulating agent associated with poor survival in incident Japanese hemodialysis patients. <b>2014</b> , 18, 404-13	21
696	Perihospitalization patterns of hemoglobin levels and erythropoiesis-stimulating agent doses in US hemodialysis patients, 1998-2009. <b>2014</b> , 18, 24-31	2
695	Characteristics and performance of minority-serving dialysis facilities. <b>2014</b> , 49, 971-91	13
694	Abstracts of the 15th Annual NATA Symposium, April 10-11, 2014, Porto, Portugal. <b>2014</b> , 24 Suppl 1, 1-53	
693	Height, its components, and coagulability among older Chinese: the Guangzhou biobank cohort study. <b>2014</b> , 26, 603-8	0
692	Approach to Chest Pain During Dialysis. <b>2014</b> , 151-158	
691	EPO or PlacEPO? Science versus practical experience: panel discussion on efficacy of erythropoietin in improving performance. <b>2014</b> , 51, 83-90	8

690	Hemoglobin level and risk of hospitalization and mortality in children on peritoneal dialysis. <b>2014</b> , 29, 2387-94	10
689	The influence of Erythropoietin on platelet activation, thrombin generation and FVII/active FVII in patients with AMI. <b>2014</b> , 12, 18	8
688	The effect of erythropoietin on bone. <b>2014</b> , 85, 1-27	6
687	Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). <b>2014</b> , 174, 699-707	15
686	Improving outcomes for ESRD patients: shifting the quality paradigm. <b>2014</b> , 9, 430-4	72
685	Sickle trait in African-American hemodialysis patients and higher erythropoiesis-stimulating agent dose. <b>2014</b> , 25, 819-26	11
684	Preoperative hemoglobin and outcomes in patients with CKD undergoing cardiac surgery. <b>2014</b> , 9, 1536-44	14
683	Anemia in chronic kidney disease treating the numbers, not the patients. <b>2014</b> , 174, 708-9	9
682	Probability versus causal inference in observational studies. <b>2014</b> , 37, 221	
681	Comment on the paper: Hospitalization and mortality in hemodialysis patients: association with hemoglobin variability. <b>2014</b> , 37, 47	1
680	Design of the Blood Pressure Goals in Dialysis pilot study. <b>2014</b> , 347, 125-30	21
679	Anemia and Other Hematologic Complications of Chronic Kidney Disease. <b>2014</b> , 497-506	1
678	The KDOQI US commentary on KDIGO anemia guideline and quality of life. <b>2014</b> , 63, 540	5
677	Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion. <b>2014</b> , 63, 997-1006	16
676	Obesity paradox in end-stage kidney disease patients. <b>2014</b> , 56, 415-25	204
675	Medication among patients with type 1 diabetes and predialytic renal disease. <b>2014</b> , 103, 510-5	
674	Consider methylene blue when treating acquired methaemoglobinaemia. <b>2014</b> , 30, 185-188	
673	Haemoglobin levels and health-related quality of life: a neglected hard end point. <b>2014</b> , 29, 1272-4	5

672	Blood disorders after kidney transplantation. <b>2014</b> , 28, 63-75	28
671	Erythropoiesis stimulating agents (ESAs) for congestive heart failure: the red and the black. <b>2014</b> , 25, 193-6	1
670	Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter?. <b>2014</b> , 74, 159-68	11
669	Darbepoetin alfa once every 2 weeks effectively maintained hemoglobin in dialysis patients in an observational study: Austrian cohort of ALTERNATE. <b>2014</b> , 164, 109-19	
668	Should target hemoglobin levels in dialysis patients be lowered to 9-10 g/dl?. <b>2014</b> , 27, 282-4	1
667	Clinical outcomes of erythropoietin use in heart failure patients with anemia of chronic kidney disease. <b>2014</b> , 20, 327-33	8
666	Anemia and iron deficiency in heart failure. <b>2014</b> , 10, 281-94	17
665	High hematocrit resulting from administration of erythropoiesis-stimulating agents is not fully predictive of mortality or toxicities in preclinical species. <b>2014</b> , 42, 510-23	6
664	Haemostasis in chronic kidney disease. <b>2014</b> , 29, 29-40	240
663	Interventional Nephrology. <b>2014</b> ,	4
662	Darbepoetin for the anaemia of chronic kidney disease. <b>2014</b> , CD009297	18
661	Erythropoiesis-stimulating agents and thrombotic events in dialysis patients. <b>2014</b> , 134, 1081-6	6
660	Moving away from hemoglobin-based anemia performance measures in dialysis patients. <b>2014</b> , 64, 486-8	1
659	Associations among epoetin therapy, inflammation, nutritional status, and mortality in patients on hemodialysis. <b>2014</b> , 24, 322-9	1
658	Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines. <b>2014</b> , 19, 735-9	18
657	Management of Chronic Kidney Disease. <b>2014</b> ,	1
656	Iron repletion is associated with reduction in platelet counts in non-dialysis chronic kidney disease patients independent of erythropoiesis-stimulating agent use: a retrospective cohort study. <b>2014</b> , 15, 119	7
655	Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease. <b>2014</b> , 29, 1493-505	22

654	Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis. <b>2014</b> , 29, 2021-8	13
653	[Therapy of anemia and iron deficiency in dialysis patients: an update]. <b>2014</b> , 10, 221-7	5
652	Administration of IL-1ra improves adiponectin levels in chronic hemodialysis patients. <b>2014</b> , 27, 681-8	10
651	Drug development: how academia, industry and authorities interact. <b>2014</b> , 10, 602-10	3
650	Intravenous iron dose and frequency determine infection risks. <b>2014</b> , 63, 540-1	1
649	Ischemic and hemorrhagic stroke: high incidence in hemodialysis and peritoneal dialysis patients. <b>2014</b> , 63, 547-8	17
648	Cost-Utility Analysis of Erythropoietin for Anemia Treatment in Thai End-Stage Renal Disease Patients with Hemodialysis. <b>2014</b> , 3, 44-49	4
647	Biomedical system dynamics to improve anemia control with darbepoetin alfa in long-term hemodialysis patients. <b>2014</b> , 89, 87-94	234
646	Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years?. <b>2014</b> , 113, 3-10	29
645	Development of a standardized transfusion ratio as a metric for evaluating dialysis facility anemia management practices. <b>2014</b> , 64, 608-15	8
644	Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. <b>2014</b> , 383, 1831-43	250
643	Evaluating epoetin dosing strategies using observational longitudinal data. <b>2014</b> , 8,	5
642	Effect of protoconized therapy for renal anemia on adverse events of patients with maintenance hemodialysis. <b>2014</b> , 37, 865-74	1
641	Comparative effectiveness of two anemia management strategies for complex elderly dialysis patients. <b>2014</b> , 52 Suppl 3, S132-9	13
640	Protective effect of erythropoietin against myocardial injury in rats with sepsis and its underlying mechanisms. <b>2015</b> , 11, 3317-29	24
639	Comparison between Long- and Short-Acting Erythropoiesis-Stimulating Agents in the Period Required for Haemoglobin Stabilisation in Treatment of Anaemia in Patients with Chronic Kidney Disease. <b>2015</b> , 38, 740-5	2
638	[Anemia: From Basic Knowledge to Up-to-Date Treatment. Topic: VII. Anemia in chronic kidney disease]. <b>2015</b> , 104, 1414-24	
637	Mortality and cardiovascular morbidity associated with haemoglobin levels: a pooled analysis of randomised controlled trials. <b>2014</b> , 128, 323-32	10



636	Pathophysiologic and treatment strategies for cardiovascular disease in end-stage renal disease and kidney transplantations. <b>2015</b> , 23, 109-18	20
635	Renale Anämie. <b>2015</b> , 10, 396-398	
634	Treatment with high dose of erythropoiesis-stimulating agents and mortality: analysis with a sequential Cox approach and a marginal structural model. <b>2015</b> , 24, 1068-75	13
633	Preoperative and Intraoperative Factors for Early Failure of Native Arteriovenous Fistulas. <b>2015</b> , 19, 590-7	1
632	Early versus delayed erythropoietin for the anaemia of end-stage kidney disease. <b>2015</b> , CD011122	6
631	Red cell physiology and signaling relevant to the critical care setting. <b>2015</b> , 27, 267-76	7
630	Effect of Medicare dialysis payment reform on use of erythropoiesis stimulating agents. <b>2015</b> , 50, 790-808	11
629	Government Quality Measures: First Do No Harm. <b>2015</b> , 28, 657-60	
628	Red blood cell transfusion, hyperkalemia, and heart failure in advanced chronic kidney disease. <b>2015</b> , 24, 654-62	4
627	Association Between Vascular Access Dysfunction and Subsequent Major Adverse Cardiovascular Events in Patients on Hemodialysis: A Population-Based Nested Case-Control Study. <b>2015</b> , 94, e1032	13
626	Successful creation of an anemia management algorithm for hemodialysis patients. <b>2015</b> , 8, 65-75	5
625	Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis. <b>2015</b> , 10, e0135967	21
624	Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease. <b>2015</b> , 10, e0139226	16
623	High Dose ESAs Are Associated with High iPTH Levels in Hemodialysis Patients with End-Stage Kidney Disease: A Retrospective Analysis. <b>2015</b> , 3, 258	7
622	The Labile Side of Iron Supplementation in CKD. <b>2015</b> , 26, 2612-9	32
621	Anaemia in kidney disease: harnessing hypoxia responses for therapy. <b>2015</b> , 11, 394-410	153
620	Role of vascular function in predicting arteriovenous fistula outcomes: an observational pilot study. <b>2015</b> , 2, 19	8
619	The cost effectiveness of erythropoietin-stimulating agents for treating anemia in patients on dialysis: a systematic review. <b>2015</b> , 41, 89-97	7

618	[Outcomes in randomized trials: Typology, relevance and importance for their standardization. Example of renoprotection]. <b>2015</b> , 44, 1096-102	0
617	How the Target Hemoglobin of Renal Anemia Should Be. <b>2015</b> , 131, 202-9	17
616	In Vitro Evaluation of the Link Between Cell Activation State and Its Rheological Impact on the Microscale Flow of Neutrophil Suspensions. <b>2015</b> , 137,	3
615	How to Supplement Iron in Patients with Renal Anemia. <b>2015</b> , 131, 138-44	7
614	Considerations and challenges in defining optimal iron utilization in hemodialysis. <b>2015</b> , 26, 1238-47	62
613	Erythropoiesis-stimulating agents: dose and mortality risk. <b>2015</b> , 25, 164-8	10
612	Left ventricular assist device thrombosis: another piece of the puzzle?. <b>2015</b> , 3, 154-8	7
611	Clinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist device. <b>2015</b> , 3, 146-53	19
610	A single dose of erythropoietin reduces perioperative transfusions in cardiac surgery: results of a prospective single-blind randomized controlled trial. <b>2015</b> , 55, 1644-54	62
609	Protecting the confidentiality of interim data: addressing current challenges. <b>2015</b> , 12, 5-11	17
608	Hyporesponsiveness to erythropoiesis-stimulating agent as a prognostic factor in Japanese hemodialysis patients: the Q-Cohort study. <b>2015</b> , 28, 217-25	44
607	American Society of Nephrology Quiz and Questionnaire 2014: RRT. <b>2015</b> , 10, 1100-6	
606	Autologous blood transfusion for hemodialysis patients: A case report and review of clinical reports and therapeutic features. <b>2015</b> , 52, 204-7	1
605	From Phosphaturia to Cardiovascular Protection: Is Fibroblast Growth Factor-23 the Heart of the Matter?. <b>2015</b> , 132, 7-9	2
604	Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy. <b>2015</b> , 26, 2930-7	48
603	Anaemia and chronic renal failure. <b>2015</b> , 43, 474-477	0
602	Alternative matrices for therapeutic drug monitoring of immunosuppressive agents using LC-MS/MS. <b>2015</b> , 7, 1037-58	25
601	Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis. <b>2015</b> , 41, 354-61	18

600	Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. <b>2015</b> , 26, 2578-87	77
599	Prevention of Heart Failure in Patients with Chronic Kidney Disease. <b>2015</b> , 9, 1	1
598	Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease. <b>2015</b> , 87, 1055-60	49
597	Optimal hemoglobin level for anemia treatment in a cohort of hemodialysis patients. <b>2015</b> , 34, 20-7	8
596	Is It Too Much of a Good Thing? A New Era in Phosphate Binder Therapy in ESRD. <b>2015</b> , 26, 2311-3	5
595	Cardiovascular and Renal Outcomes Trials-Is There a Difference?. <b>2015</b> , 116, 982-8	3
594	State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists. <b>2015</b> , 47, 1529-39	10
593	Iron dosing in kidney disease: inconsistency of evidence and clinical practice. <b>2015</b> , 30, 187-96	21
592	Emerging Therapies for Chronic Kidney Disease. <b>2015</b> , 771-780	
591	Evidence for the prevention and treatment of stroke in dialysis patients. <b>2015</b> , 28, 35-47	35
590	Management of Anemia in Chronic Kidney Disease. <b>2015</b> , 624-633	1
589	Very low doses of direct intravenous iron in each session as maintenance therapy in haemodialysis patients. <b>2016</b> , 01,	
588	The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients. <b>2016</b> , 9, 35-43	5
587	Association of hemoglobin with ankle-brachial index in general population. <b>2016</b> , 71, 375-80	1
586	Comparison of Hemoglobin Levels Before and After Hemodialysis and Their Effects on Erythropoietin Dosing and Cost. <b>2016</b> , 8, e38495	4
585	Erythropoietin Dose and Mortality in Hemodialysis Patients: Marginal Structural Model to Examine Causality. <b>2016</b> , 2016, 6087134	13
584	Total Red Blood Cell Transfusions for Chronic Hemodialysis Patients in a Single Center, 2009-2013. <b>2016</b> , 133, 23-34	1
583	The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease. <b>2016</b> , 11, e0157323	1

582	Iron replacement therapy: do we need new guidelines?. <b>2016</b> , 32, 128-35	11
581	Risk Factors for Early Failure of Arteriovenous Vascular Access Among Patients With Type 2 Diabetes Mellitus. <b>2016</b> , 20, 112-7	7
580	Managing Anemia and Metabolic Bone Disease in Dialysis Patients. <b>2016</b> , 93-102	
579	The greatly misunderstood erythropoietin resistance index and the case for a new responsiveness measure. <b>2016</b> , 20, 392-8	17
578	Arteriovenous Access Failure, Stenosis, and Thrombosis. <b>2016</b> , 3, 2054358116669126	40
577	Anemia in Chronic Renal Disease. <b>2016</b> , 1507-1532	
576	Bundled Payment Models for Actinic Keratosis Management. <b>2016</b> , 152, 789-97	12
575	Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients. <b>2016</b> , 38, 1076-81	5
574	Safety Issues in Iron Treatment in CKD. <b>2016</b> , 36, 112-8	16
573	Balance of Benefit and Risk in Intravenous Iron Treatment in Chronic Kidney Disease. <b>2016</b> , 36, 119-23	5
572	ESRD Payment Reform: First Do No Harm. <b>2016</b> , 27, 2924-2926	3
571	Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. <b>2016</b> , 67, 912-24	169
570	Cardiovascular Morbidity and Pure Red Cell Aplasia Associated With Epoetin Theta Therapy in Patients With Chronic Kidney Disease: A Prospective, Noninterventional, Multicenter Cohort Study. <b>2016</b> , 38, 276-287.e4	2
569	New expectations in the treatment of anemia in chronic kidney disease. <b>2016</b> , 36, 232-6	4
568	An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease. <b>2016</b> , 15, 1021-30	253
567	Investigational therapies for renal disease-induced anemia. <b>2016</b> , 25, 901-16	24
566	Intravenous iron administration strategies and anemia management in hemodialysis patients. <b>2017</b> , 32, 173-181	8
565	Cintica de la hemoglobina y pronóstico a largo plazo en insuficiencia cardiaca. <b>2016</b> , 69, 820-826	8

564	New expectations in the treatment of anemia in chronic kidney disease. <b>2016</b> , 36, 232-236	1
563	Initiation of erythropoiesis-stimulating agents and outcomes: a nationwide observational cohort study in anaemic chronic kidney disease patients. <b>2017</b> , 32, 1892-1901	8
562	[Iron deficiency, thrombocytosis and thromboembolism]. <b>2016</b> , 166, 437-446	10
561	SPRINT: The Study Nephrologists Might Take With a Grain of Salt. <b>2016</b> , 18, 1185-1188	5
560	Management of the Dialysis Patient with Sickle Cell Disease. <b>2016</b> , 29, 62-70	11
559	Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats. <b>2016</b> , 113, 62-70	13
558	Emerging drugs for the treatment of kidney disease-induced anemia. <b>2016</b> , 21, 315-30	6
557	The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease: A Systematic Review and Meta-analysis. <b>2016</b> , 164, 472-8	54
556	Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. <b>2016</b> , 90, 1115-1122	141
555	Sex and gender differences in chronic kidney disease: progression to end-stage renal disease and haemodialysis. <b>2016</b> , 130, 1147-63	112
554	Management of Bleeding Patients. <b>2016</b> ,	2
553	Hemoglobin Concentration and Risk of Incident Stroke in Community-Living Adults. <b>2016</b> , 47, 2017-24	34
552	Clinical Nanobioethical Problems: A Value Approach. <b>2016</b> , 1111-1134	
551	Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare. <b>2016</b> , 176, 1818-1825	24
550	Anesthesia for Patients with Concomitant Cardiac and Renal Dysfunction. <b>2016</b> , 34, 697-710	4
549	High Ferritin Level and Malnutrition Predict High Risk of Infection-Related Hospitalization in Incident Dialysis Patients: A Japanese Prospective Cohort Study. <b>2016</b> , 42, 56-63	10
548	Estimating Treatment Effect of High Hemoglobin Using the Principal Stratification Approach. <b>2016</b> , 37, 7-22	
547	Faster drug approval: challenges for safety. <b>2016</b> , 15, 1205-18	2

546	Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification. <b>2016</b> , 20, 400-7	2
545	Coagulopathy of Renal Disease. <b>2016</b> , 483-495	
544	Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005-13. <b>2017</b> , 32, 692-698	9
543	Hemoglobin Kinetics and Long-term Prognosis in Heart Failure. <b>2016</b> , 69, 820-6	4
542	Effect of normovolemic hematocrit changes on blood pressure and flow. <b>2016</b> , 157, 62-66	7
541	Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia. <b>2016</b> , 17, 1527-38	2
540	Core Concepts in Dialysis and Continuous Therapies. <b>2016</b> ,	2
539	Balancing the Evidence: How to Reconcile the Results of Observational Studies vs. Randomized Clinical Trials in Dialysis. <b>2016</b> , 29, 342-6	1
538	Antihypertensive Medication in Patients Pre- and Postdialysis: Still Hazy After All These Years. <b>2016</b> , 11, 1327-9	
537	Naturally nonanemic dialysis patients: Who are they?. <b>2016</b> , 20, 522-529	1
536	Pharmacological targeting of the HIF hydroxylases--A new field in medicine development. <b>2016</b> , 47-48, 54-75	86
535	Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013. <b>2016</b> , 31, 628-35	22
534	International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study. <b>2016</b> , 27, 2205-15	25
533	Targeting Iron Deficiency Anemia in Heart Failure. <b>2016</b> , 58, 407-15	5
532	The American Society of Nephrology at 50: A Personal Perspective. <b>2016</b> , 11, 369-71	1
531	Effects of Epoetin Alfa Titration Practices, Implemented After Changes to Product Labeling, on Hemoglobin Levels, Transfusion Use, and Hospitalization Rates. <b>2016</b> , 68, 266-276	5
530	The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease. <b>2016</b> , 36, 421-31	7
529	Modulation of stroke risk in chronic kidney disease. <b>2016</b> , 9, 29-38	14

528	Change in quality of life and one-year mortality risk in maintenance dialysis patients. <b>2016</b> , 25, 2295-306	15
527	Endothelial Progenitor Cell Levels Predict Future Physical Function: An Exploratory Analysis From the VA Enhanced Fitness Study. <b>2016</b> , 71, 362-9	11
526	Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. <b>2016</b> , 27, 3129-3138	36
525	Cardiorenal syndrome type 4: From chronic kidney disease to cardiovascular impairment. <b>2016</b> , 30, 1-6	22
524	Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality: The Health Aging and Body Composition Study. <b>2016</b> , 9, e002124	21
523	Anemia Management in the Elderly Dialysis Patient: Is It Different?. <b>2016</b> , 95-108	
522	Dialysis in Older Adults. <b>2016</b> ,	
521	Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure. <b>2016</b> , 9, 5-20	6
520	Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. <b>2016</b> , 27, 1234-44	124
519	Iron therapy in chronic kidney disease: Recent changes, benefits and risks. <b>2016</b> , 30, 65-72	23
518	Short Stay Management of Acute Heart Failure. <b>2017</b> ,	
517	TARGT Gene Therapy Platform for Correction of Anemia in End-Stage Renal Disease. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 189-191	59.2 8
516	Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects. <b>2017</b> , 45, 127-135	66
515	Target-based Anemia Management with Erythropoiesis Stimulating Agents (Risks and Benefits Relearned) and Iron (Still More to Learn). <b>2017</b> , 30, 142-148	5
514	Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients. <b>2017</b> , 45, 187-199	82
513	Acquired Disorders of Platelet Function. <b>2017</b> , 951-973	1
512	The Obesity Paradox in Kidney Disease: How to Reconcile it with Obesity Management. <b>2017</b> , 2, 271-281	81
511	History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology. <b>2017</b> , 45, 235-247	36

510	Influence of Erythropoiesis-Stimulating Agents on HbA1c and Fructosamine in Patients with Haemodialysis. <b>2017</b> , 125, 384-391	8
509	Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies. <b>2017</b> , 356, 160-165	30
508	Current and future chemical therapies for treating anaemia in chronic kidney disease. <b>2017</b> , 18, 781-788	7
507	HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism. <b>2017</b> , 21 Suppl 1, S110-S124	81
506	Artesunate and erythropoietin synergistically improve the outcome of experimental cerebral malaria. <b>2017</b> , 48, 219-230	14
505	Considerations and controversies in managing chronic kidney disease: An update. <b>2017</b> , 74, 795-810	6
504	Hematocrit and Stroke: A Forgotten and Neglected Link?. <b>2017</b> , 43, 591-598	8
503	Medication adherence in randomized controlled trials evaluating cardiovascular or mortality outcomes in dialysis patients: A systematic review. <b>2017</b> , 18, 42	19
502	Choosing Wisely: The Canadian Society of Nephrology's List of 5 Items Physicians and Patients Should Question. <b>2017</b> , 4, 2054358117695570	3
501	Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. <b>2017</b> , 32, 1373-1386	120
500	Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study. <b>2017</b> , 18, 97	5
499	Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease. <b>2017</b> , 45, 380-388	89
498	The optimum hematocrit. <b>2016</b> , 64, 575-585	21
497	Erythropoietin and Its Cardiovascular Effects. <b>2017</b> , 119-128	3
496	Human pluripotent stem cell-derived erythropoietin-producing cells ameliorate renal anemia in mice. <b>2017</b> , 9,	12
495	Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation. <b>2017</b> , 1407, 17-25	11
494	RAS Inhibitor Is Not Associated With Cardiovascular Benefits in Patients Undergoing Hemodialysis in Japan. <b>2017</b> , 21, 326-333	0
493	Heart failure in patients with kidney disease. <b>2017</b> , 103, 1848-1853	81



492	Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia. <b>2017</b> , 7, 188-197	13
491	The Medicare Access and CHIP Reauthorization Act: Implications for Nephrology. <b>2017</b> , 28, 2590-2596	9
490	Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. <b>2017</b> , 8, CD009904	7
489	Optimal hematocrit in an artificial microvascular network. <b>2017</b> , 57, 2257-2266	10
488	New options for the anemia of chronic kidney disease. <b>2017</b> , 7, 157-163	22
487	Recomendaciones para el estudio y tratamiento de la anemia en pacientes con enfermedad renal crónica. Actualización mayo 2017. <b>2017</b> , 14, 85-116	
486	Interactive Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers or Their Combination on Survival of Hemodialysis Patients. <b>2017</b> , 46, 439-447	3
485	Real-World Impact of Cardiovascular Disease and Anemia on Quality of Life and Productivity in Patients with Non-Dialysis-Dependent Chronic Kidney Disease. <b>2017</b> , 34, 1662-1672	27
484	2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. <b>2017</b> , 3,	99
483	Hemoglobin of 12 g/dl and above is not associated with increased cardiovascular morbidity in children on hemodialysis. <b>2017</b> , 91, 177-182	21
482	The Dialysis Outcomes and Practice Patterns Study (DOPPS) in Turkey. <b>2017</b> , 21, 430-439	5
481	On-label and off-label prescribing patterns of erythropoiesis-stimulating agents in inpatient hospital settings in the US during the period of major regulatory changes. <b>2017</b> , 13, 778-788	4
480	Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia. <b>2017</b> , 26, 718-742	182
479	Spanish Clinical Guidelines on Vascular Access for Haemodialysis. <b>2017</b> , 37 Suppl 1, 1-191	61
478	A threshold trajectory was revealed by isolating the effects of hemoglobin rate of rise in anemia of chronic kidney disease. <b>2017</b> , 8, 305-318	2
477	Chronic kidney disease-associated cardiovascular disease: scope and limitations of animal models. <b>2017</b> , 6, 120-127	4
476	Leitlinientherapie bei renaler Anämie. <b>2017</b> , 21, 242-246	
475	Spanish Clinical Guidelines on Vascular Access for Haemodialysis. <b>2017</b> , 37, 1-191	39

- 474 Epoetin Alfa: A Cause of Coronary Artery Thrombosis. **2017**, 2017, 9475180
- 473 Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients. **2017**, 18, 303-308 2
- 472 Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial. **2017**, 12, e0172735 8
- 471 Predictors of adherence to a new erythropoiesis-stimulating agent inpatient ordering policy: A cross-sectional study. **2017**, 12, e0188390
- 470 Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. **2017**, 18, 345 117
- 469 Positive association of residual kidney function with hemoglobin level in patients on peritoneal dialysis independent of endogenous erythropoietin concentration. **2017**, 3, 4
- 468 Use of Erythropoiesis-Stimulating Agents in Hemodialysis Patients. **2017**, 563-570.e1
- 467 Treatment of renal anemia: Erythropoiesis stimulating agents and beyond. **2017**, 36, 209-223 21
- 466 The HIF System Response to ESA Therapy in CKD-Anemia. **2017**,
- 465 Treatment with Erythropoiesis Stimulating Agents in Patients with Chronic Kidney Disease Complicated by Cancer. **2017**, 1, 81-86
- 464 A New Approach to the Management of Anemia in CKD Patients: A Review on Roxadustat. **2017**, 03,
- 463 Cardiovascular pathophysiology in chronic kidney disease: opportunities to transition from disease to health. **2014**, 80, 69-76 23
- 462 Is there an established hemoglobin target range for patients undergoing chronic dialysis?. **2018**, 31, 415-419 4
- 461 Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy. **2018**, 93, 1165-1174 16
- 460 Should We Increase GFR with Bardoxolone in Alport Syndrome?. **2018**, 29, 357-359 25
- 459 Changes in Excess Mortality from End Stage Renal Disease in the United States from 1995 to 2013. **2018**, 13, 91-99 44
- 458 Medical safety in the care of the person with end-stage kidney disease. **2018**, 31, 140-148 3
- 457 Hemoglobin concentration and the risk of hemorrhagic and ischemic stroke in patients undergoing hemodialysis: the Q-cohort study. **2018**, 33, 856-864 13

456	Comparing the Effectiveness of Dynamic Treatment Strategies Using Electronic Health Records: An Application of the Parametric g-Formula to Anemia Management Strategies. <b>2018</b> , 53, 1900-1918	16
455	Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis. <b>2018</b> , 33, 690-699	17
454	Cardiac Rhythm Disturbances in Hemodialysis Patients: Early Detection Using an Implantable Loop Recorder and Correlation With Biological and Dialysis Parameters. <b>2018</b> , 4, 397-408	29
453	Management of Anemia. <b>2018</b> ,	2
452	Disease State: Kidney Disease. <b>2018</b> , 1-10	
451	Anemia of Chronic Disease. <b>2018</b> , 43-80	
450	Current and Novel Drugs for Management of Anemia. <b>2018</b> , 81-112	
449	Anemia of Chronic Kidney Disease. <b>2018</b> , 113-127	1
448	Outcomes in Patients Undergoing Cardiac Surgery Who Decline Transfusion and Received Erythropoietin Compared to Patients Who Did Not: A Matched Cohort Study. <b>2018</b> , 127, 490-495	10
447	De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease. <b>2018</b> , 33, 125-137	4
446	Patient Blood Management: An Internist's Perspective. <b>2018</b> , 38, 38	1
445	Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs). <b>2018</b> , 4,	2
444	Hemoglobin targets for the anemia in patients with dialysis-dependent chronic kidney disease: a meta-analysis of randomized, controlled trials. <b>2018</b> , 40, 671-679	8
443	Predialysis anemia management and outcomes following dialysis initiation: A retrospective cohort analysis. <b>2018</b> , 13, e0203767	8
442	Association of Anemia and Iron Parameters With Mortality Among Patients Undergoing Prevalent Hemodialysis in Taiwan: The AIM - HD Study. <b>2018</b> , 7, e009206	11
441	Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients. <b>2018</b> , 48, 251-259	9
440	Working Toward an Improved Understanding of Chronic Cardiorenal Syndrome Type 4. <b>2018</b> , 25, 454-467	2
439	Evaluating the Evidence behind Policy Mandates in US Dialysis Care. <b>2018</b> , 29, 2777-2779	5

438	The anaemia control model: Does it help nephrologists in therapeutic decision-making in the management of anaemia?. <b>2018</b> , 38, 491-502	4
437	Lipid management in patients with chronic kidney disease. <b>2018</b> , 14, 727-749	82
436	Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives. <b>2018</b> , 20 Suppl 3, 24-29	7
435	Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. <b>2018</b> , 48, 260-268	21
434	Evaluation of variables associated with the patency of arteriovenous fistulas for hemodialysis created by a nephrologist. <b>2018</b> , 40, 326-332	2
433	Perspective: Will We Ever Know the Optimal Hgb Level in ESRD?. <b>2018</b> , 29, 2454-2457	1
432	Recommendations on RBC Transfusion in General Critically Ill Children Based on Hemoglobin and/or Physiologic Thresholds From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative. <b>2018</b> , 19, S98-S113	25
431	Association of Pre-End-Stage Renal Disease Hemoglobin with Early Dialysis Outcomes. <b>2018</b> , 47, 333-342	10
430	Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies. <b>2018</b> , 138, 80-98	150
429	Development of Recombinant Erythropoietin and Erythropoietin Analogs. <b>2018</b> , 217-232	1
428	Cardiorenal Syndromes. <b>2018</b> , 33-51	
427	Hematologic Manifestations of Renal Disease. <b>2018</b> , 2244-2246	
426	Measurement properties of the Short Form-36 (SF-36) and the Functional Assessment of Cancer Therapy - Anemia (FACT-An) in patients with anemia associated with chronic kidney disease. <b>2018</b> , 16, 111	13
425	The Incidence and Pathophysiology of the Obesity Paradox: Should Peritoneal Dialysis and Kidney Transplant Be Offered to Patients with Obesity and End-Stage Renal Disease?. <b>2018</b> , 20, 84	7
424	Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis. <b>2018</b> , 50, 2201-2206	9
423	Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease. <b>2018</b> , 27, 613-621	21
422	Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease. <b>2018</b> , 19,	41
421	Rational Management of Iron-Deficiency Anaemia in Inflammatory Bowel Disease. <b>2018</b> , 10,	25

420	Will there still be a role for the originator erythropoiesis-simulating agents after the biosimilars and the hypoxia-inducible factor stabilizers approval?. <b>2018</b> , 27, 339-344	2
419	Mineral and bone disorders in conventional hemodialysis: Challenges and solutions. <b>2018</b> , 31, 592-598	6
418	The anaemia control model: Does it help nephrologists in therapeutic decision-making in the management of anaemia?. <b>2018</b> , 38, 491-502	6
417	Anemia in conventional hemodialysis: Finding the optimal treatment balance. <b>2018</b> , 31, 599-606	8
416	Misdistribution of iron and oxidative stress in chronic kidney disease. <b>2019</b> , 133, 248-253	27
415	Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial. <b>2019</b> , 14, 1701-1710	13
414	Usefulness of mid-week hemoglobin measurement for anemia management in patients undergoing hemodialysis: a retrospective cohort study. <b>2019</b> , 20, 295	1
413	High Cardiovascular Risk Profile in Young Patients on the Kidney Transplant Waiting List. <b>2019</b> , 51, 1717-1726	1
412	Contemporary Trends in Clinical Outcomes among Dialysis Patients with Medicare Coverage. <b>2019</b> , 50, 63-71	3
411	A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD. <b>2019</b> , 30, 1495-1504	38
410	Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1011-1022	59.2 226
409	Renale Anemie. <b>2019</b> , 14, 305-317	
408	Kidney Disease and Anemia in Elderly Patients. <b>2019</b> , 35, 327-337	3
407	Clinical and Socioeconomic Predictors of Heart Failure Readmissions: A Review of Contemporary Literature. <b>2019</b> , 94, 1304-1320	11
406	Large Magnetoresistance in an Electric-Field-Controlled Antiferromagnetic Tunnel Junction. <b>2019</b> , 12,	8
405	The Evolution of Target Hemoglobin Levels in Anemia of Chronic Kidney Disease. <b>2019</b> , 26, 229-236	2
404	Red Blood Cell Lifespan Shortening in Patients with Early-Stage Chronic Kidney Disease. <b>2019</b> , 44, 1158-1165	11
403	The association of the difference in hemoglobin levels before and after hemodialysis with the risk of 1-year mortality in patients undergoing hemodialysis. Results from a nationwide cohort study of the Japanese Renal Data Registry. <b>2019</b> , 14, e0210533	1

402	Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification. <b>2019</b> , 4, 1585-1597	9
401	Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience. <b>2019</b> , 26, 253-266	75
400	Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective. <b>2018</b> , 9, 1498	10
399	Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease. <b>2019</b> , 85, 935-948	37
398	Buttonhole versus Stepladder Cannulation for Home Hemodialysis: A Multicenter, Randomized, Pilot Trial. <b>2019</b> , 14, 403-410	7
397	High sensitivity Troponin-I levels in asymptomatic hemodialysis patients. <b>2019</b> , 41, 393-400	12
396	Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial. <b>2019</b> , 143, 77-85	28
395	Risk Factors for Primary Arteriovenous Fistula Dysfunction in Hemodialysis Patients: A Retrospective Survival Analysis in Multiple Medical Centers. <b>2019</b> , 48, 276-282	10
394	Responsibilities of the Data Monitoring Committee and Motivating Illustrations. <b>2019</b> , 35-88	
393	Statistical, Philosophical, and Ethical Issues in Data Monitoring. <b>2019</b> , 265-334	1
392	Erythropoiesis-Stimulating Agents and Mortality. <b>2019</b> , 30, 907-908	5
391	Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis. <b>2019</b> , 30, 1037-1048	43
390	Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. <b>2019</b> , 22, 593-604	22
389	Temporal Trends in Incident Mortality in Dialysis Patients: Focus on Sex and Racial Disparities. <b>2019</b> , 49, 241-253	8
388	Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing. <b>2019</b> , 20, 76	6
387	Acquired Disorders of Platelet Function. <b>2019</b> , 905-920	1
386	Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial. <b>2019</b> , 36, 1438-1454	44
385	Comparison of Clopidogrel and Ticlopidine/ in Patients With Clopidogrel Resistance and Carotid Stenting. <b>2019</b> , 10, 44	4

384	PIVOTAL trial: iron loading improves clinical outcomes. <b>2019</b> , 15, 260-261	1
383	Haemoglobin concentration and survival of haemodialysis patients before and after experiencing cardiovascular disease: a cohort study from Japanese dialysis outcomes and practice pattern study (J-DOPPS). <b>2019</b> , 9, e031476	3
382	Prolyl hydroxylase domain inhibitors: a new era in the management of renal anemia. <b>2019</b> , 7, S334	2
381	Authors' Reply. <b>2019</b> , 30, 1773-1776	
380	Long-Term Risks of Intravenous Iron in End-Stage Renal Disease Patients. <b>2019</b> , 26, 292-297	8
379	Cardioprotection Against Acute Myocardial Infarction. <b>2019</b> ,	1
378	. <b>2019</b> ,	1
377	. <b>2019</b> ,	11
376	Iron Oxide Nanoparticle Formulations for Supplementation. <b>2019</b> , 19,	8
375	Anemia. <b>2019</b> , 52, 239-251	
374	Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease. <b>2019</b> , 28, 600-606	6
373	LVAD Pulsatility Assesses Cardiac Contractility: In Vitro Model Utilizing the Total Artificial Heart and Mock Circulation. <b>2019</b> , 65, 580-586	1
372	Anemia in patients of diabetic kidney disease. <b>2019</b> , 82, 752-755	8
371	Effects of Molidustat in the Treatment of Anemia in CKD. <b>2019</b> , 14, 28-39	51
370	Increased Mortality Associated with Higher Pre-Dialysis Serum Sodium Variability: Results of the International MONitoring Dialysis Outcome Initiative. <b>2019</b> , 49, 1-10	4
369	Anemia in Non-Dialysis-Dependent CKD: To Treat or Not to Treat?. <b>2019</b> , 73, 297-299	5
368	Anemia of Renal Failure/Chronic Kidney Disease. <b>2019</b> , 147-156	3
367	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <b>2019</b> , 73, 309-315	15

366 Health Issues and Care System for the Elderly. **2019**,

365 Anemia in the Young and Old. **2019**,

364 Definition and Validation of a Novel Metric of Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients. **2019**, 59, 418-426 1

363 Anemia in Chronic Kidney Disease. **2019**, 136-144.e6 1

362 The Pathophysiology of Uremia. **2019**, 273-285.e5

361 Achievement of renal anemia KDIGO targets by two different clinical strategies - a European hemodialysis multicenter analysis. **2019**, 20, 5 3

360 Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. *New England Journal of Medicine*, **2019**, 380, 447-458 59.2 187

359 Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. **2019**, 12, 139-148 57

358 Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. **2019**, 34, 90-99 49

357 Trends in the treatment of chronic kidney disease-associated anaemia in a cohort of haemodialysis patients: the Irish experience. **2019**, 188, 223-230 7

356 Efficacy of Primary Stent-Graft Placement in the Treatment of Vascular Access Graft Outflow Tract Stenosis. **2020**, 54, 25-35 1

355 Low hemoglobin at hemodialysis initiation: an international study of anemia management and mortality in the early dialysis period. **2020**, 13, 425-433 9

354 Hematologic and Infectious Complications of Chronic Kidney Disease. **2020**, 477-502 0

353 Management of Anemia in Chronic Kidney Disease. **2020**, 991-1000

352 Emerging Therapies. **2020**, 1189-1205

351 How Acquisitions Affect Firm Behavior and Performance: Evidence from the Dialysis Industry. **2020**, 135, 221-267 15

350 Patient-Centred Outcomes in Anaemia and Renal Disease: A Systematic Review. **2020**, 6, 74-84 1

349 Association between Severe Anemia and Outcomes of Hemodialysis Vascular Access. **2020**, 62, 295-303 3



348	Can the fistula arm be used to lift heavy items? Six-pound dumbbells versus handgrip exercise in a 6-month follow-up secondary analysis of a randomized controlled trial. <b>2020</b> , 21, 602-608	3
347	Red cell transfusion in chronic kidney disease in the United States in the current era of erythropoiesis stimulating agents. <b>2020</b> , 33, 267-275	
346	Peripheral Vein Thrombophlebitis in the Upper Extremity: A Systematic Review of a Frequent and Important Problem. <b>2020</b> , 133, 473-484.e3	2
345	Different risk factors are associated with vascular access patency after construction and percutaneous transluminal angioplasty in patients starting hemodialysis. <b>2021</b> , 22, 707-715	3
344	Interdialytic Weight Gain Effects on Hemoglobin Concentration and Cardiovascular Events. <b>2020</b> , 5, 1670-1678	4
343	Revisiting the treatment of anemia in the setting of chronic kidney disease, hematologic malignancies, and cancer: perspectives with opinion and commentary. <b>2020</b> , 13, 1175-1188	1
342	Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS). <b>2020</b> , 2, 286-296	9
341	. <b>2020</b> ,	1
340	Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. <b>2021</b> , 36, 2039-2048	6
339	The current and future landscape of dialysis. <b>2020</b> , 16, 573-585	78
338	Clinical and genetic markers of erythropoietin deficiency anemia in chronic kidney disease (predialysis) patients. <b>2020</b> , 14, 1099-1108	2
337	Low rather than high mean corpuscular volume is associated with mortality in Japanese patients under hemodialysis. <b>2020</b> , 10, 15663	0
336	Continuous Glucose Monitoring and Use of Alternative Markers To Assess Glycemia in Chronic Kidney Disease. <b>2020</b> , 43, 2379-2387	12
335	A new insight into the treatment of renal anemia with HIF stabilizer. <b>2020</b> , 6,	3
334	Onco-nephrology highlights: Chronic kidney disease, end-stage kidney disease, and cancer patients. <b>2020</b> , 4, 7-14	
333	We use our judgment and do the best we can. <b>2020</b> , 33, 185-186	
332	Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis. <b>2020</b> , 13, 821-827	4
331	Coronary Artery Disease in patients with End-Stage Kidney Disease; Current perspective and gaps of knowledge. <b>2020</b> , 33, 187-197	2

330	Perioperative Anemia: Prevention, Diagnosis, and Management Throughout the Spectrum of Perioperative Care. <b>2020</b> , 130, 1364-1380	33
329	Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease. <b>2020</b> , 29, 414-422	6
328	Identifying Biomarker Profiles Through the Epidemiologic Analysis of Big Health Care Data â Implications for Clinical Management and Clinical Trial Design. <b>2020</b> , 447-468	
327	Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients. <b>2020</b> , 7, 2054358120927532	1
326	How I treat renal anemia. <b>2020</b> , 136, 783-789	3
325	Are all erythropoiesis-stimulating agents created equal?. <b>2021</b> , 36, 1369-1377	3
324	Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. <b>2020</b> , 31, 456-468	46
323	Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients. <b>2020</b> , 60, 1432-1440	8
322	Renal Medicine and Clinical Pharmacy. <b>2020</b> ,	0
321	Physical health-related quality of life at higher achieved hemoglobin levels among chronic kidney disease patients: a systematic review and meta-analysis. <b>2020</b> , 21, 259	1
320	Red Blood Cell Dysfunction in Critical Illness. <b>2020</b> , 36, 267-292	3
319	The Influence of Inflammation on Anemia in CKD Patients. <b>2020</b> , 21,	19
318	Anemia management in dialysis patients: a PIVOT and a new path?. <b>2020</b> , 29, 351-355	2
317	Compliance With Biochemical Objectives in Patients on Renal Replacement Therapy Before Kidney Transplantation in Mexico. <b>2020</b> , 52, 1090-1093	1
316	Platelets in Advanced Chronic Kidney Disease: Two Sides of the Coin. <b>2020</b> , 46, 342-356	9
315	Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial. <b>2020</b> , 15, 608-615	7
314	Hemoglobin and erythrocyte count are independently and positively associated with arterial stiffness in a community-based study. <b>2021</b> , 35, 265-273	3
313	Targeting optimal PD management in children: what have we learned from the IPPN registry?. <b>2021</b> , 36, 1053-1063	5

- 312 Long- or short-acting erythropoiesis-stimulating agents: take no shortcuts in their evaluation. **2021**, 36, 205-207
- 311 Meeting Treatment Goals in Patients on Extramural Dialysis in Health Social Security in Mexico. **2021**, 50, 93-101
- 310 Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin. **2021**, 38, 52-75 14
- 309 Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan. **2021**, 25, 110-119 3
- 308 Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease. **2021**, 36, 267-274 5
- 307 A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps. **2021**, 11, 1784 7
- 306 Variability in Hemoglobin Levels and the Factors Associated with Mortality in Hemodialysis Patients: A 78-Month Follow-Up Study. **2021**, 18,
- 305 Encyclopedia of Systems and Control. **2021**, 290-298
- 304 Current Status and Growth of Peritoneal Dialysis. **2021**, 1-19
- 303 Management of Anemia in Children Receiving Chronic Dialysis. **2021**, 609-631
- 302 Anemia as an adaptive phenomenon. **2021**, 195-200
- 301 Randomized Controlled Trials 1: Design. **2021**, 2249, 193-211
- 300 Roxadustat in treating anemia in dialysis patients (ROAD): protocol and rationale of a multicenter prospective observational cohort study. **2021**, 22, 28 1
- 299 ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia?. **2021**, 10, 2
- 298 Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease. **2021**, 17, 155-163 4
- 297 Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. **2021**, 36, 1717-1730 17
- 296 Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial. **2021**, 52, 26-35 12
- 295 Factors associated with hepcidin-25 levels in maintenance hemodialysis patients. **2021**, 25, 565-574

294	Factors affecting pre-end-stage kidney disease haemoglobin control and outcomes following dialysis initiation: a nationwide study. <b>2021</b> , 14, 1780-1788		2
293	Hyporesponsiveness to long-acting erythropoiesis-stimulating agent is related to the risk of cardiovascular disease and death in Japanese patients on chronic hemodialysis: observational cohort study. <b>2021</b> , 7,		0
292	Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. <b>2021</b> ,		3
291	Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis. <b>2021</b> , 6, 613-623		15
290	Evaluation of Hematocrit in Adults with Dengue by a Laboratory Information System. <b>2021</b> , 2021, 8852031		1
289	Roxadustat for CKD Anemia - Starting the Jigsaw Puzzle, What Will the Finished Picture Show?. <b>2021</b> , 6, 559-561		1
288	Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. <b>2021</b> , 8, 642296		12
287	Comparison of Bleeding Risk Scores in Elderly Patients Receiving Extended Anticoagulation with Vitamin K Antagonists for Venous Thromboembolism. <b>2021</b> , 121, 1512-1522		1
286	Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1601-1612	59.2	23
285	The evolving science of anemia management in chronic kidney disease. <b>2021</b> , 11, 1-2		0
284	Development and Validation of a Transfusion Risk Score for Patients Receiving Maintenance Hemodialysis.. <b>2021</b> , 2, 948-954		
283	Temporal Trends in Hemoglobin, Use of Erythropoiesis Stimulating Agents, and Major Clinical Outcomes in Incident Dialysis Patients in Canada. <b>2021</b> , 6, 1130-1140		0
282	Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. <b>2021</b> , 11, 8-25		17
281	Anemia management: a historical perspective. <b>2021</b> , 11, 3-7		1
280	Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD. <b>2021</b> ,		4
279	Therapy for Anemia in Chronic Kidney Disease - New Interventions and New Questions. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1657-1658	59.2	1
278	Arteriovenous fistulas for hemodialysis: Brief review and current problems. <b>2021</b> , 11297298211007720		0
277	Erythropoietin treatment and the risk of hip fractures in hemodialysis patients. <b>2021</b> , 36, 1211-1219		1

276	JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: Comparative study against recombinant erythropoietin in rat. <b>2021</b> , 898, 173990	1
275	A new paradigm in treating patients with chronic kidney disease and anaemia after a journey lasting more than 35 years. <b>2021</b> , 36, 1559-1563	
274	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. <b>2021</b> , 99, 1280-1295	18
273	Treatment of Anemia in Kidney Disease: Beyond Erythropoietin. <b>2021</b> , 6, 2540-2553	0
272	The Perioperative Surgical Home, Enhanced Recovery After Surgery and how integration of these models may improve care for medically complex patients. <b>2021</b> , 64, E381-E390	0
271	Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation. <b>2021</b> , 78, 709-718	4
270	Treatment practices and outcomes in incident peritoneal dialysis patients: the Swedish Renal Registry 2006-2015.. <b>2021</b> , 14, 2539-2547	
269	miR663 Prevents Epo Inhibition Caused by TNF-Alpha in Normoxia and Hypoxia. <b>2021</b> , 2021, 3670499	2
268	Erratum: Interdialytic Weight Gain Effects on Hemoglobin Concentration and Cardiovascular Events. <b>2021</b> , 6, 1999-2007	1
267	Erythropoietin Use and the Risk of Stroke in Patients on Hemodialysis: A Retrospective Cohort Study in Taiwan. <b>2021</b> , 10, e019529	1
266	Long-term changes in anemia-related parameters among Japanese dialyzed patients assessed by newly developed web-based system. <b>2021</b> ,	
265	Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy. <b>2021</b> , 9, 518-527	1
264	A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study. <b>2021</b> , 6, 1829-1839	11
263	Challenging patient phenotypes in the management of anaemia of chronic kidney disease. <b>2021</b> , 75, e14681	0
262	Iron Deficiency in CKD Without Concomitant Anemia. <b>2021</b> , 6, 2752-2762	0
261	Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial. <b>2021</b> , 22, 284	
260	Trends in Adaptive Design Methods in Dialysis Clinical Trials: A Systematic Review.. <b>2021</b> , 3, 925-941	1
259	Anemia: A Connection Between Heart Failure and Kidney Failure. <b>2021</b> , 39, 319-333	0

258	Proactive High-Dose IV Iron Is Preferred Therapy in ESKD Patients: PRO..	2022, 3, 208-210	
257	Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials.	2021, 16, 1190-1200	3
256	Evaluation of switching treatment from high dose of darbepoetin to lower dose of roxadustat in Japanese hemodialysis patients.	2021,	0
255	Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).	2021, 38, 5361-5380	4
254	Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial..	2021, 2, 1761-1769	1
253	Current Status of Renal Anemia Pharmacotherapy-What Can We Offer Today.	2021, 10,	0
252	Epidemiologic and Genetic Associations of Erythropoietin With Blood Pressure, Hypertension, and Coronary Artery Disease.	2021, 78, 1555-1566	0
251	Therapie der renalen Anämie.	2021, 25, 280-284	
250	Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.	2021, 38, 5345-5360	6
249	Erythropoiesis stimulating agent recommendation model using recurrent neural networks for patient with kidney failure with replacement therapy.	2021, 137, 104718	2
248	Bleeding in Uremia.	2021, 193-199	
247	Adaptive design methods in dialysis clinical trials – a systematic review.		1
246	Current Status of Peritoneal Dialysis.	2009, 19-37	1
245	Chemotherapy-associated thrombosis.	2009, 148, 181-206	8
244	Cardiac disease in chronic uremia.	2004, 765-790	1
243	Vascular access for hemodialysis.	2004, 203-230	4
242	Ten years of meta-analyses on erythropoiesis-stimulating agents in cancer patients.	2011, 157, 217-38	9
241	Management of Renal Anemia in Children with Chronic Kidney Disease.	2012, 531-568	1

240	Identifying and Addressing Safety Signals in Clinical Trials: Some Issues and Challenges. <b>2013</b> , 137-156	4
239	Analyzing Longitudinal Health-Related Quality of Life Data: Missing Data and Imputation Methods. <b>2002</b> , 103-112	1
238	Randomized controlled trials 1: Design. <b>2015</b> , 1281, 159-75	1
237	Introduction to Hematopoietic Growth Factors. <b>2004</b> , 3-10	2
236	The design of randomized controlled trials. <b>2009</b> , 473, 95-111	1
235	Sleep and Quality of Life in Renal Disease. <b>2008</b> , 389-399	1
234	Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin (rhEPO). <b>2002</b> , 203-221	3
233	Use of erythropoietic stimulating agents in the setting of renal disease. <b>2009</b> , 225-248	1
232	Quality of life after peritoneal dialysis. <b>2000</b> , 709-735	4
231	Chronic Kidney Disease (CKD) as an Emerging Risk Factor in the Elderly. <b>2019</b> , 137-150	1
230	Kidney Disease. <b>2012</b> , 1523-1607	5
229	Cardiovascular Aspects of Kidney Disease. <b>2012</b> , 2059-2080	5
228	Hematologic Aspects of Kidney Disease. <b>2012</b> , 2081-2121	1
227	Hemodialysis. <b>2012</b> , 2294-2346	4
226	Treatment of Anemia and Bleeding in Chronic Kidney Disease. <b>2008</b> , 756-764	1
225	Association Between Implementation Of Novel Therapies And Improved Survival In Patients Starting Hemodialysis: The Swedish Renal Registry 2006-2015. <b>2020</b> ,	1
224	Clinical evaluation of a new high efficiency hemodialyzer: polysynthane. <b>2000</b> , 46, 288-92	27
223	Pressure-overload cardiomyopathy in end-stage renal disease. <b>1999</b> , 8, 179-186	13

222	Erythropoietin therapy in chronic uremia: the impact of normalization of hematocrit. <b>1999</b> , 8, 573-8	10
221	Optimizing erythropoietin therapy. <b>1999</b> , 6, 121-6	5
220	Clinical considerations and practical recommendations for the primary care practitioner in the management of anemia of chronic kidney disease. <b>2007</b> , 100, 1200-7	8
219	How to improve survival in pre-dialysis patients. <b>2000</b> , 85 Suppl 1, 15-22	9
218	How I treat anemia in heart failure. <b>2020</b> , 136, 790-800	5
217	Erythropoietin, iron, and erythropoiesis. <b>2000</b> , 96, 823-833	4
216	Erythropoietin update 2011. <b>2011</b> , 17, RA240-247	9
215	Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease. <b>2014</b> , 6, 72	10
214	Hemoglobin targets for chronic kidney disease patients with anemia: a systematic review and meta-analysis. <b>2012</b> , 7, e43655	19
213	Resistance to erythropoiesis stimulating agents in patients treated with online hemodiafiltration and ultrapure low-flux hemodialysis: results from a randomized controlled trial (CONTRAST). <b>2014</b> , 9, e94434	23
212	The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients. <b>2015</b> , 10, e0140241	6
211	The Different Association between Serum Ferritin and Mortality in Hemodialysis and Peritoneal Dialysis Patients Using Japanese Nationwide Dialysis Registry. <b>2015</b> , 10, e0143430	21
210	Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients. <b>2016</b> , 11, e0148938	19
209	Relationship between Hemoglobin Levels Corrected by Interdialytic Weight Gain and Mortality in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study. <b>2017</b> , 12, e0169117	7
208	The clinical epidemiology of cardiac disease in chronic renal failure. <b>1999</b> , 10, 1606-15	412
207	An indistinct balance: the safety and efficacy of parenteral iron therapy. <b>1999</b> , 10, 2029-43	75
206	Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. <b>2000</b> , 11, 335-342	152
205	Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. <b>2000</b> , 11, 530-538	176



204	Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. <b>2001</b> , 12, 2465-2473	209
203	Left ventricular hypertrophy in the renal patient. <b>2001</b> , 12, 1079-1084	187
202	Iron administration and clinical outcomes in hemodialysis patients. <b>2002</b> , 13, 734-744	107
201	The differential effects of anemia on mortality in young and elderly end-stage renal disease patients. <b>2020</b> , 39, 192-201	2
200	Obesity may be erythropoietin dose-saving in hemodialysis patients. <b>2018</b> , 37, 148-156	6
199	Use of agents stimulating erythropoiesis in digestive diseases. <b>2009</b> , 15, 4675-85	19
198	Cardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction. <b>2014</b> , 11, 100-5	4
197	2008 JSDT &ldquo;Guideline for Renal Anemia in Chronic Kidney Disease&rdquo;. <b>2008</b> , 41, 661-716	29
196	Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients. <b>2008</b> , 14, 151-7	8
195	Sickle Cell Trait, Hemoglobin Levels and Anemia among Black Patients with Predialysis Chronic Kidney Disease: A Post Hoc Analysis. <b>2016</b> , 06, 258-264	1
194	Erythropoietin therapy after out-of-hospital cardiac arrest: A systematic review and meta-analysis. <b>2017</b> , 9, 830-837	1
193	Individualized anemia management in a dialysis facility - long-term utility as a single-center quality improvement experience?. <b>2018</b> , 90, 276-285	8
192	Randomized double-blind clinical trial of a new human epoetin versus a commercially available formula for anemia control in patients on hemodialysis. <b>2014</b> , 69, 547-53	2
191	Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients. <b>2021</b> , 52, 702-713	1
190	Approach to Chest Pain During Dialysis. <b>2022</b> , 147-155	
189	Anemia in Chronic Kidney Disease. <b>2022</b> , 235-251	
188	Improvements in six aspects of quality of care of incident hemodialysis patients - a real-world experience. <b>2021</b> , 22, 333	
187	The spectrum of kidney dysfunction requiring chronic dialysis therapy: Implications for clinical practice and future clinical trials. <b>2021</b> ,	2

- 186 An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease. **2021**, 1-10 3
- 185 Anemia and the heart. **2000**, 111-117
- 184 Antianēmika. **2000**, 55-62
- 183 Anemias of Chronic Disorders and Nonhemolytic Normochromic, Normocytic Anemias. **2000**, 325-339
- 182 Antianēmika. **2001**, 88-96
- 181 Antianēmika. **2001**, 111-119
- 180 Prevention, Diagnosis and Management of Heart Disease in Patients with Renal Failure. **2002**, 129-145
- 179 When does anemia impact the heart in chronic kidney disease?. **2002**, 37-47
- 178 Reducing Mortality for Diabetic Patients on Hemodialysis. **2002**, 147-154
- 177 Impact of anemia on organ functions. **2002**, 147-172 1
- 176 Die normale Niere. **2002**, 1-22
- 175 Anemia of Chronic Kidney Disease and its Management with Recombinant Human Erythropoietin and Darbepoetin Alfa. **2002**, 9-27
- 174 Normalizing hematocrit in renal failure: dangerous or desirable?. **2002**, 65-80
- 173 Is long-term intravenous iron therapy risky?. **2002**, 115-121
- 172 Has the best route of administration for epoetin been established?. **2002**, 15-28
- 171 Optimal level of hemoglobin in cancer patients. **2002**, 369-390
- 170 Literatur. **2002**, 200-216
- 169 References. **2003**, 195-211

168 Antianñhika. **2003**, 114-124

167 Management of anemia in patients with chronic kidney disease. **2004**, 927-963

166 Antianñhika. **2004**, 238-249

165 Preservation of native renal function at different stages of renal impairment. **2004**, 1161-1179

164 Antianñhika. **2004**, 147-159

163 Quality of life of the dialysis patient. **2004**, 1315-1331

162 Erythropoietin ã Novel Therapeutic Option for Cachectic Patients. **2005**, 407-424

161 Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. **2007**, 2007, 215-217

160 Anemia and heart failure: a cause of progression or only a consequence?. **2007**, 3, 1

159 Antianñhika. **2008**, 267-278

158 Iron and Erythropoietin-Related Therapies. **2008**, 749-755

157 Impact of anemia and red blood cell transfusion on organ function. **2008**, 317-367

156 Role of Anemia in Acute and Chronic Heart Failure and the Role of Erythropoietin in Its Correction. **2008**, 519-527

155 Chronic Kidney Disease. **2008**, 287-311

154 Cardiovascular Complications of End-Stage Renal Disease. **2008**, 773-782

153 Hematologic Manifestations of Chronic Kidney Disease. **2009**, 506-513

1

152 Antianñhika. **2009**, 271-281

151 Outcome of End-Stage Renal Disease Therapies. **2009**, 472-477

- 150 Anemia in PD Patients. **2009**, 713-736 1
- 149 Hemoglobin variability in hemodialysis patients treated with erythropoiesis stimulating agent. **2010**, 43, 507-513
- 148 Die normale Niere. **2010**, 1-12
- 147 Pathophysiological Mechanisms and Prognostic Significance of Renal Functional Impairment in Cardiac Patients. **2010**, 189-203
- 146 Erythropoietin and Iron Therapy in Patients with Renal Failure. 357-367
- 145 Anemia and Cardiovascular Disease. 229-251
- 144 Influence of ankle-brachial blood pressure index(ABI) on mortality and cause of death. **2011**, 45, 157-162 1
- 143 Transplantation of Genetically Engineered Cardiac Fibroblasts Producing Recombinant Human Erythropoietin to Repair the Infarcted Myocardium. **2011**, 197-216
- 142 Hematopoiesis in 2010. **2012**, 3-13
- 141 Autologous peripheral blood-derived mononuclear cells induced by erythropoietin improve critical ischemic limbs. **2012**, 5, 52-60
- 140 Epidemiology of Kidney Disease. **2012**, 728-741
- 139 Neurologic Aspects of Kidney Disease. **2012**, 2138-2155
- 138 Bone Marrow Toxicity: Red Blood Cells. **2013**, 333-364
- 137 Past, Present, and Future of Drug Safety Assessment. **2013**, 157-173
- 136 Monthly variability of hemoglobin in patients undergoing hemodialysis when treated with epoetin beta pegol. **2013**, 46, 119-124
- 135 Prevalence of Anemia and Calcium-Phosphorus Abnormalities in Hemodialysis Patients in Southwestern Seoul. **2013**, 85, 378 1
- 134 Erythropoiesis-Stimulating Agent Therapy. **2013**, 29-43
- 133 Reducing cardiovascular mortality in chronic kidney disease: something borrowed, something new. **2013**, 123, 542-3 10

132 Intensive versus standard haemodialysis water treatment for preventing low grade aluminium intoxication in chronic haemodialysed patients.

131 The EVOLVE Study: Another Disappointment for Nephrologists?. **2013**, 25, 261-265

2

130 Alternatives to Allogeneic Transfusion. 800-845

129 Parameter Identification for Population Equations Modeling Erythropoiesis. **2014**, 599-614

128 Chronic Kidney Disease and Cardiovascular Risk. **2014**, 49-61

127 Similar Outcomes for Two Anemia Treatment Strategies among Elderly Hemodialysis Patients with Diabetes. **2014**, 1,

126 Anaemia Management in Chronic Kidney Disease. **2014**, 569-579

1

125 Anemia and Disorders of Hemostasis in Chronic Kidney Disease. **2014**, 205-221

124 Pharmacoepidemiology as Part of Pharmacovigilance for Biologic Therapies. 685-702

123 Chronic Kidney Disease (CKD) in Cancer Patients. **2015**, 25-46

122 High-dose darbepoetin therapy in a diabetic kidney disease patient with myelodysplastic syndrome. **2015**, 48, 365-370

121 ??? ?????????Hb?????. **2016**, 49, 114-122

120 Bleeding in Uremia. **2016**, 151-157

119 ?6? ESA?????????. **2016**, 49, 140-144

118 Identification of predictors of hemoglobin overshoot during the administration of ferric citrate hydrate. **2016**, 49, 401-405

117 Nephrologie/Hypertonie. **2017**, 371-405

116 Improving Outcomes for End-Stage Renal Disease Patients: Shifting the Quality Paradigm. **2017**, 283-290.e2

115 Heart Failure and Kidney Disease: Management in the Short-Stay Unit. **2017**, 295-307

- 114 Evaluation of the management of anemia in hemodialysis patients in Lebanon. **2017**, 6, 68-73 ○
- 113 Maintenance Dialysis in End-Stage Renal Disease. **2017**,
- 112 Bone Marrow Toxicity: Red Blood Cells. **2018**, 407-426
- 111 Novel treatment options for anaemia in patients with chronic kidney disease. **2018**, 32, 8-13
- 110 The authors' reply. **2018**, 37, 310-311
- 109 Hemodialysis in Adolescents. **2019**, 169-185
- 108 Cytokine Therapy. **2019**, 37-46
- 107 6. ?? **2019**, 52, 773-775
- 106 Low Quality of International Classification of Diseases, 10th Revision, Procedural Coding System Data Undermines the Validity of the Standardized Transfusion Ratio: Time to Chart a New Course?. **2019**, 26, 237-249
- 105 Testing two (of several) intravenous iron dosing strategies in hemodialysis. **2019**, 7, S129
- 104 Influence of anemia on the perioperative blood loss during total hip arthroplasty in patients with end-stage renal disease. **2019**, 178, 52-57
- 103 Chronic Kidney Disease and End Stage Renal Disease. **2020**, 45-115
- 102 Encyclopedia of Systems and Control. **2020**, 1-9
- 101 Erythropoietin role in the therapeutic management of heart failure patients with anemia. **2020**, 13, 77-79
- 100 Effects of Erythropoietin Payment Policy on Cardiovascular Outcomes of Peritoneal Dialysis Patients: Observational Study. **2020**, 8, e18716
- 99 ESAs und HIF-Stabilisatoren. **2020**, 24, 413-416
- 98 Nutrition and anemia in chronic kidney disease. **2022**, 741-760
- 97 Blood Pressure Control among Adult African Chronic Kidney (CKD) Patients—How Close Are We to Target?. **2020**, 10, 50-59

96 Anaemia in chronic kidney disease - a review. **2020**, 1, 189-190

95 ????????????? (?????) ??????. **2020**, 53, 449-451

94 Clinical perspectives on the treatment of renal anemia with HIF stabilizers. **2020**, 53, 493-503

93 Kidney dysfunction requiring dialysis is a heterogeneous syndrome: we should treat it like one. **2022**, 31, 92-99 2

92 Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. *New England Journal of Medicine*, **2021**, 59.2 14

91 Hemoglobin Level Analysis in Hemodialysis Patients Treated With Erythropoiesis Stimulating Agents. 145-164

90 Antianfika. 308-317

89 Use of recombinant erythropoietins in the setting of renal disease. **2003**, 153-161 0

88 Case Study: Immunogenicity of rhEPO. **2008**, 113-126 1

87 Cardiovascular Complications in Patients With Renal Disease. **2005**, 729-746

86 Anemia Management. **2008**, 337-356

85 Anemia and Diabetic Nephropathy. **2006**, 527-548

84 Antianfika. **2007**, 308-319

83 Die normale Niere. **2007**, 1-12

82 Antianfika. **2008**, 267-279

81 Sex-based approach for the clinical impact of polycythaemia on cardiovascular outcomes in the general population. **2020**, 1

80 Recombinant human epoetin beta in the treatment of renal anemia. **2007**, 3, 433-9 8

79 Angina pectoris and intensive intravenous iron treatment in hemodialysis patients. **2007**, 11, 30-4

78	Inflammation and anaemia as predictors of cardiovascular mortality in hemodialysis patients. <b>2007</b> , 11, 39-43	5
77	Heart failure: chapter 3. Underlying pathology in heart failure 'Failure of the circulation versus failure of the heart'. <b>2004</b> , 12, 303-307	1
76	Relationship between inflammatory cytokines and cardiorenal anemia syndrome: treatment with recombinant human erythropoietin (rhepo). <b>2008</b> , 12, 153-6	5
75	Cardio-renal anemia syndrome. <b>2008</b> , 12, 11-6	9
74	End stage renal disease. <b>2007</b> , 2007,	4
73	Clinical use of erythropoietin in chronic kidney disease: outcomes and future prospects. <b>2011</b> , 15, 109-15	19
72	End-stage renal disease. <b>2010</b> , 2010,	16
71	The case for intervention bias in the practice of medicine. <b>2013</b> , 86, 271-80	19
70	The elderly patients on hemodialysis. <b>2010</b> , 62, 87-101	7
69	Correlation between CRP and early failure of arteriovenous fistula (AVF). <b>2015</b> , 29, 219	4
68	Effects of novel anemia nurse manager program on hemodialysis: a retrospective study from Qatar. <b>2021</b> , 2021, 46	
67	Evaluation of recombinant human erythropoietin responsiveness by measuring erythrocyte creatine content in haemodialysis patients.. <b>2021</b> , 22, 413	1
66	Association of anemia and iron parameters with mortality among prevalent peritoneal dialysis patients in Taiwan: the AIM-PD study.. <b>2022</b> , 12, 1269	0
65	Role of Erythropoiesis-Stimulating Agents in Cardiovascular Protection in CKD Patients: Reappraisal of Their Impact and Mechanisms.. <b>2022</b> , 1	
64	Practical guidance for new multiple myeloma treatment regimens: A nursing perspective.. <b>2022</b> ,	
63	An updated systematic review on heart failure treatments for patients with renal impairment: the tide is not turning.. <b>2022</b> , 1	1
62	Quality of Life of Hemodialysis Patients during COVID-19 Pandemic in Gatoel Hospital, Mojokerto City. <b>2022</b> , 10, 293-302	
61	Design and Methodology of the Impact of Roxadustat on Left Ventricular Hypertrophy in Hemodialysis Patients (ROFIH-HD): A Multicenter, Prospective, Randomized Controlled Trial.	



60	Effect of Phosphate Binders and a Dietary Iron Supplement on the Pharmacokinetics of a Single Dose of Vadadustat in Healthy Adults.. <b>2022,</b>	
59	Treatment of Anemia Associated with Chronic Kidney Disease with the HIF Prolyl Hydroxylase Inhibitor Enarodustat: A Review of the Evidence.. <b>2022,</b>	0
58	Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.. <b>2022,</b> 33, 850-866	3
57	The ASCEND-ND trial: Study design and participant characteristics. <b>2021,</b>	1
56	Trimming the fat: is there a health economic case for the use of new lipid-lowering drugs in chronic kidney disease? A scoping review.	
55	Shortcoming of Measuring Patient Satisfaction's Association With Anemia-Based Cardiovascular Risk in End-Stage Kidney Disease Patients.. <b>2021,</b> 12, 344-350	
54	A single-centre, retrospective analysis of mortality over 80 months comparing paclitaxel-coated balloon versus standard balloon angioplasty in the treatment of dysfunctional arteriovenous access.. <b>2021,</b> 11297298211066749	
53	Coronary Artery Disease in Chronic Kidney Disease: Need for a Heart-Kidney Team-Based Approach.. <b>2021,</b> 16, e48	0
52	An Investigation into Possible Sex Differences in Association of Hemoglobin with Survival Among Hemodialysis Patients in the J-DOPPS Cohort.. <b>2022,</b>	
51	Table_1.docx. <b>2019,</b>	
50	Debate: Are HIF Stabilizers a Viable Alternative to ESAs in the Management of Anemia in CKD? PRO.. <b>2022,</b> 1-5	0
49	Efficacy of Different Doses of Daprodustat for Anemic Non-dialysis Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis. <b>2022,</b> 11, 2722	
48	Efficacy of daprodustat on anemia in hemodialysis patients with sustained inflammation: a case report.. <b>2022,</b>	
47	Liquid chromatography-tandem mass spectrometry methods for quantification of roxadustat (FG-4592) in human plasma and urine and the applications in two clinical pharmacokinetic studies. <b>2022,</b> 123274	0
46	Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis.. <b>2022,</b>	2
45	An analysis of vascular access thrombosis events from the Proactive IV Iron Therapy in Hemodialysis Patients (PIVOTAL) trial. <b>2022,</b>	0
44	Hemodialysis and biotransformation of erythrocyte epoxy fatty acids in peripheral tissue. <b>2022,</b> 181, 102453	0
43	Anaemia Management in Chronic Kidney Disease. <b>2022,</b> 1207-1219	

- 42 Addition of roxadustat to erythropoiesis-stimulating agent ( ESA ) effectively corrects ESA-hyporesponsive anaemia in patients on peritoneal dialysis.
- 41 Management of Anemia in Peritoneal Dialysis Patients. **2022**, 1-21
- 40 Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. ○
- 39 Administration of Klotho Does Not Rescue Renal Anemia in Mice. 10, ○
- 38 Relevance of pre-existing anemia for patients admitted for acute coronary syndrome to an Intensive Care Unit: A retrospective cohort analysis of 7,418 patients.
- 37 ??????????????????????????????????????. **2022**, 55, 365-369
- 36 Predictors of iron versus erythropoietin responsiveness in anemic hemodialysis patients.
- 35 Erythropoietin –An Outstanding Success for Genetic Modification. **1999**, 29, 311-314
- 34 Gut Microbiota Correlates With Clinical Responsiveness to Erythropoietin in Hemodialysis Patients With Anemia. 12, 1
- 33 A longitudinal analysis of the effect of anemia on executive functions in children with mild to moderate chronic kidney disease.
- 32 Is HIF-PHI the Answer to Tackle ESA Hyporesponsiveness in the Elderly?. **2022**, 2, 446-453
- 31 Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients. CJN.00550122 ○
- 30 Bioinspired Design of Artificial Signaling Systems.
- 29 Improving Outcomes for End-Stage Renal Disease Patients: Shifting the Quality Paradigm. **2023**, 613-618
- 28 Resistance to Erythropoiesis Stimulating Agent (ESA) Treatment. **2023**, 351-362
- 27 Hemodialysis facility star rating affects mortality in chronic hemodialysis patients: a longitudinal observational cohort study. 1
- 26 Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors. **2022**, 239, 108272 ○
- 25 Chronic Kidney Disease. **2022**, 1-18 ○

24	Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations.	1
23	Evaluating group-sequential non-inferiority clinical trials following interim stopping: The HIV Prevention Trials Network 083 trial. 174077452211183	0
22	Association between haemoglobin concentration and intradialytic hypotension in patients undergoing maintenance haemodialysis: a retrospective cohort study. <b>2022</b> , 12, e064026	0
21	New developments in anaemia treatment - erythropoietin versus prolyl hydroxylase inhibitors?. <b>2022</b> , 68, 438-443	0
20	Synergistic deterioration of prognosis associated with decreased grip strength and hyporesponse to erythropoiesis-stimulating agents in patients undergoing hemodialysis. <b>2022</b> , 44, 1801-1810	0
19	Association Between Nephrologist Ownership of Dialysis Facilities and Clinical Outcomes.	0
18	Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors.	0
17	Treatment of Anemia in Chronic Kidney Disease. <b>2022</b> , 542-548	0
16	Risk of sudden cardiac death and preventive measures in athletes. <b>2022</b> , 8, 89	0
15	HIF-PH-Inhibitoren in der Therapie der renalen Anämie. <b>2022</b> , 26, 453-459	0
14	A Retrospective Study of the Perioperative Period Management of Joint Arthroplasty in Patients with Chronic Kidney Disease.	0
13	Hemoglobin and Clinical Outcomes in Hemodialysis: An Analysis of US Medicare Data From 2018 to 2020. <b>2022</b> , 100578	0
12	Low-Dose Erythropoietin Amplifies Beneficial Effects of Angiotensin II Blockade on Glomerulosclerosis. <b>2023</b> , 100015	0
11	Not baseline but time-dependent erythropoiesis-stimulating agent responsiveness predicts cardiovascular disease in hemodialysis patients receiving epoetin beta pegol: A multicenter prospective PARAMOUNT-HD Study. <b>2022</b> ,	1
10	Management of Anaemia in Chronic Kidney Disease. <b>2023</b> , 93-114	0
9	Prolylhydroxylaseinhibitoren âNew kids in the bloodâ <b>2023</b> , 18, 107-111	0
8	Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies. <b>2023</b> , 40, 1546-1559	0
7	Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. <b>2023</b> , 2023,	0

- 6 Clinical features of anemia in membranous nephropathy patients: a Chinese cohort study. **2023**, 45, ○
- 5 Management of Anemia in Peritoneal Dialysis Patients. **2023**, 631-651 ○
- 4 Current Status and Growth of Peritoneal Dialysis. **2023**, 27-45 ○
- 3 Anemia and Other Hematologic Complications of Chronic Kidney Disease. **2018**, 515-525 ○
- 2 Predictors of quality of life in patients within the first year of commencing haemodialysis based on baseline data from the PIVOTAL trial and associations with the study outcomes. ○
- 1 Anemia in Chronic Renal Disease. **2023**, 1603-1630 ○